%PDF-1.4%‚„œ”
70 0 obj
<</Metadata 72 0 R/PageLabels 12 0 R/Pages 66 0 R/Type/Catalog>>
endobj
72 0 obj
<</Length 1664/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2009-01-30T16:23:02Z</xmp:CreateDate>
         <xmp:CreatorTool>QuarkXPress(tm) 6.52</xmp:CreatorTool>
         <xmp:ModifyDate>2016-01-20T06:05:48-08:00</xmp:ModifyDate>
         <xmp:MetadataDate>2016-01-20T06:05:48-08:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>QuarkXPress(tm) 6.52</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Layout 1</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:XPressPrivate>%%DocumentProcessColors: Black&#xA;%%EndComments</pdfx:XPressPrivate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:53125936-1dd2-11b2-0a00-f609271d9a00</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:5312593c-1dd2-11b2-0a00-1e0000000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
12 0 obj
<</Nums[0<</S/D/St 194>>]>>
endobj
66 0 obj
<</Count 8/Kids[59 0 R 67 0 R]/Type/Pages>>
endobj
59 0 obj
<</Count 6/Kids[60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R]/Parent 66 0 R/Type/Pages>>
endobj
67 0 obj
<</Count 2/Kids[68 0 R 69 0 R]/Parent 66 0 R/Type/Pages>>
endobj
68 0 obj
<</Annots 73 0 R/Contents 74 0 R/MediaBox[0 0 612 792]/Parent 67 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 75 0 R/GS2 76 0 R>>/Font<</T1_0 40 0 R/T1_1 28 0 R/T1_2 32 0 R/T1_3 16 0 R/T1_4 20 0 R/T1_5 24 0 R/T1_6 58 0 R/T1_7 77 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
69 0 obj
<</Annots 78 0 R/Contents 79 0 R/MediaBox[0 0 612 792]/Parent 67 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 80 0 R/GS2 81 0 R>>/Font<</T1_0 58 0 R/T1_1 24 0 R/T1_2 20 0 R/T1_3 16 0 R/T1_4 32 0 R/T1_5 77 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
78 0 obj
[82 0 R]
endobj
79 0 obj
<</Length 12016>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.013 Tw 8 0 0 8 323.7231 749.5293 Tm
[(Ef)20 (fectiveness of a Phar)-25 (macist-Delivered Smoking Cessation Program)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(201)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60 139.9229 492 598.077 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.019 Tc 0.019 Tw 8 0 0 8 60 732.5292 Tm
[(45.)-481 (Dent LA, Carter JT)75 (. Motivating tobacco users to quit: an ef)20 (fective phar-)]TJ
-0.005 Tc 0.004 Tw 1.6875 -1.25 Td
(macist-managed program. Presented at: Spring Practice and Research)Tj
-0.0242 Tc 0 -1.25 TD
(F)Tj
-0.024 Tc 0.024 Tw [(orum, American College of Clinical Phar)-25 (macy Spring Meeting, Myrtle)]TJ
-0.02499 Tc 0.013 Tw T*
(Beach, SC, Apr 12, 2005.)Tj
-0.021 Tc 0.021 Tw -1.6875 -1.375 Td
[(46.)-479 (Ferry LH, Burchette RJ. Ef)20 (ficacy of bupropion for smoking cessation in)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.25 Td
(nondepressed smokers \(abstract\). J Addict Dis 1994;13:249. )Tj
-0.013 Tc -1.6875 -1.375 Td
[(47.)-487 (Hughes JR, Stead LF)79 (, Lancaster T)76 (. Antidepressants for smoking cessa)-1 (-)]TJ
-0.02499 Tc 1.6875 -1.25 Td
(tion. Cochrane Database Syst Rev 2007;\(1\):CD000031.)Tj
T*
(DOI: 10.1002/14651858.CD000031.pub3)Tj
ET
0 0 0 1 K
114 628.029 m
240 628.029 l
S
BT
/T1_4 1 Tf
-0.0251 Tc 0 Tw 9 0 0 9 60 603.5292 Tm
(E)Tj
-0.02499 Tc 0.01199 Tw (nsayo Randomizado para Evaluar la Efectividad de un Programa)Tj
-0.02521 Tc 0 -1.22222 TD
(F)Tj
-0.02499 Tc [(ar)-25 (mac\216utico para la Supresi\227n del Habito T)70 (ab\207quico)]TJ
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 60 578.5293 Tm
(LA Dent, KJ Harris, y CW Noonan)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 60 562.5292 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 8 0 0 8 120.0947 562.5292 Tm
[(2009;43:194)-75 (-)-25 (201.)]TJ
ET
BT
/T1_4 1 Tf
7.5 0 0 7.5 60 537.0292 Tm
[(EXTRACT)20 (O)]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 60 523.5292 Tm
(INTRODUCCION)Tj
ET
BT
/T1_4 1 Tf
-0.0251 Tc 8.5 0 0 8.5 106.5236 523.5292 Tm
(:)Tj
-0.02499 Tc 0.01199 Tw 0.49024 0 Td
[(Los far)-25 (mac\216uticos, como profesionales sanitarios entre-)]TJ
-0.03999 Tc -5.9636 -1.11764 Td
(nados y accesibles, est\207n en una posici\227n ideal para realizar inte\rvenciones)Tj
-0.02499 Tc 0 -1.11765 TD
(para la supresi\227n del h\207bito tab\207quico. De los 15 estudios iden\tificados)Tj
0 -1.11764 TD
(en la literatura valorando la efectividad de las intervenciones para la)Tj
T*
[(supresi\227n del habito tab\207quico suministrada por far)-23 (mac\216uticos, este es el)]TJ
0 -1.11765 TD
(primer estudio randomizado controlado de un programa sobre tabaco)Tj
T*
[(facilitado por un far)-25 (mac\216utico realizado en Estados Unidos y utilizando)]TJ
0 Tw 0 -1.11764 TD
(confir)Tj
0.01199 Tw 2.26211 0 Td
(maci\227n bioqu\222mica. )Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 60 444.5293 Tm
[(OBJETIV)21 (O)-1 (S)-1 (:)]TJ
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 96.7354 444.5293 Tm
(Se realiz\227 un ensayo abierto, prospectivo, randomizado)Tj
-0.03999 Tc -4.32181 -1.11765 Td
(controlado, para valorar la efectividad de un programa grupal face-to-fa\ce)Tj
-0.02499 Tc T*
(comparado con una breve sesi\227n telef\227nica est\207ndar para abandon\ar el)Tj
T*
[(habito tabaquico facilitada por un far)-23.5 (mac\216utico. El primer resultado de)]TJ
T*
[(auto declaraci\227n de abstinencia fue confir)-22.9 (mado qu\222micamente por una)]TJ
0 -1.11765 TD
(cotinina urinaria a los 6 meses de la fecha del abandono. )Tj
ET
BT
/T1_3 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 60 384.5293 Tm
[(MET)22 (ODOS:)]TJ
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 93.3631 384.5293 Tm
[(El estudio se realiz\227 en la V)110 (eterans Health Administration,)]TJ
-3.92507 -1.11764 Td
(Community-Based Outpatient Clinic en la regi\227n del Rocky Mountain.)Tj
T*
(Los participantes fueron asignados aleatoriamente para recibir un)Tj
T*
(programa grupal de 3 sesiones face-to-face o una sesi\227n telef\227nica\)Tj
0 -1.11764 TD
[(est\207ndar de 5 a 10 minutos facilitada por un equipo far)-25 (mac\216utico. A los)]TJ
0 -1.11765 TD
(participantes en ambos grupos se les ofreci\227 indistintamente bupropio\n)Tj
T*
(LI \(liberaci\227n inmediata\) tabletas o parches de nicotina sin coste.\ A los 6)Tj
0 -1.11764 TD
(meses, los participantes que autonotificaron abstinencia se les ofreci\227\)Tj
0 -1.11765 TD
(volver a la cl\222nica para realizar una prueba de cotinina urinaria. )Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 60 296.0293 Tm
[(RESUL)91 (T)75 (ADOS:)]TJ
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 102.0434 296.0293 Tm
(Se randomizaron 101 fumadores desde el 3 de Octubre del)Tj
-0.035 Tc -4.94628 -1.11765 Td
(2005 al 30 de Marzo del 2007, con los \234ltimos seis meses de seguimien\to)Tj
-0.02499 Tc 0 -1.11764 TD
(completados el 6 de Noviembre del 2007. El an\207lisis de los datos se)Tj
T*
(completo en Diciembre del 2007. Utilizando los procedimientos por)Tj
0 -1.11765 TD
[(intenci\227n de tratar)40 (, los niveles de abstinencia confir)-25 (mados al final de los)]TJ
0 -1.11764 TD
[(seis meses fueron del 28% en del tratamiento far)-25 (mac\216utico grupal y de)]TJ
T*
[(un 1)34.7 (1.8% en el grupo control de tratamiento est\207ndar \(p < 0.041\). )]TJ
ET
BT
/T1_3 1 Tf
-0.041 Tc 0 Tw 6 0 0 6 60 226.5293 Tm
(CONCLUSIONES:)Tj
ET
BT
/T1_4 1 Tf
-0.043 Tc 0.01199 Tw 8.5 0 0 8.5 108.552 226.5293 Tm
[(Este estudio demuestra que las intervenciones far)-25 (mac\216uticas)]TJ
-0.035 Tc -5.712 -1.11764 Td
(sobre supresi\227n del h\207bito tab\207quico son efectivas. Una mayor u\tilizaci\227n)Tj
-0.02499 Tc T*
[(de los recursos far)-24.3 (mac\216uticos en las intervenciones para el abandono del)]TJ
0 -1.11765 TD
(habito tab\207quico pueden tener un impacto considerable en los niveles \de)Tj
0 -1.11764 TD
[(tabaquismo, en la prevenci\227n de las enfer)-24.1 (medades relacionadas con el)]TJ
T*
(tabaco, y una mejora global en la salud p\234blica en los Estados Unidos\. )Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 8 0 0 8 189.3765 162.5293 Tm
(T)Tj
-0.02499 Tc 0.013 Tw 0.55069 0.00001 Td
(raducido por Corinne Zara Y)Tj
0 Tw 10.88058 0.00001 Td
(ahni)Tj
ET
BT
/T1_4 1 Tf
0.01199 Tw 9 0 0 9 318 731.8455 Tm
[(Essai Randomis\216 \203valuant l\325Ef)20 (ficacit\216 d\325un Programme de)]TJ
0 -1.22222 TD
[(Cessation du T)70 (abagisme G\216r\216 par un Phar)-25 (macien )]TJ
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 318 706.8455 Tm
(LA Dent, KJ Harris, et CW Noonan)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 318 690.8455 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_4 1 Tf
0 Tw 8 0 0 8 378.0947 690.8455 Tm
[(2009;43:194)-75 (-)-25 (201.)]TJ
ET
BT
/T1_4 1 Tf
7.5 0 0 7.5 318 665.3455 Tm
(R\203SUM\203)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 6 0 0 6 318 651.8455 Tm
[(H)-1 (I)-1 (S)-1 (T)21 (ORIQUE:)]TJ
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 358.9155 651.8455 Tm
[(Le phar)-25 (macien, un professionnel de la sant\216 bien for)-25 (m\216 et)]TJ
-4.81359 -1.11764 Td
[(accessible, est en position id\216ale pour of)20 (frir des interventions dans le)]TJ
0 -1.11765 TD
(cadre de la cessation du tabagisme. Des 15 \216tudes publi\216es dans la\)Tj
0 -1.11764 TD
[(litt\216rature m\216dicale et \216valuant l\325ef)20 (ficacit\216 des interventions li\216es \210 la)]TJ
T*
[(cessation du tabagisme faites par des phar)-25 (maciens, cette \216tude)]TJ
0 -1.11765 TD
(am\216ricaine est la premi\217re randomis\216e et contr\231l\216e dont l\\325objet est un)Tj
0 -1.11764 TD
[(programme de cessation du tabagisme impliquant des phar)-25 (maciens et)]TJ
-0.0251 Tc T*
(u)Tj
-0.02499 Tc [(tilisant une confir)-25 (mation biochimique. )]TJ
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 572.8455 Tm
(OBJECTIF:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 350.6682 572.8455 Tm
(Une \216tude ouverte, prospective, randomis\216e, et contr\231l\216e a \216\t\216)Tj
-3.84332 -1.11764 Td
[(men\216e afin d\325\216valuer l\325ef)20 (ficacit\216 d\325un programme de groupe de type)]TJ
T*
(face \210 face \(groupe de soin standard\) compar\216 \210 une br\217ve \session visant)Tj
-0.0251 Tc 0 -1.11765 TD
(\210)Tj
-0.02499 Tc 0.65628 0 Td
[(cesser le tabagisme faite par un phar)-25 (macien, et ce, par t\216l\216phone. La)]TJ
-0.65628 -1.11764 Td
(mesure de r\216sultat primaire \216tait l\325abstinence rapport\216e par\ le sujet lui-)Tj
0 -1.11764 TD
[(m\220me; cette abstinence \216tait confir)-25 (m\216e par la mesure urinaire de la)]TJ
T*
(cotinine 6 mois apr\217s la date d\325arr\220t du tabagisme. )Tj
ET
BT
/T1_3 1 Tf
-0.039 Tc 0 Tw 6 0 0 6 318 503.3455 Tm
(M\203THODOLOGIE:)Tj
ET
BT
/T1_4 1 Tf
0 Tc 8.5 0 0 8.5 370.4386 503.3455 Tm
(L)Tj
-0.03999 Tc 0.01199 Tw 0.48075 0.00001 Td
[(\325\216tude a \216t\216 conduite dans une clinique exter)-25 (ne commun-)]TJ
-6.65 -1.11765 Td
[(autaire de la V)110 (eterans Health Administration dans la r\216gion des Montagnes)]TJ
-0.02499 Tc 0 -1.11765 TD
[(rocheuses. Les participants \216taient assign\216s de fa\215on al\216ato\ire \210 un p)15 (r)15 (o)15 (-)]TJ
-0.03999 Tc 0 -1.11764 TD
[(gramme de 3)-460 (sessions de th\216rapie de groupe ou \210 une session t\216l\216phon)-15 (i)-15 (q)-15 (u)-15 (e)]TJ
-0.02499 Tc 0 -1.11765 TD
[(de 5 \210 10)-475 (minutes faite par une \216quipe de phar)-25 (maciens. Les participants)]TJ
T*
[(dans les 2)-475 (groupes pouvaient recevoir gratuitement des comprim\216s \210)]TJ
0 -1.11764 TD
(lib\216ration imm\216diate de bupropion ou des timbres de nicotine. \313\ 6 mois,)Tj
0 -1.11765 TD
[(les participants qui af)20 (fir)-25 (maient leur abstinence ont \216t\216 invit\216s \210 venir \210 la)]TJ
0 -1.11764 TD
(clinique afin de mesurer la cotinine urinaire. )Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 414.8455 Tm
[(R\203SUL)91 (T)75 (A)76 (TS:)]TJ
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 354.7457 414.8455 Tm
(Les fumeurs 101 fumeurs ont \216t\216 randomis\216s du 3 octobre)Tj
-4.32302 -1.11765 Td
[(2005 au 30 mars 2007; le der)-25 (nier suivi apr\217s 6 mois a \216t\216 compl\216t\216 le 6)]TJ
-0.03999 Tc T*
[(novembre 2007. L)90.1 (\325analyse des donn\216es a \216t\216 compl\216t\216e en d\216cembre 20\07.)]TJ
-0.02499 Tc 0 -1.11765 TD
(En utilisant la m\216thode intention de traitement, les taux d\325abstin\ence)Tj
0 Tw T*
(confir)Tj
0.01199 Tw 2.2621 0.00001 Td
(m\216s apr\217s 6 mois \216taient de 28% dans le groupe de traitement de\)Tj
-2.2621 -1.11765 Td
[(l\325\216quipe de phar)-24.4 (maciens et de 1)35.1 (1.8% dans le groupe contr\231le de soin)]TJ
0.00001 -1.11764 Td
(standard \(p < 0.041\). )Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 345.3455 Tm
(CONCLUSIONS:)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 364.2133 345.3455 Tm
[(Cette \216tude montre que les phar)-25 (maciens sont des)]TJ
-5.43686 -1.11764 Td
[(professionnels ef)21.4 (ficaces lors d\325interventions pour cesser le tabagisme.)]TJ
T*
[(Une plus grande utilisation des phar)-25 (maciens dans les ef)20 (forts afin de)]TJ
-0.03999 Tc T*
(contrer le tabagisme pourrait avoir un impact significatif sur la pr\216\valence)Tj
-0.02499 Tc 0 -1.11764 TD
(du tabagisme, la pr\216vention des maladies li\216es au tabagisme, et su\r)Tj
0 -1.11765 TD
(l\325am\216lioration globale de la sant\216 publique aux \203tats-Unis. \)Tj
ET
BT
/T1_4 1 Tf
0.013 Tw 8 0 0 8 468.1624 281.3455 Tm
[(T)35 (raduit par Denyse Demers)]TJ
ET
BT
0 g
/GS2 gs
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 291.13251 11 Tm
( at Library - Periodicals Dept on January 20, 2016)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
58 0 obj
<</BaseFont/YDRKKU+Times-BoldItalic/Encoding 55 0 R/FirstChar 32/FontDescriptor 57 0 R/LastChar 118/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 333 250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 667 722 667 0 0 0 0 0 0 611 0 0 0 611 0 0 556 0 0 0 0 0 0 0 0 0 0 0 0 0 500 0 444 500 444 333 500 556 278 0 500 278 778 556 500 0 0 389 389 278 0 444]>>
endobj
24 0 obj
<</BaseFont/DUNHYS+Times-Italic/Encoding 21 0 R/FirstChar 32/FontDescriptor 23 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 0 500 500 500 0 0 0 0 500 0 0 0 0 0 0 0 611 0 0 0 0 611 0 0 0 0 0 0 0 0 0 611 0 0 0 556 0 611 0 0 0 0 0 0 0 0 0 0 500 500 444 0 444 278 0 500 0 0 0 278 722 500 500 500 0 389 389 278 500 0 667 0 444]>>
endobj
20 0 obj
<</BaseFont/CRHBKG+ZapfDingbatsITC/Encoding 17 0 R/FirstChar 110/FontDescriptor 19 0 R/LastChar 110/Subtype/Type1/Type/Font/Widths[761]>>
endobj
16 0 obj
<</BaseFont/RYSLID+Times-Bold/Encoding 13 0 R/FirstChar 44/FontDescriptor 15 0 R/LastChar 131/Subtype/Type1/Type/Font/Widths[250 332 0 0 499 499 499 499 499 499 499 499 499 499 332 0 0 0 0 0 0 721 666 721 721 666 610 776 776 388 499 0 666 942 721 776 0 776 721 555 666 721 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 666]>>
endobj
32 0 obj
<</BaseFont/LLAXWR+Times-Roman/Encoding 29 0 R/FirstChar 32/FontDescriptor 31 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 500 833 778 0 333 333 0 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 564 564 564 444 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 722 722 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 611 0 0 0 444 444 0 0 0 0 444 444 444 444 0 278 0 0 0 0 500 0 500 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 564 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 500 1000 444 444 0 333]>>
endobj
77 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
29 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 36/dollar/percent/ampersand 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater/question 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 131/Eacute 135/aacute/agrave 141/ccedilla/eacute/egrave/ecircumflex 146/iacute 151/oacute 153/ocircumflex 156/uacute 177/plusminus 181/mu 203/Agrave 208/endash/emdash/quotedblleft/quotedblright 213/quoteright]/Type/Encoding>>
endobj
31 0 obj
<</Ascent 684/CapHeight 662/Descent -215/Flags 34/FontBBox[-168 -218 1000 899]/FontFile3 30 0 R/FontName/LLAXWR+Times-Roman/ItalicAngle 0/StemH 0/StemV 84/Type/FontDescriptor/XHeight 677>>
endobj
30 0 obj
<</Length 10729/Length1 10729/Subtype/Type1C>>stream
  LLAXWR+Times-Roman   @¯ ¯¯¯¯˚<˚n˙|˙
 ãã
 ãã   ˚   ˜  æ¨  )» }àç002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  `  T  P O F G U I N B D J C M Q S 6 4 Z  L  E W V X  . H 1 ' ) R " * Y     0   5 # [   	 & 
 7 3  / % o  $ ( i 8 w  â  - ò     2  ú K     , + ; :  œ ÿ » 9 ” ﬁ ≤ À “ Ÿ – Œ Æ b   ë î ŸN¨	U√uP´E”@¶ ò‘YpË	I	≥
K
k
’üÉÓ[ºÛ|ØËVπñÁ3“>∏ˆs¥ÜÎKØ∆k‚KÍPâ†Dä'ÉÔp?mÿGjê¥8Äø-Ó w È!¢"7"°#6#‚$ô% %è&&±'B˚ôÇ°êv¯Zwí¢æ»˜:—ú˜˜ªt´M∞ Ànú|§ã©Ø≠®∂≈Æd6úõ¨á˜ÉÜáâÖÜÑåéÖúôcçs:QXDO™e·Z≈j≠xùqãn_koYEiØÚs{\˚/òîíêéîìïäàñúÅ¥§á•Ÿ ƒ”¸$˚*Ç¶¯4ß®‰˜ö‰¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚*†v¯)¬åw⁄‹:ﬂ˜Eﬂ‘¯xõ]}õº˜yË^ƒB[p|ID€¨ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠Ãª√õî¨ª£kJ˚eN}xZà{˚bÅ–˜o´˜Ø§–F“˜cÒÙ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÏ˚˜-˚cŸöÆØ«∆•m7ó˚—†v¯7´˜_®Úﬂ7ﬁ¯˘´\ßU˚QA˚2ä:k‹˚œBÅÄBá{˜òõ:çñ÷˜œ˜´Ë˚˜∆ùß≤†îÖoük°îÑú¢ûû¢¸Åø¯´–ﬂ˜™Õ~ñvrzÅtãg|¶ ˜≥´&˜ñâéÖU<midpÑÜâàãÖãáåâéãø˚¬5©b…∏≤§æ¨˚*†v¯+¡”ﬂ˜Nﬂ¯zõXêÇó–˜[ˆa¿9R_rQ`â˜¬Öè\{òè kzåìëãè∞ìÇa¸kFÇUÜ{˜kõTç~úŒ˜Öπµ´ù±∫¶eF˚ZGÄ}Rá{˜†v¯-øåw·ﬂ˜Lﬂ˜Kﬁ‹˘ôõRåïª˜c˜d∆=SXpSU≈xk§SbvÇXFÜáÉÜÅÉ÷ºÉéZyåã1pyéõêåñ§ïx^˚íV}}Sâ{˜rõYyô∞˜Øéïïóï‹£®´ó™ª°iC˚mU~Sà{˜sõSå|ú»˜ê∏´™ú∫¡ûn9˚gSÑÉPÑ{˚bñvåƒ¯§∞„˜6›x¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω∏Tëùx∑™ßõ≠ß˚0ﬂsàÄÉx{yb{sfo≠π»∫µ˜±˚bÅ”¯®§◊¯0˜(}ì`HapQã1K›˜ƒ‘ÿ≤ñÇcóëwïkö|£ã¶ûù•¡E∫<˚+!˚!˚⁄/˜ﬂ∆∫˜¿¸†v¯^w˜$◊8ﬂ˜E˘ßt¢opttop°tßß¢¢¶÷˝õËKèÅñ”˜˜ÜèWwZyVy|é©åãì¶î{_˚{CÅGà{˚*Å´¯Àœﬂ˜w‰¯h˜á˜?Ë$SWlXpâ˜¡Üéa{U{[~{åïíãèÆîÅc¸úm„i⁄˜Ú˜˜!2b˚	]L5[\££˜ê∂µ¨ƒ◊ø;˚¸†vÏﬂ˜îõMå~ó√¯ÁáéHwvÖEy{åôíãó∞ìÄY¸pV{}Ná{˚*˚Vv˜a´¯«åw’ﬂ˜v‡Ï¯i˜à˜F‰*R_sVaâç‘‹ÖéTvää4m{åóéãó´ëÅ[¸gUÑÑMÑ{˜ÖõAå}ó…˜0m´©≤˜Ê˜˜$6f˚YAArmóûs}óÇóï˜äÏØìª™∫’º>˚˚—†v¯`w†w÷ﬂ–˜‚¯+¨wühblsH]â‰∞ÜéJqwÑMu{éöìåï§ï{_˚éYÇÉNÅ{˜ÉõKvùƒ˜súò§ûûôòôìîíìáÉîx†ìáõ°õû•”}∑¯˙ûÚÚ˜¸∂˘S˘ü˚{w÷âûr(˚¢=Å`slakTtJO\ùÆnnÆÇ∞€˜‘‘ññ⁄èü˚Æy⁄ÉïÅB˚À˚@›6˜:˜HŸ›˜P˜ôõ†Ÿè-~Ø¯¯¥—·˜~Ô¯~˜<€\ƒ˚’Q≠"º‹¿µ≤∆Â–L˚ ¶§u˜hvsÖÇÅzÑ|éê}üOwëq"?D)9≠a˜C˜>¨hNGZ\C0M¿˜Wu©˚h††çñóùØ´jÁ˜
„ÿÛ˚*˚m¯Àwô¯`¯n¯Iô˚}ØàóÑzÑéîqB<˚q˚˜êÇûãíãñúííΩëô˚a}®ÜóÑîw˜˚ä¶PÆJ|tpG{rt|z||wuùloxzpk™r¥“µº˜*ƒ˜/¯-ñ©ôò°é¸$õv£v√˜ †˜Xñøh≤\jrskl¢wØ`ôêéãîïêáÅäâiogVgïxŒ≠∏»ƒ˚*†v›ﬂ¯çõ`çi°dº˚.˜V®¶ÔËΩÆÃâô˚_}ìêäãè¢äîáå~åÅÉÉ{|˚˚âç¯3ÜéOxzÜ>w{åòïãíØîZ¸uUââBÄ{˜~õMç~î¥˜Iç˜˚LûrçáãÖÉÇÖy{˚—†v˜UÀ≤˜ä˜±˜UÀ˚äK˚*Åø¯ß¶·˜wﬂ¯µõÉÇäãáfÇó∏¯ÀÜéUx|á=v{åòëãêØìÇa˚0¨crïb˚.˚˚˚◊2˜¿µ†∂™çNêàŸßoÅÎ≠˚+»m^l_9Sﬁ˜˜æ◊‘¬ª\U˚*ív¯ewû¯\¯o¯Gõ˚{´äöÄv|Çoy]=˚[%˜îÜòáúãíúòî¨çõ˚W{üäïÜó§s˜˚ø£NéÇòeîãíãèíù∑˜˜‘¶Œíî©ç˚*Åƒ¯(w—ﬂ˜Fﬂ=ŸË¯rØôYäñ∫˜Ï˚2{ÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶Ë∑∂9çàŸßîéæô”ív°v¯dw†˘4p˘I¯Gõ˚{™àòÅy~áu~l0˚r<˜kt…çÑãò£ôì∂èõ˚^{µäôv≠%/˚\k‚H˜CãÜõäìíüòî¨çõ˚G{¢äîÄüX˜˚Èkòëíëëî©ô˜˜ÉÂ˚∞^úãåíìååªû˜˜Óúµêíûê¸$Ä˜—˜˜I∑™r§mlrrlm§r™©§§©˜Éãû˘ûˆ∑¯ú˘ÔüFçyù–¯Q”ôô‘éü˚[˚o¸é˚{¯é˚Zw›Üò~D¸+&|x;Ñw˜}ü@éx•Ì¯$ç˜é¸∑ô˜ê¯Œç¸V9Ä~<Üw˚*˚nƒ˜&÷@‘Ê§˜k≤êßß–nﬁ˜EŸ•®›¿¯i¯≤?u~çìwù]têm*AE-L§h–gCKyvtuö|≤{æ¿FZnfgTÿ`Ô˜˜ŸÊ ]¥@é˚êTçsïãùîòûôòóòôìîúêÜ®ÁœÕ‰®áû|∞P˚Snf_›¿MaÃÌ»¶Æªƒ∏B.Û˚ﬁR?b˚ﬁ¿3M©µ£ïú≤π¨Ñéõâ§àªâ¿âà°Äãi-ãû˜°≥˜Ω±xûÓÚ$Ò˜{˜⁄¯±¯w˜$—˚3˚öw’ÉìÇD¸FCäp9âw˜¨ü<å|ö’˜Hä§¢äû⁄≈ñ°≤»≠Æ«œ˚â!S\˚ÊzÅãçt˜ôßíë≠˜ÕY--ãû˜»µb¥˜ì≤xûÓ˜î¢¥¢œ¯µ¯úà˜#¸¶w’áò~C¸QC~~Aáw˜´ü@é{ö“˜p˜&âﬂäñÅö7¢˜|t6|Å8˚&˜q∑®êêß˜˜û~0ù”ãû˜º∑˜±ûıÒ˜√Ò˘PüAè~ò”¯Q”òò’èü˚®w’áò~C˚W˚√˜W”òò’èü˚®w’áò~C¸QC~~Aáw˜®üAè~ò”˜b˜√˚bC~~Aáw˚*˚Vv˜a…¯ß£‡˜|ﬂ¯|˚kõ]çzö¥¯ÍÜêNgU™|ê_ã˚,˚˚&˚Õ4Ï¿¿§ªπçä˚NT|~AÑ{‰˜ÎkÑ~t~srÖs>W◊˜˜	¡Ÿ‹Õ™kF”ãû˜[¥¯4wö˘G˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ß˚—ãû˘û˜Ò˜Ãü8é~ó÷¯O÷òóﬁéü˚∫wﬁàò@¸O@~8àw˚*†v¯Wwú¯b¯sõhçyòn∑˚˜Xﬂ˜û¶ßõ≠åö˚3}¨áíá}~uU?~üèÖs≥x™Ñöãìãõïë´çô˚b}µäêá∞SÍ˚%˚˚9pd}Ålä{˜%õnÄêóìêóô°€˜‹˚õsãäãÄ{ÄÑrá{˚—⁄˜ ˜o¯ﬁøh≤\jrskk¢wØîñèãìîåëÜäÅâhohVgïwŒ≠∏»≈˚*†v˜i·¯ö=åyñ∫¯ÌÇç˚G0~•ïúíúèîã¢ï}j¸m\yÄ=ä|˚*~∞¯‚‡Ÿ˜˘—¯J˘?ÇëyuÉáwã˚e˚˚Ääâäàãâáçâëä˜É˜5Y˚.&O?;uÑé´^°l}êpr}~tb∑u›˜5˜ Ú˜.˜@˚ƒ˚)¶µ‡˜Xúéåíé˚*~•˘•£Î˜òÎ¯p˜ﬂ˜c˜E∆§ndò[[d~rnFPb˚˚˚≥˚—Or®≤~ªª≤ò§®—«≥˜˜+˚h`!44`ı˜h˜i∂ı‚‚∂!˚i”}Ø¯˛Ø≠˜¯?˜˘C˜ﬁ˜_˚˜#˚S˚T˚˚#˚_˚]˜˚#˜T˜S˜˜#˜]˚å˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R˚*~ß˘ß√÷F’˜o–T◊‘¯Q˜0ÿiª˚ÊÿÓ¡ÆµŒﬁC≈#!;H0J¢iÒ4‰˚<ulG&ÿI˜	˜
ÿÕÚÿ1¯PuiCVTØEø‘ƒ∏≥ œ∂_G‰ô¸-G__IAU«›Œû±…æ™tîÑãËE£rN˚*ã◊¯§‘˜Â·¯n˜~êmdÜpPã˚Ñ˜=˜D‚Ê≥⁄ã⁄Ì:Ÿ&˚HK˚lüÜØÍ≤Ø”ã›ƒP6?\*95˚F˚P~¯dãû¯Ì∂ü°˜gÒ˜|v¯„¯ÅÑ˜>¸ƒÑ˚>§˜°†õ˜¡¸í@~8àw˜∫ü8é~ó÷¯í¡˜†{˚°úã∞fû˜»≥c≤˜ó±xû˜Ò˜Ü;˜¶Ä¯Â˜D≈oΩ\ßröyíZôçg Ë°≤∂⁄˜.«˚<˚¨wﬁàòA¸QA~8àw˜‚¶Ä˜%Ï“Ùß ˚˜Ã<Yb)äõ -ä˜yßèç√˜»]0¶Ä†˚»*O]˚O|ì¨˜ç˜Vå–d˚˚bã©¯©¶¯¯6˜yèv*|~/ã˚˜¢¯*ö˚Ôà˚ú’ïôö»˜˚ù¸*|¯˚*ôv¯Ë‘ü¯@¯T˘ö¸|_`%úÉ≤Ã¢õ¡ã˜m˚Z¸ËÃ˚*}Ø¯Á∆˜—⁄g“–¯C˜lÍkπ+∑‡œπ§∞≈⁄K¬/,MX˚döá≥÷∏´ ãÃ∏^L^r_cnpwvÅWyû¡¶Üz™–ªp®XO8QICqvì†h£cÇéys}~ug∑v÷˜1˜Î˜˚—˚1v˘Íwª‡˜ƒ˚6˚·Z˜˜l˜[∂Ò˜ÓÇõ˚@˚@˚ã˚L˚µ#Î%≤aßt≤tdã±eû˜»µb¥˜ì≤xûÓ˜ú¢¨¢´Ä¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•WÄw’áò~C¸QC~~Aáw¯Ø˚—˚1v˘Íw˜\‡˜±˜ä˜aÛ+Òdµo¢d¢{˜5º˚˚l˚[`%˚(î{˜@˜÷˜ã˜L”ïv˘#ûõ˘;‡˘K˘ü˚`‡x∆ÜôÇm}Ñqm˚&¸˚,˜ÊmÕÅ©ãô§ñê èû˚ù‡wΩàú{±6˜ã¸∫ö˜p¯∆®’õõ∫çúãû˜¡§˜ÆØxûÒÒ˜}˜‹˘'üdçvóp¨˚b˜ë˜¢ƒ¿Ë˜/ ˚7˚ßw‘Üó~D¸D4ÖÑ=Éw˜®ü=íó“˜X√é˜Ç˚…N¯"Kc˚=ä˜äÏ®óíΩ˜≈]1˚*}ß¯∫˜Çö≠Á˜ë‰¯h˜m˜Bﬂ˚[wÑeL™˜1ÓÍ˜;´áö˚vá˚M˚;˚˚D‰˚˜˜·Í˜2j˚ cME4SÈ˜'≤ê≠îô°ò∑ù¥ÂæC˚”ïvñû˘û˜ ∏¯1∑x˘T˘ü˚~wÂÑëk4˚„â¸¯u˚?w∂åñÑµ[¸M%~y8Éw˜ü>éz£¯ç∏¯J¸πú¯§Ôöü⁄ë”ãûx∞¯·∞xûÚÒ¯˜ú˘?˜‚˜b˚)˜˚é˚†w’áò~C¸QC~~Aáw˜Ø˜Ç˜&˜˜cl˚Ö˚U#)˚a\~î´¯ê≠îë¡˜Q˜	˚˚L˚*†v˜]ºã¯à¯à˜]º¸àZ˚*†v˜;À¯Qw˜∑⁄>ÿË¯k˜;À&¯Q_˚Œ¸QK˜≠˚;ÿ˜;<À˚Ñ˜Ç˜Èçú}∑¯Ov˜M≤ß˜˘˜yú=AOp5ã˚+,˜˜K˜SÂ˜	˜(ˆ“N˚∞°Ç˜tvÉu|wåÅå{éxíbôYìaã˚Zã˚!˚#ã˚]ã˚f˜˚˜_ã˜ã˜ øæ◊”}≥˜…û˜Æ≥´˜¯Î˘W˜„û˚íxŸáïÅ@˚4iOq?˚3'˜
˜O˜KÏ˜˜%Ù–U˚µ£É˜fuuÑ{ÄsÖÄçéÄ°Ejë\˚[˚"˚&˚b˚|˜A!˜K˜˜¬ù˜\≈ôö√é˚b†v¯E˜ ∂˜ Ê˜ ¯2¯}´tügÅÅáãÉÇäÜêïçÆßÆ¿ØÅüHh^OQWÆd∫¨§£´˚{´tügÇÄáãÉÇäÖêåïçÆßÆ¿ØÅüHi^NQWÆd∫¨§£´˜∫ñv˘"ûê˙1˙6˘ü˚Zw¬ÜôÇl|ÑkÇs˚˚Ë˚˜Èp–ãäãó§°ï¬ü˚üw áèá≠:≠9 ˚Ø˚%¯É†àïãò°óë¿êü˚àw…Çéá“˚SÃ˚CçÜË˚°ö˜.¯;ëyë|éÇë|°U™;±*ú[™4ôŸ˜Éñ™Ã˜H¶‘ö≥ñ©öµõóªë˚b†v¯Õˆ©˜ Ê˜ ¯%¯›øh≤\jrskl¢wØïîéãîïêáÅäâiogVhïwŒ≠∏»ƒ˚{øh≤\jrskl¢wØïîéãîïåêÜäÅâiogVhïwŒ≠∏»ƒ¸Ä˜˜ç˜‹˜˜T¯)©r§mlrrml§r™©§§™˚˝™r§mlrrlm§r™©§§©˜Ú†v˜]ºã˙|˙|˜]º˛|Z˚*ã¶qß¯Ûßo¶ø‘Û≠˜ÿn¯\˜B€hº#√U®˜å⁄Üª^ü5ö˜^f®PüIéÃiÆK"áCN4dôg¶mßl¶x‹]˚∞-çXπrı|˚g«√|–4≠n„˜ï‘ÀÓ˚w˜}~ì~ìÄîZ±y¶ã±ã¿∂¥»í˜*¸|I^^DÉ˜õ‰X¶gRdã≤dû˘ûÓ∞¯Ë˜Bs˚
Siz˚I0Åè∞¯n”òò’èü˚ßw’áò~C¸QpC~~Aáw¯≠˚*˚Yv˜d»¯$wØÁG„3ª˜~„6‡È¯ì∫ìutÄÖ{vÅü∑˜¸Í3˚Âgy]p`Uj≠≈˜»3¸!ÒHsLãHZõq©™ö§æÂ®Ü™|«ÇØàôá®éçZ´¨wæøµ¶∆±çQç£oªÆ©ù≤¶¸ív˘FwÇ˜∫˜±˘8I˚x˝FŒ¸õv£v˜Û˜€˜ ˚˜h˜T¯)©r§lmrrml§r©™§§™∞ß¸øh≤\jrskl¢wØpïîéãîïêáÅäâiogVgïxŒ≠∏»ƒ˚bÑÛ¯π®˜MÛ´Ë¯2¯õÊ?Ã .EM9dút©•õõ§ôÖò}ö}õáíï©ª™ª∆∫UGb}PuVoIy`ÄXä\ùï÷ö©œ‡¿Õ¢Ωãº˚¸n®t¢nnttnn¢t®®¢¢®”˚Fû˜Gw˘Ø≠˜¯?˜˘P˚Eù˚å=∂5˜ ˜2•Ú˜ã˜Eã˜_˚˜#˚Sã˚Tã˚˚#ã˚_ã˚¡˚‚SÆu©}•ÖπT=Õ˜_˜,íåãå≤˚¯ê˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R˜Kìvò™˜óÆö´˜g§œw»◊˜r§Ã÷˜q•¿˘ó˜ö—f≥H˚˚ ˚˚;ªW’ÛÎ˜˜˚¯2eYYbyDd{í†oür{ëo˚ ˚	˚BæQÕıÔ˜˜ôâñáûÉ£óâ£∑ßí†∞çâø¿˚˝∫¿¯Ö˜£˚:˚<du•∑œÀ˜?‚≤™f^¸˜º˚:˚<cu£∏»∞ÊπΩ£°°òúëçäÑíïÅöÑ®Éëéwã}5ãÕ˜mÃ˜çÃ¯©˜ØÃ˚o˜2J˚2˚oJ˜o˚5Ã˜5˜o˚ØÕ¸ãI¸˚Xv˘7w˜$Á8ﬂ˜U˘ßt¢pottop¢tß¶¢¢¶Ëå˝¯^ÜèXwXyWy|é©åãì¶î{_¸!Äjg}ÇêóÄ≥iÜéwwwywk≤t¬˜∆÷˜"˚*âw˜ó∂¯ß©Á˜ÄÔ+ÎÙ¯^¯!˜5/˜
˚˚4'˚ ˚
‘:ˆ¿ªù±π¯åàm˚%˚˚>qçw˜Öõ˜3˜<ã˜Ù+bváÇÅuod}j>\’˜˜± œ‰∏4˚;5†v˜Õ˜Õ©¯ã¯©˜’Õ¸ãI¯ã˚]Õ¸ãI5óv¯†wß¯èßÇ¯è˜{…¸è˜{G¯=˚V¸=˚V5óv¯†wß¯è¯´Çœ¸=˜V¯=˜Vœ¸è˚{M”ãû˘û˜Ò‡˘eüXzñÎ2˚|˜é˜Q˜Q««£óŒêü˚òw«áíàtrxs4:tu∫∂˚@˚0˜W‡ﬁñóŸëû˚¨xŸÖñ8¸;8Ä=Öx˜¨û=ëÄóﬁ˜D•°ı!ÿ>¿Fãt‡yÇàOâw˚ôív˘&û˜CÒ¯˘ü˚¥w⁄âô}C¸d\Äwq|Üë£Ñ≤|õqqutp_≤n∆˜ »”˜¯”ôô⁄çdã±¯ﬂ±î¯ﬁ¯Á˜Dt˚hjq%˚ñ¯C¯ˆö¸°x˚>§Úü∞®˜˜q¸H¸ˆ|¯∆”ãû˘û˜œÒ˘R˘ü˚owæåùÇtÅáÄÅ{˚!˚x˚)˜tÄõÖöãò°ôëƒü˚¨wØâôÑßiüt≤W•e˜˚T˚M>~Ä2âw˜∆ü2ç~ñÿ˜U˜'˜w¡ﬂ®¢¬ë˜~”Cø¯°˜n™µÁœŸ˜2øæ˘ÅÔ{ónct~`ãY]ßÀW≈ÿìïÆ…•π£µüòºè°˚kuΩáôÅkalPO<NŸ{¢TÛ˜¿≤∫ã‘ã–RΩ<ã5ãIGã3ãSûcõ\eu#OVD7-ÕPˆÿ ¶À’E÷±v√ √¥”´˚À¯bRh^9_iŸÑ§≤¿™≠ª∑Æg\~i¸^]QaxbEPÃ◊Ãß±Â«√ ¨Y 9˚bÅ–˜o´˜Ø§–F“¿˜rGÒ√˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝Ú¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ó˚*Ç¶¯4ß®‰∆˜rx‰ﬂ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸#˝Ë¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚bñvåƒ¯§∞„§˜r6›ƒ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝t¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±”ãû˘ûï˘H‡˘RüWêwòe¬˚S˜¶˜%˜K≈’§öÃèü˚Äw≈àñÜr|É}kd˚˚`∆CÓ~¶ã¢£öë»ü˚¡w–Ö¢w„˚˜˚5˚0˚U;)~ÅWÜw˜}‡ûVçsñå°åúò§∞∏˜˜(Í˚!´\ùgã}‡uwÉSäw¸†v¯bwÃ˜r˚Uﬂo ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú˚≥˝–˜êõKèÅñ”˜˜ÜèXyWxXx|é©åãì¶î{_˚{CÅGà{˚*Åƒ¯(w—ﬂ°˜rIﬂ=Ÿﬁ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸"˝‰¯rØôYäñ∫˜Ï˚2{ËÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶‰∑∂9çàŸßîéæôdã±eû˜»µb¥˜ì≤xûÓ¨˜rî¢¨¢˜ ˜i ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸[˝™¿¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•V¿w’áò~C¸QC~~Aáw¯Ø˚bñvåƒ¯§∞„Y˜rÅ›√˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚ï¸èt¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±˚bÅ–˜o´˜Ø§–F“v˜rëÒ√˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚ï¸èÚ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ó˚*Ç¶¯4ß˜hw®‰t˜ r‰ﬂ(˜’¯ê˚˜:K˚˚:¨˜Ú˜$¸¸ê‘¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚bÅ–˜o´˜Ø˜jw§–F“t˜ ;Ò…˜’¯ê˚˜:K˚˚:¨˜Ú˜$˚Ú¸êÈ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÂ˚˜-˚cŸöÆØ«∆•m7ó˚b˚jÆ˜Gvñ”¯®§◊í˜e√ƒ˜ô˚∑k•WÑÑäâ}£Ãib)ëÖûéïåñãßöuouzfxyéîr}l•£á±ã‘ª´Ω˚—˜8¯0˜(}ì`HapQã1K›˜ƒ‘ÿ≤ñÇcóëwïkö|£ã¶ûù•¡E∫<˚+!˚!˚⁄/˜ﬂ∆∫˜¿”ãû˜[¥¯4wö˘G¸Ä˜r˜W˜i˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*¸ ˝d˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ßu°¯Wñ˜\öíã˜öî¸}é¶
ﬂ
_˜é˘
endstream
endobj
13 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[44/comma/hyphen 48/zero/one/two/three/four/five/six/seven/eight/nine/colon 65/A/B/C/D/E/F/G/H/I/J 76/L/M/N/O 81/Q/R/S/T/U/V 131/Eacute]/Type/Encoding>>
endobj
15 0 obj
<</Ascent 912/CapHeight 676/Descent -203/Flags 262178/FontBBox[-168 -218 998 934]/FontFile3 14 0 R/FontName/RYSLID+Times-Bold/ItalicAngle 0/StemH 0/StemV 25/Type/FontDescriptor/XHeight 921>>
endobj
14 0 obj
<</Length 3621/Length1 3621/Subtype/Type1C>>stream
  RYSLID+Times-Bold   @¯ ¯¯¯¯˚<˚n˙z˙:
 ãã
 ãã   ˘   ı  >∞    }áå002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku  !              * / 5 3 0 % 6 $ # + & 7 4  . - " ) 2 ' ≤ ( #   < ¢ ˘Pê ^x§/|Á~À?ì˜]¬Gî	]ﬁ		á	Œ
/
ùw˛x˚+ã§˘+w˜O˜&¯N§1çxõ◊¯Õz˚è˚q†ƒôèô§óu\¸:wz(är˚+~•˜Ñπ˜˝¶•¯R¯l¯&˜>.˜˚˚1*˚˚’9ˆ∞£êô®]˚0DD˚(kq˜ù§˜C˜8˜v˚1¶häoÉSÜsÖxMt≈˜5˜ó®ª°ùÅxïõoñ62˚+†v˜#˜¯Ew˜ù˜&˚$˜$Ë¯m˜#˜M¯E;dYk_xr˚˚4êë#˚2˚˜ä˚#˜&˜#Ë˚$˜˚c˜a˜ªËç˚+ã˜¯M˜˜Ω˜¯q˜hrEo|Ç(˚*˜3˜.ﬁ€´«ã÷˜@◊˚*DI˚Y¶ƒ•∂´ø–ºV@YwSaN^K]U˚˚s¯3¸$öv£v≤˜L‡˜sµÕ`∫O[jj[[©k∑‡ííéãìóìÇ}fkd>Sñt…∞¢û¶©¨±†æª˚+}˜(˚(Ω¯œ€˜≠˜&@˜®¯f˜ã‹b«:Ø∞À±û©«ﬁMø(&@Y$U†Æ«∞§¿ã«≤bMIig,mxË˜ `«P+EdZT®DqÌã7iprlS«gÈ˜9˜˜˜&˚+É«O˜(˜S˜‹˜¯	ÿ∏¯i˘8˚’+˚Ì˜
Å∫ÉªuŒm¥VTU^\X¯DZ„ãBgqrhV»hÂ˜4˜	˜‹fÕH≥V´eì˚î°‹˜©˚“†v˜@˜∑˜Ü˜≤˜@˜˚Ü˚˚+†v¯Ø˜ú¯^¯o˘8¸3`˚r§Àú£†√˜b˚Z¸ØÍ˚+~™˘ßß˜˚˜˜9˜˚˜
ÿ¯j˜M„b«˚“‘‚£ºΩÃ„A√˚
˚ 6H˚A≥UÔPË"l]X5&·H˜˜Á⁄˜‘˚˜ÙaÇgjeR®Cƒ“∂±±∑¬≠]?ËÖ¸+Gi_XOe¡‡≈ï™≥∆˜C£kD˚+~ß˘ß£¯V¯n˜ﬂ˜b,˜*˚˚,˚+˚a˚ZÎ˚&˜˜Î˜&˜Z˚2˚ ˚'wN\\w»˜'˜y˜&ü»∫∫üN˚&˚+~¶˜˛π˜Ñ•ß¯R¯n˜p˜Aﬁ˚ kxá}e≥˜*—–˜/≤•˚®j˚8˚/˚w˚BÊ˚˜"˜ÊÓ˜˚-K˚nZuyñ°Ä|¶Ç⁄Âµç®ë∫íå†ìùÃ¢Q˚6˚öã§˘§˜˜4¯§BétúΩ¯x¿¢ù‘å§˚Òr“â°zV¸xZuzDár“évù§˘§Ú∂¯B∑¯˘N˘§˚kr’ÑûvD˚√â˚Ó¯?˚fr£áô∫S¸oT|}CÅr˜v§>ïxüœ¯%ç¯¯Q¸≤¶¯·ƒòôÃîõã§¯ˇ´¨¶˜U˜6˜T¶˘¯oà˜]¸Íá˚]®°˜±≠˜î¸£BÄ6Ñr˜¯§7ê}ò’¯£˜Äæoû˚“ã§¯˛¨r§˜˜5˜K˜>¯˘]§tçÇèÇò˚]˜≤˜∞∂πﬂ˜
,»˚O˚”r‘áô{D¸NBÉÇ<Är˜Â§@ï}ö–˜V•˜c˚ÕY¯à˚dj˚$ä˜î¯´öï∫ﬁ±^)˜x¨˘¨Æ˘V˘y˜„˜d˚'˜(˚b˚b˚'˚(˚d˚b˜(˚(˜a˜a˜(˜(˜b˚Eå˚hO˚˚˚	P˜˜h˜_À˜˜˜Ã˚˚_“ã§rÆ¯Û≠r§Î˜6˜ï˜A‹˘D˜Î˜e˚˜˚}˚√rÃÖú}\¸Å^vzNár˜Œ˜p˜ ˜˜f¸˚A{˚VH)˚a|ö∂¯ä∞òïª˜“˚˚]“xº˘§Ì˜2˜’∑˘O˘§˚pr€ÉùyB˚ƒ˚*TG˚(]…˜˜·÷úõ€å§˚ÂrÕÜõyF˚·/ù\ø`aºœv‡◊€©∂≤Ø≥üœ·˜”∆ôõÀî“y∫˘	≠áwº˜E˚E˘`§Ù˘A˜m§;4Ig;ã˚IÒ˜a˜k»ˆ˜Á€E˚«§Ù˜~pk~}yËoBΩã#˚V˚)˚0˚`˚d˜%˚"˜j˜ŒÆ˜Óõã§r´˜ °˜Æ©r§Ú˜3˜L˜?Æ¯˝˜NÂH ˚£ç˜∞≤∞ÿÚ/ƒ˚;˚«rŒàüzX¸yXÅ@Çr˜’˜?˜”˜˛˚[˜Ÿ˚ lp˚à˜tÆöô±—¨`/ß˚›&cZ8`yù∂˜ç©ÙºX˚˚+,¨˘]§é˜"›˜5¯p˘§˚Ûr‹â†}U¸¿Myr_qvòù£¶îã´≤iÆddmj`D’SÍ˜#‘‘˜&¯H‘õõ”çõã™l§˜ƒ¨˜≠¨r§Ú˜5˜6•˜§∑˘˜dp˚QBZ˚Kwòµ˜á˜
Ñ©nô˚•˜Áqz˚kn˚à˜}¥óíœ˜#ƒ`˚†§˜\¸“ˇr–Öù|Y¸wW~ÄAÇr¯€“çv˘2§õ˘?˘O˘§˚hr´à¡åa{àÅz]˚˚‹˚˜–pÃàîãõßòë‘è§˚„rΩÇóÅ°X˜î¸Ï¶˜v¯ﬂ£…óñ¡ï,x≠v˘:´Æ®w˜˜Ö˜
Ï¯î˜SŸa—G≠˚'÷9µw†ãº»∂≤ Á—I˚≠ß˜mmoÉÖÖxgg≠1˚7<˚1ºO˜PÕlÁ_†rãTHY_?Ù$Bÿ˜on˚å®Ï¢êîïõ≠±iÌ˜(Ô‡˜˚“ìv¯yw›˜<˜é¯πf±]\ee]\±e∫π∞±∫˚—∫f±]\ee\]±e∫π∞±π˜∏ã§˘§s£Ûµ¯¶˜.¯˙+§<ïÅñ“¯O”ôö‘ê£˚è˚[¸l˚\¯l˚è¯r’ÉôÅW¸pOÄÇ<Är˜~§7ìyù‘¯fç˜é¸‚¶˜ç¯Òç¸çS}@Ñrõã™l§˘§Û˜6˘˜xn˚*KO\˚Dxó∏¯lÿôó‚ç§˚rŒáù|X¸yXÇÉ?r¯’“ã§˜@≤¯Zwî˘9˘B£]èÅóW˜˚s¯¢n˚p¸∏e.ÇYr˜_§Oètó§öò±´Ÿ˜sßQûRt~ÉÅ|àÄàéãYÜrû˜Ä˚VË˜á˜ã§˜¿∫˜´§Ù˜5˜Ö˜5˘á§Fîyô∫¯xæùô–í§˚Âr“Ñù}X˚c˚Ö˜dΩ†ú–è§˚„rÕÑù{[¸y\ÄCr˜„§Cìyôº˜y˜Ö˚z[w{EÖr˜˚Eª˘ß¨Æ˘V˘y˜„˜d˚'˜(˚b˚b˚'˚(˚d˚:ﬂ˚˜-W˚ªÙK˜¡…ó¢∆Ö£kÇ|âwã>U±‡a˜8º‰˜˜?˚Eå˚gO˚˚˚	P˜˜g˜`À˜
˜˜Ã˚˚_cã§˜ƒ¨˜≠¨r§Ú˜5˜.§˜£ﬁ¯Ÿ¯o˜]¸…r–áù}W¸zY}CÉr˜˚§2éuô¿˜~ıà¨iô˚	§˜Êrx˚	jk&â˜~˛≤óì«˜#∆\˚ùõ†v˘Mv¯X˜˘˜dd˚d¸€§’îòñø¯wΩyöFë§¯“˚\r˜vR∂˚#GÑb˚}˜é´®ú˜•˚Áq}˜m®˚
í˚áaü~À˜‘º˜≈˚˘1vÅ~mx˚#4T˜˜0õùûïüã§üws˜x¨˜ã§¯¨âw∞˜E˜æ˜0e§Ï˘Ö˜ô§˚Ír·ÜöÇT"YntI˚F˜˜e˙˜l»˜ ˜Ë€E˚∆§˜~pf}ÇÇwgNª!˚Y˚(˚.˚aÏ˚a˜'˚%˜dÎ˜©´∑˜”òò”ëxû¯aó˜_õ˜pî˜üì¸ué§
§å
_˜é˘
endstream
endobj
17 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[110/a73]/Type/Encoding>>
endobj
19 0 obj
<</Ascent 1667/CapHeight 1667/Descent -293/Flags 4/FontBBox[0 -143 976 814]/FontFile3 18 0 R/FontName/CRHBKG+ZapfDingbatsITC/ItalicAngle 0/StemH 0/StemV 0/Type/FontDescriptor/XHeight 0>>
endobj
18 0 obj
<</Length 178/Length1 178/Subtype/Type1C>>stream
  CRHBKG+ZapfDingbatsITC   6ã˚πœÉ
 à?ãã
 à?ãã   h   e   kë   ¨ a73    á %<¯
˙0˚π…˝Ã˘7˘Ã˝YV¯Á˙¸Á‰˙!—ç˙s˙sçç¯Õ˘
endstream
endobj
21 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period 48/zero 50/two/three/four 57/nine 65/A 70/F 80/P 84/T 86/V 97/a/b/c 101/e/f 104/h 108/l/m/n/o/p 114/r/s/t/u 119/w 121/y]/Type/Encoding>>
endobj
23 0 obj
<</Ascent 684/CapHeight 654/Descent -205/Flags 98/FontBBox[-169 -217 1009 884]/FontFile3 22 0 R/FontName/DUNHYS+Times-Italic/ItalicAngle -11/StemH 0/StemV 23/Type/FontDescriptor/XHeight 677>>
endobj
22 0 obj
<</Length 3543/Length1 3543/Subtype/Type1C>>stream
  DUNHYS+Times-Italic   C¯ ¯¯¯¯Ä˚=˚m˙Ö˙
 ãã
 ãã      ¸  =¨  ∂ }âé002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z    ' C V  7   X     Y ÏLO≥Eø|¡>≥ﬁ+ü ≠Z∆	?	§
4
b
∑
˝n7-†v¯ˇÆ∆¯—˘˘"¸ßa˚.ùá°∫ú§•ü§¨¶ë˜˚#¸•}YszFÑ{˜∂õ9ëÇè´ïë•í•˜ ¯á¡÷®rKÅäÇâxúä˚*óv©v¯Ovû¯]¯pÙó_QvwzãÉÑíïñëôçìƒ˜eïÆë©ãò≤pßfKFM˚#-âç˜
¯KÖêL}wÜBÉz§åúå§âãtuj|P˚¸ã÷±˜)õµ≤∆¡‹Õ∆ÆãõãóÄã}ãÜåãÉnW˚S}WÇapú{ßæ∑Æ⁄ª˚bÅ∏¯¢™·˜yÃ¯/¯
∏o¢T˚˚2˚9˚&3æV‡Œ’≤œ…óCQk{`ãSe∞¡ôéüí•®è˜,†Ú◊ã‚Jí7+G˚vù∑∞Êœ‘¿é†åö{t¸$d†v˜vØ¯+vX¯˚¯»õSéÉï”,¯Ãq˚µ¸âA˚}{bÉ{˜Oõ\ê~í¢òì•ó¢≈˜˜pü˚åÅåÇãÅgx~Pä{æ˜ö˚V˜(˜òç˚*óv©v¯Nvô¯`¯nÛ|òUFÅÅyãÇÖíîíê†ï±∑˜4ó∑î¥ãö∞q§e,4˚&H^âçÀ˜eáç˚tëå[Ç{æâòÜx~ÇnÖvãÉl@˚ß÷¥˜$¢√º— „±¨ØãòãïãzãÄÖlÅf`˚7{PäÉ|lõ{´π©§„À˚*Äº[ª¯°úﬁ¯pÔñ~~YSyãÑÜêìïê¶ñµÿ˜∆ÖéLÑÄ[äåÄÆoûdã˚˚1˚J˚-=ÆbŒ—≤©˜„çà{LÜqãwoò®±¨•ﬂÕ˚˜î3,˚z!drß∑ÂÈ˜q˜Æ¢qd¸ïv¥˜Ç˜´˘;ÜêQ{à9{§ç∑ärÑèñv>"¸v;à}ãziõy™¡ß¢Ò—îUCwxuãÅÜëïíéöì©˚ôìv¢v¯A£åv˜ ‘πÿ|¯¯O}}ÇÑá~|nqúãcC[aJ-˜?ã@[nkaRl≥Ïz|¸w˚4öõíëêñ|≠™xã±ﬂ…¬÷Í˚Ÿã‘¨¢ü≠Ω´g=ï|õ˚*ïv¯Yv¶ﬂ˜¶ﬁ¯h˜πËU√2˚(˚*˚0˚-/¬WÎ˜ ˜*˜<˜8´)B˚m˚[k∞¬Ó›˜p˜∂ßfP¸˚Mv¯Ô´˜x°ØÍ¯:¯˙±g¶Xaexdjibu\j#0ÉkÂ3¸9t˚lX_ãÑëïîîêãô†zösw}zsi¨q∑Â–Ï˜Mµ‘˜’˜ ë´ ˜0¶±”¬ôïÜÑäÜÅÄã|sö{°¢ùù°d†v˜≈∞˜Æ©¯âÚ¯¯äÓB¿˚˚åz´Ü±è`}áv`˚
¸={RÑÖPÄ{˜âõSíìßöéóî≠¿˜U∂Ö§â±ã˜,Û€˜	$ë˚OW˚xtçè{—˜ãë†óì®ãÊ¥g;˚ô†v˜ËÒåv∏¯¯0¯™xünX@7(^Çwäçº˜[àéWÅWÇWÇ{éûìåì†òÅy~ÖiÅh:˚π◊∂˜ ö¥Æ–∞’µ¿†ã†fã∂®úû´”óv©v¯ø\∫ó˘Fx˘RÙ}óZOxyzäÉÜêïîåêí£ƒ˜gî≠ë©ãòØsßk24˚Haâç¶„ï±ãúØt£iO?D˚8àéƒ˜[àé$vååPÄ{¿äñázÉçë{M8˚ ÷™üﬂ…„x—º¬ª®òìÇ|Éåç|Tãâ;˚∫◊≤˜,†¬ªœ∫œ¡ª¶ãóãîÇã}ãÜåéÄ^Z˚Z}Qáz~¯oö{¶π∫∞ÿ¿˚bÄØ¯5w©‡¯<˜¸Ωa´H˚%˚ ˚'˚.)øUÎ‘…Æ‘¿{îcZSk[ãSh∏“˜$Ï˜Ò£öÉ{|Çãruõ|£¶ûû•¸ñv¯+¨Ø˜ò˜º¯B;ßÚåçãçãçêàèÖÖääÄÇ\Sbib{mÄáàãÅãÇãîãÇ÷B˚ßt5åéãÇuä†y¶§£ñü¢ùõòú≥ƒ~ërlpj{}ãÅÖëñêåçèõﬂ˜“ﬂ˚*˚Mv˜Wû¯∂¯Â¯i˜…ﬂaºBL[l=TâéßÓáí˚0uéz©é≠àãpÑÜsÇj˚¸N~YÖÖ[Ü|˜bö\yî°©®ìÆ}¶òà®˜!˜0˜=˜+1ì˚(˚ ˚5'ltö°πª˜(ùπÃ§ƒºø≥°mW˚b˚Lv˘v˜‡Èc≥–¯>¯≤u£h‡v{|w–Z¡óãdP,˚/p]w˜Ö¨N˜qyãvE}ÅVzéüìåî¡§Y˚lºöGïV~{Ñ|tmxqplwwÄÖÇãwã}®pãtãz{ãuãpüy™ã∞ãº≤–‡˜	˜#˜˜Éã⁄˚*ã÷¯•‘¯‡¯W¯éÌF‘-*?Q%güÑ≤Õµß…ã“¿WDP`C%˚˚e˚tz˜˜Ω˜zírXv~Uã˚Rê˜U˜U˜
˜
©∫ãœ˚*Ñß˘ß´⁄˜»Ÿ¯Ö¯H˜*OÊ(˚.˚,˚|˚~˚Œ0Í˜1˜&˜j˜y=‚˚*T˚]J5_jjvhUjΩ‹˜Ω˜U¡Ó∆¨∑≠∑ø™\<˚*êv˜äπ¯•–„˜ò÷¯Ä¯[˜E‚˚˚˚˚˚ "…@‰±∑õ©∫èáM˚˚˚˚uy˜úŒ¢÷æ˜Â›˜$ã˜&@≈Tv3wijwWp^Keæ·˜”ı‰Ã≠\0d†v˜€Æ˜ó¨ì˘˘˘"¸Ü{œÖïÜn}ÜpÖt˚¸O{RÉÑRÄ{˜êõQèyñ®ñåèì©…˜s≈ä¡äπéãYxâ|ÖsúÖ◊˜xëZ,ìè˚BàÃ˜}ë¢ïéÕã˜,™~M}ãÇâxüâ˚*Å°¯º¯‡¯n˜‘‘[ºD2V:J^äç¯ÜêUÇêã#|{†â∏ënyfá{˚¸äàr’n…˜)˜:˜B˜06~#˚˚S˚h|ó¶ÏÎ˜â˜µßiW˚*Ä¿mv¯Nv™v˜‡˜∏¯o˜ }î[Nyy|ãÑÖëïóçåòºãê†Ÿ˜ºAa˚rT`HP/XUnãqãç•çìÊ¯ ∏àéQ}zà@Ä}†â≤ílÉãäÇgY˚W\ÜpãzgùxØ–ææ˜O˜çh˚Éhw¯lúy©œØ–ªÆ¸$á˜˜¨≥sßinvxpzíù{ö}êÉrurVgïx‡º∂¡ã∆dév˘4v◊¯¯˘D˘õ˚N{øÑñÖuy|hfK˚^˚ÛáI¯Jäëãëãê´öî…íõ˚Ö{¿ÑëÉô9Á¸√û¯¯˝õ¶ôï•ç˚*†v˜EÕKÀå¯q∞¯r˘:c¸5¸CwG˜ôZ˚G⁄∫˜EÓöÕ,ô˜◊,˚◊˚iç˜≈˜’˚*Ö±¯Ôµ˜Ÿ€p‚–¯e¯Ω—O¡<FKcLlöÜ¥º®ú∑ãæØfU8,I˚$zå{°‡Ù≈N˚3QCDzrñüm•eÑéwpz|rf¥v”˜1˜˜˜#ÿr¥E≠é–˜ª¨´“úév¯`v°v˜’˜: ˜Hª¸˘¯¨v†jt}|xj∂Üãf]_I˚˚&k˜˝ãèáçÜãáâäÉÜ˚S˚ƒâÖÁÉÊzÂ¸ØÑâêÉ¸âàãäà[ÅzáVÇ}°åéããßåìÖìtïmö˚ë#ê4Äåäfôìëî∑§˜:˜∫ç®˚–çqéÖíåëìí¢û…÷˜=˜]Ô¸$Ä˜¶˜˜∑™r§mlrrlm§r™©§§©xû¯Aô˜g¢íã˜°ç¸sé°
¢
_˜é˘
endstream
endobj
55 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 45/hyphen/period 65/A 67/C/D/E 76/L 80/P 83/S 97/a 99/c/d/e/f/g/h/i 107/k/l/m/n/o 114/r/s/t 118/v]/Type/Encoding>>
endobj
57 0 obj
<</Ascent 700/CapHeight 669/Descent -204/Flags 262242/FontBBox[-200 -216 992 921]/FontFile3 56 0 R/FontName/YDRKKU+Times-BoldItalic/ItalicAngle -11/StemH 0/StemV 79/Type/FontDescriptor/XHeight 685>>
endobj
56 0 obj
<</Length 3147/Length1 3147/Subtype/Type1C>>stream
  YDRKKU+Times-BoldItalic   C¯ ¯¯¯¯Ä˚\˚l˙t˙-
 ãã
 ãã  	    @Ø  ' }éì002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku    - " % F O U  B M  & G D J W T P 1 I S N  E 4 L H $    T ±ÇÛ@Cª$™6ÉO≈á R™	$	ò
N
´dã´¯¯§u¯˜¯…˜\˚I+U˚_vï†íçôéñ˜¯rô¡°õÀå§˚œr…ÜóÖpÄÜoÖw˚¸V~Zy{ZÑr¯º∆˜Wúã§˜L≤¯Hw¯˜ ¯/˘@s¸¸‡m\x{hÉr˜Y§Zézì§ñëùîõ«Ú˜jãö7ã_d|ÄKÖr˜√§KèÑì~’˚\¯±˚â˚M”ã≠¯Ò©r§¯¨˜'Á˘1rœÉëÑoÄâÖ{P˚¸?}X{|YÑr˜≤˜ï˜N˜9˜x˜D˚Ô˚TIGßíõïÆ˜¿N˚˚f˚WCBWBf5ayñ£ååòããó∑˚b~À˜´˜l¨ê˜#˚#˜˜>ÁÙ˜(˜j˜´æ‡∫ùîu(AM8v˜<CLegocÏ^uß¡úåîê¢Âî˜:Œ˜Ω`ØO˚'˚"˚<˚13 L‚Ÿ¬≥Ìƒ-óv©v¯bw˜wp˜Ö¯aS~YÑ.Öp†´åoqj äÜãÉlP˚h˜˜Ë‚Ω•òñÇ~i4˚[ã:b£u∏ƒº¥ÂæuòeP}{zäÉÑíï§„˜iã÷Ωp¢X6N/*Jâç¸óv¯4∂Ä˜∑˜ã¯ÁhZ>^f2dhæL˚pÇmxFãn`•r∏≈ª≥Î∆uôgStsyãÉÑíìöìØú»»˜oﬁ∂C¸$˚*ívç—˜ˇµv˜p˜û¯9¢äôxnIH˚å1rx¢™Ã‹˜çﬁÜ˜PØ˚ÖySâ∑Ös£b˚˚)˚R˚3=µ[Œ«∑≠Á√çåÄbâÉã}dßp≥∏Ω∂ﬁ¡vöfWxx|ãÉÜëïßë®ßÁ¸óvç˜≥˜µ˘P3ymá1Çq¢≥èjw}\Ñq'˚ˇ}WÑjãzb§sµ‹º÷«≤uöiUqqyãÇÖíïóí¨ö¿¸$˜'Ç˜'Ã˜bjjcb¨j¥≥¨¨¥≥j¨cúã´˜∆¨˜ü™s£p˘:ÿ˘˘1¸ØsœÇëánáuÖu˚¸V}X}~WÉr¯º«˜WrêK˚+U˚!ã_uñ°ååñâÜõ≈ƒ˜e˜©xD~äàxßÜ‘˜¶qèe6gp˚ë»˜s¯≠îòïÆ˜Ωf#¶Ü˚—˚`˜˚™¯Ÿµ˜˜Çv˜˜	˚˜™˜Ä¯Vù“§Ï©æ≠ãóëáÉÄ{Åãw≤o†u¶©††´ªd´Q˚ @8˚:_BÉaÙ‘|NÑmáwM˚≠,v~-SÄÉêëîõìã§¥ßwûmoutn\≥k≈˜=Ω˜f¯&‹‰îµ˚b~Ã¯¨Ü˜˜)˜˜—˜!GYov`_nØƒœƒ˜mÂôîÑÇ}vzãpm§t™≤£¶∂¬^ÆE˚˚%˚:˚//…LÁ◊º≠Ò“¸óv¯√˜˜˜˜V˘@fmmff©m∞∞©©∞∞m©f®˚r/zÖä#ÅqπäóÖrÜâÑá{S˚lÄbávã|e¶q¥«√∏ÂøuôjWqoxãÉÑíìîäãîÆã»˜z™˜˚bìv¯pw„˜ﬁ˜B‘Ë˜~˜^˜U„˜Ê±p™inqqlË_∂~ãijbN6.à˜VÖ√v‡W}rá=Äqõüå{ïörò0â!ããâ˚âM˚ôìvå®¯1´äwπÎ¥Í\˜ﬂ¯ao{ÉÖÜ}|nv°ã^:VZ?TônŒ=≥[õmrlrsjYj∫·~qé¸u˚:•ôììëô|°§xã∑‰»¬Ÿı˚‹ã“ßü¢´∏©c<ò\¶à˚*}©¯5®à˜˜`˜˜Ø¯b˚'˚˚3˚;5œKÁ˜%˜˜0˜9ËL….Én©äövaBS˚¨+iy°∑÷ø˜≠ˆÜdã§˜πÆ˜±™s£¯e˜&Ë˜‡¯Â±ïìí¨æ™iRWyMrhmud|SÄÑãçxÇká≤úä§˜7˜ Ÿ˜
ÚDø˚"˚≤¯sœÇëào~áuÖt˚¸V}YUÅr˜∫§Qè~ì©óé¢ë°-óv©v¯bw˜Ù˜p˜π˘O.zná6Çq£≤èhÅâ}Öv˚.¸À˜¶Ïß›°∏∏Ë ”ØãôãîÖã{ãa3˚Sã8h¶r∞·¥‘…µvõeSrp}ãÉÑíìùÂ˜ã»∏n®^GT^˚4âå˚ô†v˜◊˜ v¯-˜w¯cQ|âã˚ ~p∂äñÜw}V~]>˚°˜Ω˜2©Î ˆ•ãúìeãÆÆ£©∑¥u§h\`X˚JÜé˜óv©v¯‘äw¯⁄˜h˜}¯aO~~â˚q∑äïÜwÑåÑk˚ãÉkM˚q˜˜˜Ê˜≠ññíÇ|Çâ~Ü|ãG˚oi˚˜∞˜µ˜·˜πãôïÅ~b3˚Oã8Ë_¢vπ«¥≠Ï√uóeQ|z|ãÇÑíì∞„˜LãÁ∫m®YXL`˚?éú∏ê°®¯¥q§b-D˚H]àç˚—†v˜:˜ç˜†ç˜:˜â¢˜˚â˚*”D“˜˝µv˜p˜¢¯9¢öwkbD˚†/rz£ÆÕ€˜Ä‚˜ä˜´FyWÜ4Öp†ßòÇwÑázÖue˚t£wîpã˚
˚/˚S˚1B∏U«ÃπØÊ¿çÇcäÇ{pd°u±ººµﬂΩuõmZwu{äÖäÜëì¢∫˜:î¨-y≠˘Æáw˜˜˜¯˜≈¯@Gø}ü∑Õ±≥À‹µY˚ï¶á¯≥˜\nyÅÑu¯]l®ãA˚26!˚?˜â_ã˚!FVVC!^·Òàmåh˚s©ßóííûØ∑hÊ˜‰€˜ﬁi»˚Ì˚*É—bv¯=§t¯çp˜±˘OB~oá ~p§≤èhÅàzÜz˚0¸À˜Ω˜O≥ß˚1§ÆI…æ´®Èøuñq\{zxã`s˜Hæ ¬œ«ùîºì§˚brµáîá|p`a˚
0äç˚*˚_≠˜Kv˜4´˜ã™W‚ã˜˜˜ @˜	ˆ˜ÑùÿoÇù•~öwt`_qEC^©ª∑»≥õı˜!¯K®útcWi˚En|ü±æ¨˜–˙˚C¸>+uipSN◊`˜ ˜&Î«Ê«g¨˚™VöiïyôãõõúùòöôÉã†ı˜Í⁄ÌúäíáûŒ√˚•ikìa˚$9*V¶d¿v9]}}emùw¥|úy¿¯˚Æ´˘˘7˘Ant}ÇÖyÑÑåëyöXbía˚t˚K˚\˚à˚-˜!˜4˜Ì¿Î m°N<Gd;ã-SÕ˜ ˜*Ë˜∑˜Q⁄ªO)~ãÖà|´Öxû¯Vò˜bõöã˜úñ¸vé§
⁄å
_˜é˘
endstream
endobj
1 0 obj
<</OPM 1/Type/ExtGState>>
endobj
80 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
81 0 obj
<</OP false/OPM 0/op false>>
endobj
82 0 obj
<</A 83 0 R/Border[0 0 0]/Rect[250.388 9.0 292.133 16.0]/Subtype/Link/Type/Annot>>
endobj
83 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
73 0 obj
[84 0 R]
endobj
74 0 obj
<</Length 16866>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.024 Tc 8.5 0 0 8.5 60 731.8055 Tm
(Reprints: )Tj
ET
BT
/T1_1 1 Tf
-0.034 Tc -0.004 Tw 8 0 0 8 97.5835 731.8055 Tm
[(Dr)55 (. Dent, Department of Pharmacy Practice, Skaggs School)]TJ
-0.021 Tc -0.017 Tw -4.69794 -1.125 Td
[(of Pharmacy)74 (, The University of Montana, 32 Campus Dr)54 (., #1522, Mis-)]TJ
-0.00999 Tc -0.01401 Tw 0 -1.125 TD
[(soula, MT 59812, fax 406/243-4353, larry)74 (.dent@umontana.)-1 (e)-10 (d)-10 (u)]TJ
0 Tc 0 -1.625 TD
(This study was sponsored by the Prevent Cancer Foundation. )Tj
-0.0201 Tc T*
(A)Tj
-0.02 Tc -0.008 Tw 0.89702 0 Td
(platform presentation of the findings was made at the Annual Meet-)Tj
-0.01199 Tc -0.01601 Tw -0.89702 -1.125 Td
[(ing of the American College of Clinical Pharmacy)74 (,)-1 ( )-1 (L)-1 (o)-1 (u)-1 (i)-1 (s)-1 (v)-1 (i)-1 (l)-1 (l)-1 (e)-1 (,)-1 ( )-1 (K)-1 (Y)128 (, Oc)-1 (-)]TJ
0 Tc -0.01401 Tw 0 -1.125 TD
(tober 20, 2008.)Tj
ET
BT
/T1_1 1 Tf
0 Tw 6.5 0 0 6.5 60 649.8055 Tm
(W)Tj
0.0031 Tc 0.92928 -0.00001 Td
(e)Tj
0.00301 Tc 0.011 Tw 0.85093 0 Td
(thank Kathrene Conway and Casey Ruggiero, University of Montana, School)Tj
0.0065 Tc -1.78021 -1.23076 Td
(of)Tj
0.007 Tc 0.007 Tw 1.13887 -0.00001 Td
[(Public and Community Health Sciences, for their assistance in conducting\ fol)-1 (-)]TJ
0 Tc -0.01401 Tw -1.13888 -1.23077 Td
[(low-up surveys, data entry)74 (, and database management.)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0 Tw 10.5 0 0 10.5 60 605.8055 Tm
(References)Tj
ET
BT
/T1_2 1 Tf
0.019 Tw 8 0 0 8 63.8 587.9555 Tm
[(1.)-475 (Gunderson SK, Cultice JM, Knapp K. How many phar)-25 (macists are in our)]TJ
-0.015 Tc 0.201 Tw 1.2125 -1.23125 Td
(future? The Bureau of Health Professions Projects Supply to 2020.)Tj
-0.03999 Tc 0.013 Tw 0 -1.23125 TD
[(www)65 (.hhs.gov/phar)-25 (macy/phphar)-25 (m/howmany)65 (.html \(accessed 2008 Sept 10\).)]TJ
-0.02299 Tc 0.02299 Tw -1.21046 -1.35625 Td
[(2.)-477 (Mar)20 (golis JA, Meshack AF)80 (, McAlister AL, Boye-Doe H, Simpson L, Hu)]TJ
-0.035 Tc 0.019 Tw 1.21046 -1.23125 Td
[(S. Smoking cessation activities by phar)-25 (macists in East T)70 (exas. J Am Phar)-25 (m)]TJ
-0.02499 Tc 0.013 Tw T*
[(Assoc 2002;42:508)-25 (-9.)]TJ
-0.01601 Tc 0.01601 Tw -1.20358 -1.35625 Td
[(3.)-484 (Harris KJ, Noonan CW)90 (, Dent LA. T)70 (obacco treatment practices of phar-)]TJ
-0.022 Tc 0.022 Tw 1.20358 -1.23125 Td
(macists in a frontier state. Poster presented at: Fourteenth Scientific \Ses-)Tj
-0.011 Tc 0.011 Tw T*
[(sions, Society for Research on Nicotine and T)70 (obacco Annual Meeting,)]TJ
-0.02499 Tc 0.013 Tw T*
(Portland, OR, 2008. )Tj
-0.019 Tc 0.019 Tw -1.20611 -1.35625 Td
[(4.)-481 (Hudmon KS, Prokhorov A)130 (V)129 (, Corelli RL. T)70 (obacco cessation counseling:)]TJ
-0.03999 Tc 0.013 Tw 1.20611 -1.23125 Td
[(phar)-25 (macists\325 opinions and practices. Patient Educ Couns 2006;61:152-)-75 (60.)]TJ
-0.024 Tc 0.024 Tw -1.21188 -1.35625 Td
[(5.)-476 (Hudmon KS, Corelli RL, Chung E, et al. Development and implementa-)]TJ
-0.00301 Tc 0.00301 Tw 1.21188 -1.23125 Td
(tion of a tobacco cessation training program for students in the health)Tj
-0.02499 Tc 0.013 Tw T*
(professions. J Cancer Educ 2003;18:142-9.)Tj
0.009 Tw -1.2125 -1.35626 Td
[(6.)-475 (Hudmon KS, Kroon LA, Corelli RL, et al. T)35 (raining future phar)-25 (macists at)]TJ
-0.0251 Tc 1.2125 -1.23125 Td
(a)Tj
-0.02499 Tc 0.01801 Tw 0.66135 0 Td
(minority educational institution: evaluation of the Rx for change tobac-\)Tj
0 Tc 0.13699 Tw -0.66135 -1.23125 Td
(co cessation training program. Cancer Epidemiol Biomarkers Prev)Tj
-0.02499 Tc 0 Tw T*
[(2004;13:477-)-25 (81. )]TJ
-0.01199 Tc 0.01199 Tw -1.1994 -1.35625 Td
[(7.)-488 (Rx for change: clinician-assisted tobacco cessation. http://rxforchange.\)]TJ
-0.02499 Tc 0.013 Tw 1.1994 -1.23125 Td
(ucsf.edu/ \(accessed 2008 Sept 4\).)Tj
0 Tc 0 Tw -1.1875 -1.35625 Td
(8.)Tj
0.045 Tw 1.25 0 Td
[(White paper on phar)-22.9 (macy technicians 2002: needed changes can no)]TJ
-0.02499 Tc 0.013 Tw -0.0625 -1.23126 Td
(longer wait. J Am Phar)Tj
-0.0251 Tc 8.77194 0 Td
(m)Tj
-0.02499 Tc 0.99039 0 Td
(Assoc 2003;43:93)Tj
0 Tw 6.88658 0 Td
(-104.)Tj
-0.01401 Tc -17.85028 -1.35626 Td
(9.)Tj
0.01401 Tw 1.20841 0 Td
(Ferro LA, Marcrom RE, Garrelts L, et al. Collaborative practice agree)Tj
0 Tc 27.22264 0 Td
(-)Tj
-0.02499 Tc 0 Tw -27.22968 -1.23126 Td
[(ments between phar)-25 (macists and physicians. J Am Phar)-25 (m Assoc 1998;38:)]TJ
T*
(655)Tj
0 Tc 1.4499 0 Td
(-)Tj
-0.02499 Tc 0.38271 0 Td
(64.)Tj
-3.52011 -1.35626 Td
(10.)Tj
-0.00999 Tc 0.013 Tw 1.64999 0 Td
[(Delaware Phar)-22.7 (macists Society)]TJ
-0.0101 Tc 11.86532 0 Td
(.)Tj
-0.00999 Tc 0.49234 0 Td
[(Smoking cessation program. www)69.2 (.)]TJ
-0.02499 Tc -12.32014 -1.23127 Td
[(dephar)-25 (macy)65 (.net/smokingcessation/index.htm \(accessed 2008 Sept 10\).)]TJ
-0.013 Tc -1.6875 -1.35625 Td
[(1)35 (1.)-487 (Hudmon KS. Phar)-25 (macists for tobacco cessation. San Francisco: Rx for)]TJ
-0.02499 Tc 1.6875 -1.23125 Td
(Change, February 2005.)Tj
-0.007 Tc 0.007 Tw -1.6875 -1.35625 Td
[(12.)-493 (Dent LA, Harris KJ, Noonan CW)89 (. T)70 (obacco interventions delivered by)]TJ
-0.022 Tc 0.022 Tw 1.6875 -1.23125 Td
[(phar)-25 (macists: a summary and systematic review)65 (. Phar)-25 (macotherapy 2007;)]TJ
-0.02499 Tc 0 Tw 0 -1.23126 TD
[(27:1040)-75 (-51.)]TJ
0.008 Tw -1.6875 -1.35625 Td
[(13.)-475 (Howard-Pitney B, Killen JD, Fortmann SP)110 (. Quitting chew: results from a)]TJ
0 Tc 0.054 Tw 1.6875 -1.23125 Td
[(randomized trial using nicotine patches. Exp Clin Psychophar)-25 (macol)]TJ
-0.02499 Tc 0 Tw 0 -1.23125 TD
(1999;7:362-71.)Tj
-0.022 Tc -1.6875 -1.35625 Td
(14.)Tj
0.022 Tw 1.6619 0.00001 Td
[(Maguire T)81.2 (A, McElnay JC, Drummond A. A randomized controlled trial)]TJ
-0.002 Tc 0.002 Tw 0.0256 -1.23126 Td
[(of a smoking cessation intervention based in community phar)-25 (macies.)]TJ
-0.02499 Tc 0.013 Tw T*
(Addiction 2001;96:325)Tj
0 Tc 8.8173 0.00001 Td
(-)Tj
-0.02499 Tc 0 Tw [0.3 (31.)]TJ
-0.01401 Tc 0.01401 Tw -10.5048 -1.35625 Td
[(15.)-486 (V)61 (ial RJ, Jones TE, Ruf)20 (fin RE, Gilbert AL. Smoking cessation program)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.23125 Td
(using nicotine patches: linking hospital to the community)Tj
-0.0191 Tc 21.95231 0.00001 Td
[(.)-249.9 (J)]TJ
-0.019 Tc 0 Tw 1.10064 0 Td
(Phar)Tj
-0.0192 Tc 1.78159 0.00001 Td
(m)Tj
-0.019 Tc 1.00866 0 Td
(Prac)Tj
-0.02499 Tc 0.013 Tw -25.84319 -1.23127 Td
[(Res 2002;32:57-)-75 (62.)]TJ
0 Tw -1.6875 -1.35625 Td
(16.)Tj
0.02299 Tw 1.64999 0.00001 Td
(Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patch)Tj
0 Tc 27.26725 0.00001 Td
(-)Tj
-0.024 Tc 0.024 Tw -27.22974 -1.23127 Td
[(es in smoking cessation: a randomized trial among over)20 (-)1 (t)1 (h)1 (e)1 (-)1 (c)1 (o)1 (u)1 (n)1 (t)1 (e)1 (r)1 ( )1 (c)1 (u)1 (s)1 (-)]TJ
-0.02499 Tc 0.013 Tw T*
[(tomers in Denmark. Am J Epidemiol 1997;145:309)-25 (-18.)]TJ
0.011 Tw -1.6875 -1.35625 Td
[(17.)-475 (Sinclair HK, Bond CM, Lennox AS, Silcock J, W)40 (infield AJ, Donnan PT)75 (.)]TJ
0 Tc 1.6875 -1.23125 Td
(T)Tj
-0.00101 Tc 0.00101 Tw 0.57496 0.00001 Td
[(raining phar)-25 (macists and phar)-25 (macy assistants in the stage-)-75 (of-change)]TJ
-0.01199 Tc 0.01199 Tw -0.57496 -1.23125 Td
(model of smoking cessation: a randomised controlled trial in Scotland.)Tj
-0.02499 Tc 0.013 Tw 0 -1.23127 TD
[(T)70 (ob Control 1998;7:253)-25 (-)-74 (61.)]TJ
0.008 Tw -1.6875 -1.35625 Td
[(18.)-475 (Carroll P)110 (, Rois R, Sarson D, Flynn J. A community phar)-25 (macy-based pro-)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.23125 Td
[(gram using transder)-25 (mal nicotine replacement therapy\321actions and out-)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23125 TD
[(comes. Aust Phar)-25 (macist 2000;19:51)50 (-5.)]TJ
-0.02 Tc 0.02 Tw -1.6875 -1.375 Td
[(19.)-480 (Roth MT)75 (, W)80 (estman EC. Use of bupropion SR in a phar)-25 (macist-managed)]TJ
-0.035 Tc 0.013 Tw 1.6875 -1.25 Td
[(outpatient smoking-cessation program. Phar)-25 (macotherapy 2001;21:636)-25 (-)-125 (41.)]TJ
-0.00301 Tc 0.00301 Tw 30.5625 85.61551 Td
[(20.)-497 (Zillich AJ, R)40 (yan M, Adams A, Y)100 (eager B, Farris K. Ef)20 (fectiveness of a)]TJ
-0.01601 Tc 0.015 Tw 1.6875 -1.23312 Td
[(phar)-25 (macist-based smoking-cessation program and its impact on quality)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23313 TD
[(of life. Phar)-25 (macotherapy 2002;22:759)-25 (-)-75 (65.)]TJ
0 Tc 0.019 Tw -1.6875 -1.35812 Td
[(21.)-500 (Smith MD, McGhan WF)80 (, Lauger G. Phar)-25 (macist counseling and out-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23313 Td
[(comes of smoking cessation. Am Phar)-25 (m 1995;NS35:20)-75 (-9.)]TJ
-0.017 Tc 0.017 Tw -1.6875 -1.35812 Td
[(22.)-483 (Isacson D, Bingefors C, Ribohn M. Quit smoking at the phar)-25 (macy\321an)]TJ
-0.0231 Tc 1.6875 -1.23313 Td
(e)Tj
-0.02299 Tc 0.02299 Tw (valuation of a smoking cessation programme in Sweden. J Soc Admin-)Tj
-0.02499 Tc 0.013 Tw 0 -1.23312 TD
[(istrative Phar)-25 (m 1998;15:164)-75 (-73.)]TJ
0.004 Tw -1.6875 -1.35812 Td
[(23.)-475 (Doescher MP)110 (, Whinston MA, Goo A, Cummings D, Huntington J, Saver)]TJ
0 Tc 0.02 Tw 1.6875 -1.23313 Td
(BG. Pilot study of enhanced tobacco-cessation services coverage for)Tj
-0.02499 Tc 0.013 Tw 0 -1.23313 TD
[(low-income smokers. Nicotine T)70 (ob Res 2002;4\(suppl 1\):S19)-25 (-)-25 (24.)]TJ
-0.01801 Tc 0.01801 Tw -1.6875 -1.35812 Td
[(24.)-482 (Kennedy DT)75 (, Giles JT)75 (, Chang ZG, Small RE, Edwards JH. Results of a)]TJ
-0.022 Tc 0.022 Tw 1.6875 -1.23313 Td
[(smoking cessation clinic in community phar)-25 (macy practice. J Am Phar)-25 (m)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23312 TD
[(Assoc 2002;42:51)50 (-)-75 (6.)]TJ
-0.008 Tc 0.008 Tw -1.6875 -1.35813 Td
[(25.)-492 (Huntzinger PE. SMOKED: a phar)-25 (macist-monitored tobacco cessation)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23312 Td
[(program. Mil Med 2002;167:1001)50 (-5.)]TJ
0 Tc 0.009 Tw -1.6875 -1.35813 Td
[(26.)-500 (Dent LA, Scott JG, Lewis E. Phar)-25 (macist-managed tobacco cessation)]TJ
-0.024 Tc 0.02299 Tw 1.6875 -1.23312 Td
[(program in V)110 (eterans Health Administration community-based outpatient)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23313 TD
[(clinic. J Am Phar)-25 (m Assoc 2004;44:700)-75 (-14.)]TJ
0 Tc 0.08 Tw -1.6875 -1.35812 Td
[(27.)-500 (Roth MT)75 (, Andrus MR, W)80 (estman EC. Outcomes from an outpatient)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23313 Td
[(smoking-cessation clinic. Phar)-25 (macotherapy 2005;25:279)-25 (-)-25 (88.)]TJ
-0.02299 Tc 0.02299 Tw -1.6875 -1.35812 Td
[(28.)-477 (Society for Research on Nicotine and T)70 (obacco. Biochemical verification)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23313 Td
[(of tobacco use and cessation. Nicotine T)70 (ob Res 2002;4:149)-25 (-59.)]TJ
-0.017 Tc 0.017 Tw -1.6875 -1.35812 Td
[(29.)-483 (V)111 (eterans Health Administration. Montana Regional Healthcare System.)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23313 Td
[(V)110 (ets W)40 (ithout Cigarettes Smoking Cessation Program. 2000.)]TJ
-0.019 Tc 0.019 Tw -1.6875 -1.35813 Td
[(30.)-481 (Prochaska JO,)-482 (V)110 (elicer WF)80 (. The transtheoretical model of health behav-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23312 Td
[(ior change. Am J Health Promot 1997;12:38)-25 (-)-125 (48.)]TJ
-0.02 Tc 0.02 Tw -1.6875 -1.35813 Td
[(31.)-480 (Glanz K, Rimer BK, Lewis FM, eds. Health behavior and health educa-)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23313 Td
[(tion. 3rd ed. San Francisco: John W)40 (iley & Sons, Inc., 2002. )]TJ
-0.006 Tc 0.006 Tw -1.6875 -1.35813 Td
[(32.)-494 (Fiore MC, Ja\216n CR, Baker TB, et al. T)35 (reating tobacco use and depen-)]TJ
-0.03999 Tc 0.005 Tw 1.6875 -1.23312 Td
(dence: 2008 update. Clinical practice guideline. Rockville, MD: US Depar\t-)Tj
0.013 Tw 0 -1.23312 TD
(ment of Health and Human Services, Public Health Service, May 2008.)Tj
-0.00101 Tc 0 Tw -1.6875 -1.35813 Td
(33.)Tj
0.00101 Tw 1.74655 0 Td
(Lichtenstein E, Glasgow RE, Lando HA, Ossip-Klein DJ, Boles SM.)Tj
-0.02499 Tc 0.021 Tw -0.05905 -1.23313 Td
[(T)70 (elephone counseling for smoking cessation: rationales and meta-analyt-)]TJ
0.013 Tw T*
[(ic review of evidence. Health Educ Res 1996;1)35 (1:243)-25 (-57.)]TJ
-0.02 Tc 0 Tw -1.6875 -1.35813 Td
(34.)Tj
0.02 Tw 1.67175 0 Td
(Hughes JR, Keely JP)Tj
-0.01961 Tc 8.01977 0 Td
(,)Tj
-0.02 Tc 0.48029 0 Td
(Niaura RS, Ossip-Klein DJ, Richmond RL, Swan)Tj
-0.008 Tc 0.008 Tw -8.48432 -1.23313 Td
(GE. Measures of abstinence in clinical trials: issues and recommenda)Tj
0 Tc 27.22991 0 Td
(-)Tj
-0.02499 Tc 0.013 Tw -27.22991 -1.23313 Td
[(tions. Nicotine T)70 (ob Res 2003;5:13)-25 (-)-25 (25.)]TJ
-0.022 Tc 0.022 Tw -1.6875 -1.35813 Td
[(35.)-478 (Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-)]TJ
-0.006 Tc 0.006 Tw 1.6875 -1.23312 Td
(release bupropion for smoking cessation in African Americans: a ran-)Tj
-0.02499 Tc 0.013 Tw T*
[(domized controlled trial. JAMA 2002;288:468)-25 (-74.)]TJ
-0.01401 Tc 0 Tw -1.6875 -1.35813 Td
(36.)Tj
0.01401 Tw 1.69243 0 Td
(Harris KJ, Grobe J, McCarter K, et al. Smoking while in college: base-)Tj
-0.00493 -1.23313 Td
[(line analysis from a longitudinal survey)65 (. Presented at: Eighth Scientific)]TJ
-0.028 Tc 0.013 Tw T*
[(Meeting of the Society for Research on Nicotine and T)70 (obacco, Savannah,)]TJ
-0.02499 Tc 0 -1.23313 TD
(GA, Feb 22, 2002. )Tj
-0.02299 Tc 0.02299 Tw -1.6875 -1.35812 Td
[(37.)-477 (Harris KJ, Okuyemi KS, Catley D, Mayo MS, Ge B, Ahluwalia JS. Pre-)]TJ
-0.00101 Tc 0.00101 Tw 1.6875 -1.23313 Td
(dictors of smoking cessation among African-Americans enrolled in a)Tj
-0.02499 Tc 0.013 Tw T*
[(randomized controlled trial of bupropion. Prev Med 2004;38:498)-25 (-502.)]TJ
-0.01601 Tc 0 Tw -1.6875 -1.35813 Td
(38.)Tj
0.01601 Tw 1.68564 0.00001 Td
[(HeathertonTF)80 (, Kozlowski L)90 (T)75 (, Frecker RC, Fagerstrom KO. The Fager-)]TJ
-0.007 Tc 0.007 Tw 0.00186 -1.23313 Td
(strom test for nicotine dependence: a revision of the Fagerstrom toler-)Tj
-0.02499 Tc 0.013 Tw T*
[(ance questionnaire. Br J Addict 1991;86:1)35 (1)35 (19)-25 (-)-24 (27.)]TJ
-0.002 Tc 0.002 Tw -1.6875 -1.35812 Td
[(39.)-498 (Cohen S, Kamarck T)75 (, Mer)-25 (melstein R. A global measure of perceived)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23312 Td
(stress. J Health Soc Behav 1983;24:385)Tj
0 Tw 15.02285 0.00001 Td
(-96.)Tj
-0.022 Tc 0.022 Tw -16.71035 -1.35814 Td
[(40.)-478 (Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for de-)]TJ
-0.006 Tc 0.006 Tw 1.6875 -1.23313 Td
(pression in well older adults: evaluation of a short for)Tj
-0.0061 Tc 21.15163 0.00001 Td
(m)Tj
-0.006 Tc 1.0218 0 Td
(of the CES-D)Tj
-0.009 Tc 0.009 Tw -22.17344 -1.23313 Td
(\(Center for Epidemiologic Studies Depression Scale\). Am J Prev Med)Tj
-0.02499 Tc 0 Tw 0 -1.23312 TD
[(1994;10:77-)-24.2 (84.)]TJ
-0.02 Tc 0.02 Tw -1.6875 -1.35812 Td
[(41.)-480 (Miller WR, Rollnick S. Motivational interviewing: preparing people for)]TJ
-0.02499 Tc 0.013 Tw 1.6875 -1.23313 Td
[(change. 2nd ed. New Y)100 (ork, NY)90 (: The Guilford Press, 2002.)]TJ
0.00999 Tw -1.6875 -1.35812 Td
[(42.)-475 (Boardman T)75 (, Catley D, Mayo MS, Ahluwalia JS. Self-ef)20 (ficacy and moti-)]TJ
-0.019 Tc 0.019 Tw 1.6875 -1.23312 Td
(vation to quit during participation in a smoking cessation program. Int \J)Tj
-0.02499 Tc 0.013 Tw 0 -1.23313 TD
(Behav Med 2005;12:266)Tj
0 Tw 9.46799 0.00001 Td
(-72.)Tj
-0.015 Tc -11.15549 -1.35813 Td
(43.)Tj
0.015 Tw 1.69019 0.00001 Td
(Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal.)Tj
-0.02499 Tc 0.013 Tw -0.00269 -1.23313 Td
[(Arch Gen Psychiatry 1986;43:289)-25 (-94.)]TJ
0 Tc 0.00101 Tw -1.6875 -1.35814 Td
[(44.)-500 (Hudman KS, Hember)20 (ger KK, Corelli RL, Kroon LA, Prokhorov A)130 (V)130 (.)]TJ
-0.02299 Tc 0.022 Tw 1.6875 -1.23312 Td
[(The role of the phar)-35.8 (macist in smoking cessation counseling: perceptions)]TJ
-0.02 Tc 0.02 Tw 0 -1.23312 TD
[(of nonprescription nicotine replacement therapy users. J Am Phar)-25 (m As-)]TJ
-0.02499 Tc 0.013 Tw T*
(soc 2003;43:573)Tj
0 Tc 6.30081 0.00001 Td
(-)Tj
-0.02499 Tc 0 Tw [0.3 (82.)]TJ
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.024 Tc 10 0 0 10 60.5 23.9116 Tm
(200)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(LA)-250 (Dent et al.)]TJ
ET
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 291.13251 11 Tm
( at Library - Periodicals Dept on January 20, 2016)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
40 0 obj
<</BaseFont/UJKZYV+Helvetica-Bold/Encoding 37 0 R/FirstChar 32/FontDescriptor 39 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 889 0 0 333 333 0 0 278 333 278 278 556 556 556 0 0 556 0 0 0 0 333 0 0 584 0 0 0 722 722 722 722 667 611 778 722 278 556 722 611 833 722 778 667 0 722 667 611 722 667 944 0 667 611 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 0 278 889 611 611 611 0 389 556 333 611 556 0 0 556]>>
endobj
28 0 obj
<</BaseFont/CNXLVS+Helvetica/Encoding 25 0 R/FirstChar 32/FontDescriptor 27 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[278 0 0 556 0 889 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 584 584 0 0 1015 667 667 722 722 667 611 778 722 278 500 667 556 833 722 778 667 778 722 667 611 722 667 944 0 667 0 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 0 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 584 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 222]>>
endobj
25 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 35/numbersign 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal 64/at/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W 89/Y 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 177/plusminus 213/quoteright]/Type/Encoding>>
endobj
27 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-166 -224 1000 931]/FontFile3 26 0 R/FontName/CNXLVS+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
26 0 obj
<</Length 5783/Length1 5783/Subtype/Type1C>>stream
  CNXLVS+Helvetica   @¯ ¯¯¯¯˚:˚t˙|˙7
 ãã
 ãã   Û   Ô  ä¨  v Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  J  " - B S Z  % F O U  , J + P ) T E $ V 8 / I G N Q W Y  D C M 0   H [ 6 4  L 5 X 7 3 . 1    R     	   
 (     *  # ú : 2 ' &   ! L   < S ﬂeh≠
L}¨›ˇ3z©#Çﬂaå∆ˇ^¬Í'7â„¯Lp«	I	p	´
,
C
v
ì
—
˙\∑˘s∫2ëÎ$§.gÖ∫ˆ`ë?\qå¯&QΩ‡(ôPú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç-ã·˘w◊Ï¯¨·˚ˇ˘*˝a-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ˚*˚j⁄˘&wñ¯q¯|¯ü+˚!¸?â˚¯?(˜V¸¨b˚Çdãv|éëv<ÖõóàúÚõ†˜_ÿÔ˜úêñﬁ˜Ç¸”ã›¯Ω›‹Ì¯Ó˘5¯˜g˚˜˚J˚∑˝a˜≥˜R˜˜˜z(Ö˚A< ˚˚O¯Ω˜I˜5¿˚˚-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥¸ãı6v‚ÛXæ–˜SìÌ‡#!–¿‡äHscÅ]”õ´ªÊú†v˘aw÷Ï˘)˚«¯@˜æ˜µ˚˚Ô˚˜*˝aÏ˜è˜˜˜è˚¸¸@†v¯üw˜ÌŒ„˜/¯ˇÌ3)„¸ˇ¯ü3¸ü˚*x›˘"wúÂ˜sÏ¯?˜V¯ü*¸•7fb>Bg≤⁄Ω1D˚ÿG˜˜÷Ÿ˜-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚”†v˜·‚˜ΩwÿÏ*Ì¯
ÏÙ˘˘a*˚Ω¸˜Ω*˝aÏÌ˜·¯
˚·˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛ-|◊cv¯_Ÿ˜HwÆÂ˜±„4‚:‹y¯Ü˘a˙4˚°âŒ[d°E˚7&˚5˚E‰˚˜!œªß≈≠yçD¸Ñ˜â˚TD24Uÿ˜˜∫ÀÍÊø>˚”w·¯›‡∑Ó¯HÁ5ÈË˘;˜ú-˚qCH˚˚&8˜˜R˜GÁˆ˜+ÔœV*§Á˜*s!‡˚7˚a˚˚%˚x˚Ç˜˚%˜\Ë˜?˜	ı˜F§-|◊cv¯üwœ‚˜â„8ﬁÙ¯|¯ü¯3˚¥ TH2Hi≤◊˜Ô4¸%…Oˆ€¥¢—∏Ùç=˜∫†v˘awõ˙"˙2˘a ˚¸€â˚4¯€"˚6¸€â˚¯€#˜O˝a˜:¯Áéå˜7¸ËÒ”†v˘aw◊Ë¯Í˘˘a,¸◊â˚˙¯◊˚˝aË¯ÿç¯¸ÿ-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È¸†v¯U’˜awﬂ„˜ò¯U’3Ã∂õû∞ìîäâù⁄åwÄåÇ/_f=1EA—¸U„¯U˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê-˚Lv˜R◊¯#⁄{w≈ﬁ8„3ﬂ˜±ÂÈ¯ô˜®˜24Ù˚H^qL`â˘‘8˝lÂ„˜òçWµÆy»˜#„˜˜H1Ö˚X?0„2U–˜˜!º’ÁÍºJ˚˚*†v¯üwì¯w¯¯ü+˚(¸=âä˚¯>'˜R¸üË˚*†v¯üwò¯r¯˚L˜†˜E˜ì˚ ˚˚M˚˜M˚˜B˚ì˚K˚†˜˜˜Y˜˚Y¸ãı‚Û˜Sı#!˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô-{ÿcv¯`Ÿ˜Gw≈„3ﬂ˜±Âz¯ô˜®˜24Û˚MZqTcâ˜ò3˝aﬁÃçˆN∏ØwŒ˜Â˜˜D1É˚W?13T“˜˜Ω◊ÊÍºI˚¸@†v˘awŒ„˜/˘a3˝a˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚d˚"˚-˚u˚v˜ ˚,˜f˜e˜ ˜,˜v(˚A%˚
˚(˚)%˜
˜A˜EÔ˜˜+˜*Ô˚	˚D-†v¯Ü“˜w˜úÍ¯Ü˜7¸ÜÍ˘REp$qx˚Ä-x◊˜–⁄˜*·´Â˜ΩË¯î˜x˜(Î˚Tfk^™˜V˜Ω·˚ˇW¸÷ÜµºÆù¿ãÊÃK1*LJ/;\≤Ÿ|1˚ú◊K˜˜1ÏÈ˜--˚n”˜◊¯!€|w≥Ê@„˜ü„7ﬂ9›‘Ä¯á∂¯t9@˘ âÃ^^§H˚4"˚0˚D‰˚˜“µ†¿´ˆ çu˚cZ˚Hg§ƒ}3"úÕZ˜˜7’›˜G˘ 7˜b˚WH/5Uÿ˜˜ªŒÁÈΩC˚˚*ã”¯’™¯I¯h”˚’˜Õ¯’¸)A˜∂˚Œ¸F”x·˘w⁄Ï¯Î˘˜ë¯d+¸Y˚FC˚˚I”˜¯V*¸r˚1˜ &˜<˜F˜Ú˜=úxﬁ˜ãŸ`Â˜nﬁºÊGË˜ÍÊCË’¯ˇ˜YÔQœ#£ˆ˚a∫Qòn¨ãΩ÷ ∫˜«Z*îÊ˜/Ä3’˚B˚2,7˚3øSÒsŸ˜&h˜
oØpãN4L_˚˚D∆ˆà0åçDïe©dGøŸi˜ ˜Kˆ€˜˚—†v˜{Â∑˜à˜¥˜{Â˚à1˚*†v¯üw˜jwŒ‡¯â˚h˜€˜\˜X˚˚v˚q¯36˝a‡˜Z‘Õ˜7˚úd†v˘‡˜ïÎ¯Á˘‡¸Ÿ6˜á˝Î˘”†v¯üwõ˘I˘Y¯ü4 ¸.â&¯.)&¸.â'¯.,˜+¸üÂÒ¯)çÙ¸)Êú†v˘awü˘˘˘a˚˚^¸˜â˚b¯˜ ˜ö˝aÚ”†v˜«ﬁ˜ä‹„Î¯Ó˘>õoöÖóâ∏Ö˜á◊y©Kß÷π§∂ã‡ã˜6–˚*ã˚ﬂ˝aÎ˜«˜ÊÆi.çé˚å}òRÇ¯ô6[a*˚v˜ä˜áﬁ∏a>˜K†v˘aw‘Ë.Ê¯äÈ/Á‰˘å˘a˚˚_¸Òâ˚a¯Ò˚˝aË¯<‘«â∆ã«Ëç˜_¸ÔÎ˜]¯‰çËä˚	ä∫;ããã¸Zú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;-x⁄˜ú‘˜w⁄≠Á˜™ÂIÈÙ¯û˜bﬁiª8≠ç¯√†¨øŒ˜6’˚˚(FD˚3É·˜ ì≤∂„›Ω`DAYd,~Öãçz?åõìãéÙ˜¬c39MU+*`π˜á/˚6ô”C˜(˜/Ó„˜-w€¯«⁄∞Ë˜∫Ë¯ô˜È˜}6˜˚/˚/6˚˚}˚z‚˚˜-˜-‚˜˜z.˚KX)++XÌ˜K˜OΩÍÏÏΩ+˚N-x⁄˜…⁄˜E⁄±‰2Ú˜ß‡AÂÚ¯ô˜q˜1Ë˚@VpOdàçï˜?«ÊÒãÏÀ≥fCò‡Ü«~´i≠e≤Q¢Rã˚5ã*˚#ã˚ã˚v·˚˜7ãÍ˜ÏÒ˜1Ü0RJ94OÀÁÁƒ»‡„√P--˚Nv˜T◊¯"⁄|wÆÊ˜≠‚7ﬂ8ﬁŸ¯Ç˚c˘n8Aâ¸…a\¶G˚4"˚1˚G„˚˜!»≥üº≥ç˚ô˙é¯Y˚UF14Vÿ˜˜∫ÕÁÈæA˚-ã›¯±⁄•Ó:‚˜ØÁË¯é›¸òÀª≥∆´‘≥Ô¬„º˜˜3ﬁ˚ÿ˚3?$˚)‚˜ë∏¡Â‡ƒW=Dmk&Q/VË˚Fc5Ö˚-†v¯Ì·˜Í¯û¯ˆÿ¸y5¯@1W:U˚O˚l/}#Í≠˜4¢“¡˜ ƒ˜¿⁄–ÿ-x⁄˜¢◊˜oŸ±ËEÊ˜åÊGËÍ¯ò˜`Ÿh¿;≤ÏÀ¨•¥Œ˜5’˚˚7?˚I®aÕmÚ5ck[/˚Ó4˜!˜$È„˜Ï˚˜—HV[BEWªÃÃπ¥—‹æcKÚ¢˚⁄5XZ1.Q¡‚◊«¿‡ÂƒV9˜Éçvò—˜\—°—˜]—≤—˜]—˜—˜]—Ä˘Â˜8È?◊,-??--◊?ÈÍ◊◊È˚J¯∞UˇÄ¸˝g¡ˆ¯µÍ?◊-,??,-◊?ÍÈ◊◊ÈÄ¯#˚˛T^^ST^∏¬¬∏∏¬√∏^T¸i˜˛T^^TS^∏¬√∏∏√¬∏^S˚—˚Mv˙>wœË˜ø˚b<˜2P˜˜J˜D≥˜Î˜;O˚˚B]˚˚=˚V—˚Ú˚0Iª¯{¯´ñ€¸˜6¯˜6€¸{˚dE-†v˜>◊¯]w˜ﬂ„¯ù˜>◊%¯]B˚’¸R4˜∆˚>„˜>3◊˚u˜t˜‘å˚—˚Nv˙>w˜@Ë˜ù˜ù˜VE˜$˜0Q⁄˚2∆˚˚J˚Dc˚+˚;«˜˜Bπ˜˜=˜xﬁ`v˜¡ﬁ˜ü‡ªÔ¯eÂ|˘S¯˚Œ8˜tà@Ågqf¸PcJm8˚09Ò˜V˜EÈ˜˜'˜ –Y&´Ë˜(o˚„˚7˚b˚˚,˚˚o˜˚)˜TˆÿÆÿ…|£.¸@†v¯¯Ù¿ÛXæ–˜1˘ Ï‡#"–¿‡äHscÅ]”õ´ªÊ-x‘˜I⁄˜ÀŸµÂ9‚˜¶Ò4‚Ú¯ï¯˜k7˜˚6˚1+˚%˚‡2˜Ÿ¡¶ƒÆçân˚X`H)ãÍEa¥’Ñ4˚î‘I˜÷∆®≈µΩŒ®˜˜Ù%Ì#XR.6Y¡ÁÒø ﬂ‚√P0¸†v¯/ı‚ÛXæ–˜S¯/ı‡#!Û¸'Ì#!–¿‡äHscÅ]”õ´ªÊ¸ãı˜≈ı‚Û˜S¯/ı#!Û¸/ı#!¸†v˘awÊÏ˜P˘a*˝a¸çv˘áwz˜Ã˜ª˘tI˚ä˝áŒúãﬁ˜êŸ˜r›‘Ï˜ÿÎMÎ¯˘˜l‡gª-±Õ≠©ª–ˆ:”˚˚Œ˝a˜ Ù˜%Î·˜¯˚˜À?Ye(˚C˜r˜CÔºgCÙ≠˚Õ7U\*˚c˜ê˜R˜≈b;Iã”˜\‘˜ì‘¯¥˜§‘˚l˜5B˚5˚lB˜l˚5‘˜5˜l˚§”¸çCú†v˘aw˜±Ï˘˘a˚˚a˚Ï˚c˜Ï˚˜£¸A˚¥Ï˜¥˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚e˚!˚-˚u˚v˜ ˚,˜f”√ö¨√˜6º≈)÷—÷≠Ëã˜(/o>WU1—ZO’Ra{qÜeã˚(%˜
˜A˜DÔ˜	˜+˜*Ô˚	˚Dd†v˜Ÿ·˜p··Ï¯⁄˘·¸Ñ˝aÏ˜Ÿ˜Ù·˚Ù˜púã·˜Ö‡˜p‡·Ï¯¸·¸E˜Ö¯‡¸˜p¯<‡¸ù˝aI†v˜‘˜‘≤¯å¯≥˜“‘¸åB¯å˚`‘¸åB-†v˜f ˜! ß¯á¯£¯q%®˜gHn˚g˚®˜gHn˚g$ÇLÛw˚!%ÇLÒn˚fŒ®˜f˜n˚fŒ®˜fÚì %û˜!Ò˚=x˚!˚û˜!¯x…ËÃJ‘˜∏”Ò»˜'‘◊ﬁ¯:Ãﬂ˘ˆ¯>˜C˚*˜˚V˚e˚:˚:˚d˚k˜:˚:˜l˜˜Œ˜ I@H8d/˚B˚˜˜C˜K˜˜˜A˜3˜˚˚$ F˚Cyäöö§ßÈ»˜cGwMlƒj†Wã˚$˚˚,5ÕAÿ∂¨òΩªçaè†v±Æ¿¢¨¥“∆±›Ëˇ˚ìy*>%A[j≥ƒÏ’Ì‘π≤`Yu°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
37 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two 53/five 58/colon 61/equal 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P 82/R/S/T/U/V/W 89/Y/Z 97/a/b/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v 121/y]/Type/Encoding>>
endobj
39 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262176/FontBBox[-170 -227 1001 963]/FontFile3 38 0 R/FontName/UJKZYV+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
38 0 obj
<</Length 4463/Length1 4463/Subtype/Type1C>>stream
  UJKZYV+Helvetica-Bold   @¯ ¯¯¯¯˚>˚w˙}˙W
 ãã
 ãã      {≤  H Äçï002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  9  # " $ , ( 3 0 6 / %  + & 5 * 7  . ) 4 - : 8 F U I P E T  ; 1 ' J H V S   M D O B C Q N  W 	    
 Z    G ;   | ∑	;°XéΩ+cè±»Úı5_Ï3û <É ,ñºË-V~˜	>	É	±	∆	›
+
s
ÛSæ/Itπ·@ç’qéS”ã˜˜U˜˜0˜◊˜$˜Æ˜#˚˜)Ù˘0˜m‡m∫:±¯ Æ§¥Œ˜5”˚˚˝a˜≈ﬁ»ïû≠Ùœ±¥—€¯˚:˜¡XdmG˚C˜0˜?◊ÆtWÙú˚∫KafC˚M˜U˜Sœ≥iQ”†v˜'˜¯Qwü˘;˘O˚ë˘a˚A˚ë˝a˜1Ω˜'˜ùπ˚'3˜§˚LÁ˜∞ç”x˜¯É˜∑˘˘?˜â˚)*n_f6˚HÁ˜,˜4ÕÊ˜
ﬁµi1ß˜(˜-~˚˚A˚]˚˚'˚|˚|˜˚$˜^˜;ˆÊ˜A∞”†v˘aw‚˘˘e˚»¯=˜∑˜∏˚U˚•˚µ˜µ˚+˝a˜+˜á—”˜q˚œ˜x˜4v˜û˜˜u˜¯◊˜x˘[¯˚Ω˚˜9¯˚ oQY*˚AÁ˜0˜4ŸÏ˜◊∆_B°˜(˜)x˚Ê˚C˚i˚˚(˚z˚v˜˚+˜YÌÃ´Ÿ»xô0”†v˜Æ˜˜T˜◊˜(˜∏˜(˘9ûsîÑù¿˜HÄ©:Ø’©Øƒﬂ˜3⁄˚˚ˇå˝a˜'˜Æ˜/Óöy˚
çåFéoòZè¯ÜIgn:˚C˜T˜OŒ±hM˜x˜¯ä˜∑˘F˘r˜˙˜m˚˜6˚v˚u˚˚4˚o˚n˜	˚3˜x˜t˜˜4˜m˚*å˚0A,˚˚AÍ˜0˜/÷Î˜˜÷+˚/”x˜¯ˆw”¯÷˘˜é¯g˚,¸m/[^*;[¬Â¯e˚-¸p˚7ı*˜F˜TÒË˜D”†v˘aw–˜ ˜ƒ˜ ˘!˘a˚ ¸àâ˚±¯à˚1˝a˜ ¯îç˜∏¸î”ã˜¯i˜◊˜'˜»˜,˘?¯˜n'˜˚S˚–˝a˜À˜J˜˜%˜{˚,˚(M0'˚&¯i˜$˜¿@˚/˚—ã˜%˜r˜%Á˜*˜Ü¯˜%˚*˚%˜*¸˜%˚*˚%-y˜¯˙w°˜˜A˜*¯w˜d¯ë˚*¸ë?snNKs±Ú¶˚l˚OÃD˜A˜'◊ÿ˜)úã˜˜O˜˜+˜◊˜'˘ ˜¸!˜O˜˜˚˜+¯˜¸¢˝ad†v¯„˜˜z˜+¯Ë¯„˜¸⁄˚˜l¸„˜+¯„¸†v˘awÀ˜*˜j˘a˚*˝aú†v˘awû˘˘˘a˚/˚0¸≥âä˚.¯¥˚4˜Ü˝a˜#¸˜K†v˘aw–˜ ¯4˜˘ê˘a˚l˚¸…à˚¯…˚o˝a˜ ¯Ïç˜¸Ï˜(˜¯Ïç¸Ï”†v˜’˜˜§w“¯◊˘˘a˚*˚§˚´˜§˚*˝a˜*˜’˜´˚’úw˜˜I˜$˜'˜6˜≤˜"˚˜˜•˜#˚˜%’˘	˜lÚS√˚¨ˆ˚C∑Sôv†ã¥¿º¨◊Ê∫hBï˜#˜$Ñ ‚˚;˚A&8˚"˚*ıo˜nŸÿyÓt™vã^NYl&,Z∞ŸÉ˚"çCôd±aøSÂk˜ã˜@ã˜Áã˜$dã˜¯ﬂw◊¯é¯⁄˜˚¯¯ﬂ˚*˝aú†v˘awö˘˘˘a˚=˚!˚À˚*˜À˚D˜å¸S˚¢˜+˜°˜∫†v˘aw˜∑œ¨Ÿç⁄¨‘˙4˘a˚+b˚Cb˚Bg˚Dâh˜UçÉB˜Ë˚3N˚æîøZ˚´âh˜Sêt7˜˘˚3˜_˝a˜ ±˜N∂˜N©˜Pç™˚O≥˚P¥˚M˜#-}˜˜Ê˜˜¢˜#˚#˜ ˜p˜#Ù¯¢˜x§˜P2Ù˚5˚4.%˚D˚IÁ&˜9˜⁄¬˜Ø˚#cyny\ÏAdµ‰ÑÙ˜pÊ˚m⁄ò´¨  Øf@ï˚—Öı˜ﬂÔ›˜ ˜»àıâ|Ñä^Ñë±˜≥·Ô5˜%˚ ˚%C'”˚’7≥kÚùûôåç´d†v¯@˜˜>wÃ˜˚˜ ˜]˜Ù¯µ¯˜C—˚CVnUoà˜ë˚˝aÏ˜ ˜≈ﬂ≥≤’∆ßjC˚◊d}˜	˜Ÿ˜
≠˜#˜ï˜#¯’˜û˜?!˜˚9˚:!˚˚?˚AÛ ˜<˜;Û˜ ˜@˚# _S76_√ˆÙ∏ƒﬂﬁ∏R"d}˜;v¯<˜˜?w≠˜$˜|˜˚˜z¯∏˘a¸˚˚ìâ ^d†D˚5˚ ˚;˚@‰˚˜œæ¶¡ÆçzH˙é˜ò&^Q=E^ ÏÛµ∆÷⁄µR -}ı˜ı©˜#˚˜˚˜˜a˜ ‘¯ö˜9˜d˚·?ãÍ©´ù¿«®uZë˜˜Ñ;≈˚-˚;D ˚X˜› ã3ggxVÃ=h¢¬à‰˚#˚çÎE˜0˜#Ê–˜¸ã˜%˜(Õ˜jû˜˚*˚%ﬂÑDvrTxV£ªƒıdã˜¯e˜§¯ƒ¯›˜¸¯
¯n˜¸∑˚˜¸¸¸f˚ú†v˜ó˜˜h˜¯q˜)˘¯Ä˜4·˚˚‹˝a˜*˜ó˜@˜ÁÈ˜˚)âCfg@˚˜h˜
ÌÆo?d†v˜¡˜˜7˜◊¯ë¯›¯„˜¸ë˝a˜*˜¡˜Œ˜˚Œ˜7¸†v¯ßwﬁ˜–˜ ˜e¯Ê˜˚ ˚˜ ¸Ê¯ß˚ ¸ßd˚mı˜ ˜
˜…˜|w≥˜#˜z˜˚˜⁄¯º®¯ä˚<â¸ÀmX©D˚4!˚<˚?‚#˜!–¥£ƒ´éáL4hh>Ktò¥Å˚,#óﬁS˜'˜èí˜.Á˚˜Ñ*eR:G`«ÈÍ∂«Œ◊∑J1d}˜
8v¯ßwÕ˜ ˜[˜˚˜Ù¯≥¯ß¯˚˚«B`\IOm¨Ã˜›˚ ˚Ò˚ÕC˜÷æß»ØÙç@˚ô†v¯(˜"|wÀ˜˚˜ ¯¯%˜"éÜãÅJgp<_âÊ˚¸ßË˜ ˜®ﬂ∑∑ﬂñîäâü-†v¯}Ó˜w˜Å˜!˚˜Ë¯˘Z˚8Td w(–˜<¸}¸ã˜%À˜*˜j˜%˚*˚%¸†v˘aw–˜ ˜e˘a˚ ˝a-}˜˜€˜
≠˜$˜`˜!¯ü˜V˚!KjnSHg¡˜ı≥≈’∫©pPò˜!˜É+‘˚˚71$˚O˚?Â(˜/˜Âÿ˜ùd†v¯?˜|wÃ˜˚˜ ˜]˜Ù¯¥¯˜Dœ˚C_rH`âÙÿ˚¸ßÏ˜ ˜ƒÿµπ—«®iE˚◊-}ÔJv˜z‹˜˜®˜˜Q˜|¯°†uíÇ£ø˜¥Î;≈˚˚0FU˚Ä˜Ωèß£¿ ®x`t|}iÜ˚x${XRã*¸.ÀMÎ”≤ù∆…|åqçÅîp¸z˜SRS[K`q§≤ª°û“ò–òàä©úd}˜;v¯=˜˜>w»˜ ˚ ˜˜É˜#z¯’˜•˜72˜˚E]rQeâ˜ë˚ ˝a˜ŒéˆSÆªr–˜·˜˜D˚#Å*]JE@[…ÏÙ∑«◊÷∑O%d˚Nv˜U˜˜Ÿ˜{w…˜˚˜!˜{˜#Í¯’˜§˜82˜˚AcsF^â˙ÿ˚˝vÊ˜!˜¶çå≠Rπr–ã˜·˜˜D˚#Ç)^KEÍ?\∆È˜¥∆Ÿ÷∑O$˜É†v¯?˜
˚	˜
|wÀ˜ ˚ ˜˜E˜˜>˜ Î˘Ã¯˜C–˚O`qPfÁŒ_jûCF^pJgâ˜ÿ˚¸ßÎ˜ ˜◊–®Øƒ…¢n:˚“˜˜“Î”´∞…Ω•m@˚÷˚—†v˜k˜¶˜™˜≈˜k˜˚™˚-†v¯ßwò¯§¯±¯ß˚'˚¸â˚¯˚/˜T¸ß˜&˚—†v˘qwÆ˜$˜Õ˚bd‘|®|≠_Òv˜ ã˜ã˜°˜¥ÓöÆîü∏ﬁ&˚˚0S˚*˚;˚3∆˚0˜
˚+I†v„˜˜˜≥¯ã¯≥˜»˜¸ã˚¯ã˚p˜¸ã˚-x˜˜ô˜˜˜	¶˜˜`˜$¯ñ˜Ä˜0Ï˚ZgÄna•˜.˜¥˜	¸[¸˜ÜùÆ©õ∂ãÀ¥Y>:aVKQm™ŒÅ˚˚ï‚>˜ ˜*ÔÒ˜--x˜¯é˜´˜$˜_˜$¯ü˜Ó˜å=˜˚<˚;=˚˚å˚éÿ˚˜<˜=ÿ˜˜é˚$å˚RqK?@qÀ˜R˜P•À÷◊•K˚P˚—†v˘qw˜-˜$˜Ω˜û˜4R˜+˚˜0%≥@ônöjµ.¢˚ã˚ã˚x˚`'|gzleE˜	˜)≈˜1˜:-˚i˜˘wï¯£¯≠¯ß˚'˚ ¸â˚¯˚/˜X¸æ{K{|UãÖàãçs˚äßûäõ˜	ûû˜_—-ã˜¯h˜
´˜˜]˜ ¯í˜˚»®ƒ˜œ ≈¿ª®¬ã⁄ã˜(„˚'ã˚'ã<6Ü˚9˜Óè•¨“«≥bL4Gk˚4˚*jSÑ˚¸çv˘àwj˜Î˜ ˘u˚	˚v˝à˜˜ÉçvìÚ˜1ÚÜÚ˜1ÚßÚ˜1ÚÛÚ˜1ÚoÄ˘Ó˜?Ô:‹'&::'&‹:Ô‹‹˚J¯∞AˇÄ¸!˝n’˜¯∑:‹'&::&'‹:Ô‹‹ÔoÄ¯ ˚˘_hh`_hÆ∑∂ÆÆ∑∂Æh`Ä¸g˜˘`hh`_hÆ∂∑ÆÆ∑∂Æh_˚—†v¯EÌ‹˜·˜ ˜—¯EÌ0†øëìµ≤˜çhÄãq#XZ%_?)◊¸E˜ ¯Ewü¯ßö˜,óíüòã˜£ó¸|ãı
˜ å
_˜™˘
endstream
endobj
75 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
76 0 obj
<</OP false/OPM 0/op false>>
endobj
84 0 obj
<</A 85 0 R/Border[0 0 0]/Rect[250.388 9.0 292.133 16.0]/Subtype/Link/Type/Annot>>
endobj
85 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
60 0 obj
<</Annots 86 0 R/Contents 87 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 88 0 R/GS2 89 0 R>>/Font<</T1_0 16 0 R/T1_1 20 0 R/T1_2 24 0 R/T1_3 28 0 R/T1_4 32 0 R/T1_5 36 0 R/T1_6 40 0 R/T1_7 44 0 R/T1_8 48 0 R/T1_9 77 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
61 0 obj
<</Annots 90 0 R/Contents 91 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 92 0 R/GS2 93 0 R>>/Font<</T1_0 32 0 R/T1_1 16 0 R/T1_2 40 0 R/T1_3 54 0 R/T1_4 24 0 R/T1_5 20 0 R/T1_6 77 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
62 0 obj
<</Annots 94 0 R/Contents 95 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 96 0 R/GS2 97 0 R>>/Font<</T1_0 32 0 R/T1_1 40 0 R/T1_2 16 0 R/T1_3 20 0 R/T1_4 24 0 R/T1_5 58 0 R/T1_6 28 0 R/T1_7 54 0 R/T1_8 77 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
63 0 obj
<</Annots 98 0 R/Contents 99 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 100 0 R/GS2 101 0 R>>/Font<</T1_0 32 0 R/T1_1 40 0 R/T1_2 16 0 R/T1_3 54 0 R/T1_4 52 0 R/T1_5 24 0 R/T1_6 58 0 R/T1_7 20 0 R/T1_8 77 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
64 0 obj
<</Annots 102 0 R/Contents 103 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 104 0 R/GS2 105 0 R>>/Font<</T1_0 32 0 R/T1_1 40 0 R/T1_2 16 0 R/T1_3 20 0 R/T1_4 24 0 R/T1_5 58 0 R/T1_6 28 0 R/T1_7 77 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
65 0 obj
<</Annots 106 0 R/Contents 107 0 R/MediaBox[0 0 612 792]/Parent 59 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 108 0 R/GS2 109 0 R>>/Font<</T1_0 58 0 R/T1_1 24 0 R/T1_2 20 0 R/T1_3 16 0 R/T1_4 32 0 R/T1_5 40 0 R/T1_6 28 0 R/T1_7 77 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
106 0 obj
[110 0 R]
endobj
107 0 obj
<</Length 12933>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.013 Tw 8 0 0 8 323.7231 749.5293 Tm
[(Ef)20 (fectiveness of a Phar)-25 (macist-Delivered Smoking Cessation Program)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(199)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60 37.254 492 700.746 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.00999 Tc 0.00999 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(methodological design for measuring ef)20 (ficacy in tobacco)]TJ
0 Tc 0.00301 Tw 0 -1.23809 TD
(cessation interventions, which include randomized con-)Tj
-0.006 Tc 0.006 Tw 0 -1.2381 TD
(trolled trial, appropriate duration of follow-up, intent-to-)Tj
-0.02499 Tc 0.01601 Tw T*
(treat analysis to account for attrition, and biochemical veri-)Tj
0 Tc 0.01199 Tw 0 -1.23809 TD
[(fication. Moreover)40 (, this study was successful in recruit-)]TJ
0.034 Tw 0 -1.2381 TD
(ment and retention of participants, which are important)Tj
0.216 Tw T*
(prerequisites for conducting a rigorous evaluation of)Tj
0.13699 Tw 0 -1.23809 TD
(smoking cessation programs. The applicability of this)Tj
-0.006 Tc 0.006 Tw 0 -1.2381 TD
[(study would have the greatest impact within the V)130 (A sys-)]TJ
0 Tc 0.054 Tw T*
(tem, managed care setting, or other similar ambulatory)Tj
-0.02499 Tc 0.02499 Tw 0 -1.23809 TD
[(care site where a lar)20 (ge number of phar)-25 (macists practice and)]TJ
0.019 Tw 0 -1.2381 TD
(are empowered with an expanded scope of practice that al-)Tj
-0.01801 Tc 0.01801 Tw 0 -1.23809 TD
(lows for the ability to meet with patients and prescribe to-)Tj
-0.005 Tc 0.005 Tw 0 -1.2381 TD
[(bacco cessation medications. Phar)-25 (macists in community)]TJ
-0.021 Tc 0.021 Tw T*
(practice may need to develop collaborative practice agree-)Tj
-0.02 Tc 0.02 Tw 0 -1.23809 TD
(ments with physicians in the community to be able to pre-)Tj
-0.008 Tc 0.007 Tw 0 -1.2381 TD
(scribe tobacco cessation medications, excluding nicotine)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(gum and patches, which are available over)20 (-the-counter)40 (, de-)]TJ
-0.008 Tc 0.008 Tw T*
[(pending on phar)-25 (macy practice laws that vary among dif-)]TJ
-0.02499 Tc 0.01601 Tw 0 -1.2381 TD
(ferent states. Also, this study provides some additional evi)Tj
0 Tc 21.95296 0 Td
(-)Tj
-0.011 Tc 0.011 Tw -21.95296 -1.2381 Td
[(dence on the ef)20 (fectiveness of the immediate-release \(ver-)]TJ
0 Tc 0.34801 Tw 0 -1.23809 TD
[(sus sustained-release\) for)-22.6 (mulation of bupropion for)]TJ
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(smoking cessation.)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 135.307 448.1197 Tm
(46,47)Tj
ET
BT
/T1_4 1 Tf
-0.006 Tc 0.006 Tw 10.5 0 0 10.5 70.5 431.9197 Tm
[(Phar)-25 (macists are particularly well-suited to provide to-)]TJ
-0.02299 Tc 0.02299 Tw -1 -1.22857 Td
(bacco cessation interventions because of immediate acces)Tj
0 Tc 21.95307 0 Td
(-)Tj
-0.005 Tc 0.005 Tw -21.95307 -1.22858 Td
(sibility and ability to assist with counseling, initiation of)Tj
-0.00301 Tc 0.002 Tw 0 -1.22857 TD
[(drug therapy)65 (, and easy follow-up for support or medica-)]TJ
-0.004 Tc 0.00301 Tw T*
(tion-related problems. Moreover)Tj
-0.00349 Tc 12.88257 0 Td
(,)Tj
-0.00301 Tc 0.49645 0 Td
(this study supports the)Tj
-0.00999 Tc 0.009 Tw -13.37902 -1.22857 Td
(findings reported in the Clinical Practice Guideline)Tj
ET
BT
/T1_3 1 Tf
-0.007 Tc 0 Tw 6 0 0 6 270.0384 370.7198 Tm
(32)Tj
ET
BT
/T1_4 1 Tf
-0.00999 Tc 10.5 0 0 10.5 278.5504 367.4197 Tm
(that)Tj
-0.02499 Tc 0.02299 Tw -20.81433 -1.22857 Td
(there is a strong dose\320response relationship between inten-)Tj
-0.02299 Tc 0 -1.22856 TD
(sity of counseling and cessation success. The more intense)Tj
-0.02499 Tc 0.017 Tw 0 -1.22857 TD
(the treatment intervention in length or number of treatment)Tj
-0.008 Tc 0.008 Tw T*
(sessions delivered, the greater the rate of smoking cessa)Tj
0 Tc 21.95282 0 Td
(-)Tj
-0.021 Tc 0.021 Tw -21.95282 -1.22857 Td
[(tion. While intensive phar)-31.9 (macist interventions may have a)]TJ
-0.02499 Tc 0.019 Tw T*
(greater impact on abstinence rates, these interventions may)Tj
0.024 Tw 24.57143 41.98094 Td
(have limited ability to reach certain smokers, such as those)Tj
-0.006 Tc 0.006 Tw T*
(who were ineligible for this study because of inability to)Tj
-0.02499 Tc 0.01401 Tw T*
(attend the group program. For example, tobacco users may)Tj
-0.013 Tc 0.013 Tw T*
[(not be interested or may lack availability)65 (, accessibility)65 (, or)]TJ
-0.02499 Tc T*
[(ability to af)20 (ford an intensive group program. )]TJ
0 Tc 0.026 Tw 1 -1.23809 Td
(This study has a number of limitations. The standard)Tj
-0.02499 Tc 0.01199 Tw -1 -1.2381 Td
(care model delivered via the telephone to the control group)Tj
-0.02 Tc 0.02 Tw 0 -1.2381 TD
[(was used to deter)-25 (mine whether the additional time and ef-)]TJ
-0.01801 Tc 0.017 Tw T*
(fort required for the proposed intervention would result in)Tj
-0.002 Tc 0.002 Tw 0 -1.23809 TD
(significantly better outcomes compared with brief inter-)Tj
-0.021 Tc 0.021 Tw 0 -1.2381 TD
(ventions delivered by healthcare providers. Therefore, one)Tj
-0.02299 Tc 0.02299 Tw 0 -1.23809 TD
(limitation of this design is that the delivery time and atten-)Tj
-0.01401 Tc 0.01401 Tw T*
[(tion dif)20 (fered significantly between the treatment and con-)]TJ
-0.013 Tc 0.01199 Tw T*
(trol groups. It is not possible to generalize the study find-)Tj
-0.02499 Tc 0.01801 Tw T*
(ings to all smokers in the general population because study)Tj
-0.01801 Tc T*
(participants were predominantly white, male, and middle-)Tj
-0.002 Tc 0.002 Tw T*
[(aged. While the reproducibility of this study in dif)20 (ferent)]TJ
0 Tc 0.09 Tw 0 -1.2381 TD
(patient populations is unknown, research suggests that)Tj
-0.005 Tc 0.005 Tw 0 -1.23809 TD
[(both men and women and dif)20 (ferent racial and ethnic mi-)]TJ
-0.019 Tc 0.019 Tw T*
(norities may benefit from similar smoking cessation inter-)Tj
-0.02 Tc 0.02 Tw 0 -1.2381 TD
[(ventions as delivered in this study)65 (.)]TJ
ET
BT
/T1_3 1 Tf
-0.01801 Tc 0 Tw 6 0 0 6 455.9627 474.5197 Tm
(32)Tj
ET
BT
/T1_4 1 Tf
-0.02 Tc 0.02 Tw 10.5 0 0 10.5 464.3455 471.2197 Tm
(While one strength of)Tj
-0.02499 Tc 0.009 Tw -13.93766 -1.23809 Td
(the study is the long \(6 mo\) follow-up period, the delay be)Tj
0 Tc 21.95297 0 Td
(-)Tj
-0.02499 Tc 0.02499 Tw -21.95297 -1.2381 Td
(tween treatment and the follow-up assessments could have)Tj
0 Tc 0.07401 Tw T*
(introduced error in participants\325 recall of distal events,)Tj
-0.002 Tc 0.002 Tw 0 -1.23809 TD
(such as their accurate use of medication and withdrawal)Tj
-0.01401 Tc 0.013 Tw T*
[(symptoms. Since the same phar)-25 (macist team delivered the)]TJ
0 Tc 0.08099 Tw 0 -1.2381 TD
(intervention in both conditions, it is possible that their)Tj
-0.015 Tc 0.01401 Tw 0 -1.23809 TD
(knowledge of the study hypothesis could have influenced)Tj
-0.004 Tc 0.004 Tw T*
(the study outcome. Detailed protocols and checklists for)Tj
-0.02 Tc 0.02 Tw T*
(steps to complete at each contact point helped systematize)Tj
-0.00999 Tc 0.009 Tw 0 -1.2381 TD
[(the intervention delivery and minimize this concer)-25 (n. The)]TJ
0 Tc 0.07001 Tw 0 -1.23809 TD
(screening process selected for individuals who had the)Tj
0.007 Tw T*
(time, availability)Tj
-0.00011 Tc 6.71812 0.00001 Td
(,)Tj
0 Tc 0.50728 0 Td
(and transportation to attend the group)Tj
-0.02499 Tc 0.013 Tw -7.22541 -1.2381 Td
(program, which could have been a possible source of bias. )Tj
-0.015 Tc 0.015 Tw 1 -1.21905 Td
(Despite these limitations, the study provides a rigorous)Tj
-0.00101 Tc 0.00101 Tw -1 -1.21905 Td
[(evaluation of an ef)20 (fective phar)-25 (macist-)-75 (delivered tobacco)]TJ
-0.013 Tc 0.013 Tw 0 -1.21905 TD
[(cessation intervention. Ultimately)65 (, this intervention could)]TJ
-0.022 Tc 0.022 Tw T*
[(serve as a model for widespread and ef)20 (fective use of phar-)]TJ
-0.007 Tc 0.007 Tw T*
(macists as providers of tobacco-cessation services, espe-)Tj
-0.01601 Tc 0.01601 Tw T*
(cially within the V)Tj
-0.01579 Tc 7.0885 0.00001 Td
(A)Tj
-0.01601 Tc 0.95607 0 Td
(and similar ambulatory care settings.)Tj
0 Tw -8.04457 -1.21905 Td
(Additionally)Tj
-0.0163 Tc 4.79546 0.00001 Td
(,)Tj
-0.01601 Tc 0.01601 Tw 0.48362 0 Td
[(establishing ef)23.9 (fectiveness of phar)]TJ
0 Tw 12.85766 0.00002 Td
[(macist-)-72.5 (de)]TJ
0 Tc 3.81596 0.00002 Td
(-)Tj
-0.01601 Tc 0.01601 Tw -21.95271 -1.21907 Td
(livered tobacco cessation services could provide justifica-)Tj
-0.01401 Tc 0.01401 Tw T*
(tion for compensation by third-party payers. Most impor)Tj
0 Tc 21.95274 0.00001 Td
(-)Tj
-0.01199 Tc 0.01199 Tw -21.95274 -1.21906 Td
[(tantly)65 (, greater use of phar)-25 (macists in tobacco cessation ef-)]TJ
0 Tc 0.047 Tw T*
(forts could have a significant impact on smoking rates,)Tj
-0.024 Tc 0.024 Tw T*
(prevention of tobacco-related disease, and improvement in)Tj
-0.02499 Tc 0.013 Tw T*
(public health across the US. )Tj
ET
BT
/T1_5 1 Tf
0 Tc 0.00301 Tw 8.5 0 0 8.5 318 115.0697 Tm
(Larry A Dent )Tj
ET
BT
/T1_6 1 Tf
8 0 0 8 371.4289 115.0697 Tm
(PharmD BCPS, Associate Professor)Tj
-0.00011 Tc 16.06651 0.00001 Td
(,)Tj
0 Tc 0.55859 0 Td
[(Clinical Phar)1.5 (-)]TJ
-0.005 Tc -0.02299 Tw -23.3037 -1.09376 Td
(macy Specialist, Department of Pharmacy Practice, Skaggs School)Tj
0 Tc -0.01401 Tw 0 -1.09375 TD
[(of Pharmacy)74 (, The University of Montana, Missoula, MT)]TJ
ET
BT
/T1_5 1 Tf
0.006 Tc 0.008 Tw 8.5 0 0 8.5 318 86.5697 Tm
(Kari Jo Harris )Tj
ET
BT
/T1_6 1 Tf
8 0 0 8 377.039 86.5697 Tm
[(PhD MPH, Associate Professor)55 (, School of Public)]TJ
0 Tc -0.01401 Tw -7.37987 -1.125 Td
(and Community Health Sciences, The University of Montana)Tj
ET
BT
/T1_5 1 Tf
-0.002 Tc -0.026 Tw 8.5 0 0 8.5 318 66.5696 Tm
(Curtis W Noonan )Tj
ET
BT
/T1_6 1 Tf
8 0 0 8 388.3628 66.5696 Tm
[(PhD, Assistant Professor)55 (, Department of Phar-)]TJ
0.01801 Tc -0.004 Tw -8.79535 -1.125 Td
(macy Practice and Department of Biomedical Sciences, Skaggs)Tj
0 Tc -0.01401 Tw 0 -1.125 TD
[(School of Pharmacy)74 (, The University of Montana )]TJ
ET
0 0 0 0.10001 k
60 123.684 234 24 re
f
60 99.683 234 12.001 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 0.011 Tw 9 0 0 9 74.4873 241.4611 Tm
[(T)74 (able 2.)]TJ
ET
BT
/T1_6 1 Tf
9 0 0 9 108.0029 241.4611 Tm
(Point Prevalence and Continuous Abstinence )Tj
ET
0 0 0 1 K
0.5 w 
60.5 224.711 m
293.5 224.711 l
S
BT
/T1_6 1 Tf
9 0 0 9 101.5874 230.4611 Tm
[(Rates Based on Intent-to-T)37 (reat Analysis )]TJ
ET
138.5 210.211 m
251.5 210.211 l
S
BT
/T1_5 1 Tf
0 Tc 0 Tw 7.5 0 0 7.5 183.6529 214.4611 Tm
(Group)Tj
-5.79988 -1.86666 Td
(Pharmacist-)Tj
0.61084 -1.06667 Td
[(Delivered)-3839 (Standard)]TJ
-0.1294 -1.06666 Td
(Program,)Tj
ET
BT
/T1_5 1 Tf
5 0 0 5 176.6833 187.2111 Tm
(a)Tj
ET
BT
/T1_5 1 Tf
7.5 0 0 7.5 212.6278 184.4611 Tm
(Care,)Tj
ET
BT
/T1_5 1 Tf
5 0 0 5 231.3815 187.2111 Tm
(b)Tj
ET
60.5 172.211 m
293.5 172.211 l
S
BT
/T1_5 1 Tf
-0.01401 Tw 7.5 0 0 7.5 72.3061 176.4611 Tm
(PP/CA Rate)Tj
-0.0002 Tc 10.69307 0.00001 Td
(n)Tj
0 Tc 0 Tw 0.87467 0 Td
(\(%\))Tj
-0.0002 Tc 7.38108 0.00001 Td
(n)Tj
0 Tc 0.87467 0 Td
(\(%\))Tj
-0.0002 Tc 5.86739 0.00001 Td
[(p)-264 (V)]TJ
0 Tc 1.48683 0.00001 Td
(alue)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 63.4998 160.4611 Tm
[(Cotinine-confirmed)-2085 (14 \(28.0\))-4570 (6 \(1)74 (1.8\))-4908 (0.041)]TJ
0.5 -1.2 Td
(7-day PP)Tj
0 Tw -0.5 -1.6 Td
(Self-reported )Tj
-0.01401 Tw 0.5 -1.6 Td
[(1-day PP)-5876 (20 \(40.0\))-4569 (8 \(15.7\))-4835 (0.006)]TJ
0 -1.6 TD
[(7-day PP)-5876 (17 \(34.0\))-4569 (6 \(1)74 (1.8\))-4909 (0.008)]TJ
T*
(30-day PP)Tj
9.97429 0.00001 Td
[(16 \(32.0\))-4569 (6 \(1)74 (1.8\))-4909 (0.014)]TJ
ET
60.5 85.211 m
293.5 85.211 l
S
BT
/T1_6 1 Tf
7.5 0 0 7.5 67.2498 91.4611 Tm
(6-mo CA)Tj
9.97429 0.00001 Td
(14 \(28.0\))Tj
-0.0002 Tc 8.55591 0.00001 Td
(6)Tj
0 Tc 0 Tw 0.81972 0 Td
[(\(1)74.2 (1.8\))-4907.7 (0.041)]TJ
-0.01401 Tw -19.84992 -2.40001 Td
(CA = continuous abstinence; PP = point prevalence.)Tj
ET
BT
/T1_5 1 Tf
0 Tw 5 0 0 5 63.4998 66.2111 Tm
(a)Tj
ET
BT
/T1_6 1 Tf
-0.00011 Tc 7.5 0 0 7.5 66.2794 63.4611 Tm
[(n)-264 (=)]TJ
0 Tc 1.66768 0 Td
(50.)Tj
ET
BT
/T1_5 1 Tf
5 0 0 5 63.4998 56.2111 Tm
(b)Tj
ET
BT
/T1_6 1 Tf
-0.00011 Tc 7.5 0 0 7.5 66.554 53.4611 Tm
[(n)-264 (=)]TJ
0 Tc 1.66768 0 Td
(51.)Tj
ET
60.25 48.245 233.5 203.348 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
5 0 0 5 291.13251 11 Tm
( at Library - Periodicals Dept on January 20, 2016)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
108 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
109 0 obj
<</OP false/OPM 0/op false>>
endobj
110 0 obj
<</A 111 0 R/Border[0 0 0]/Rect[250.388 9.0 292.133 16.0]/Subtype/Link/Type/Annot>>
endobj
111 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
102 0 obj
[112 0 R]
endobj
103 0 obj
<</Length 11973>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02299 Tc 0.02299 Tw 10.5 0 0 10.5 60 730.8196 Tm
(ers such as cost of transportation, travel distance from out-)Tj
-0.02 Tc 0.02 Tw 0 -1.23809 TD
(lying areas, and scheduling conflicts associated with work)Tj
-0.01199 Tc 0.01199 Tw 0 -1.2381 TD
(or other activities. Of the 19 eligible patients declining to)Tj
-0.02 Tc 0.02 Tw T*
(participate, the most common reasons were that they were)Tj
-0.02499 Tc 0.009 Tw 0 -1.23809 TD
(not ready to quit or their aversion to groups. There were no)Tj
-0.02 Tc 0.02 Tw 0 -1.2381 TD
[(dif)20 (ferences in age or number of cigarettes smoked per day)]TJ
-0.00999 Tc 0.00999 Tw T*
[(for those who declined to participate; however)40 (, readiness)]TJ
-0.02499 Tc 0 Tw 0 -1.23809 TD
[(to quit in the next 2 weeks was lower on the 10)-75 (-point moti-)]TJ
0.013 Tw 0 -1.2381 TD
(vational scale \(p = 0.004\).)Tj
0.02499 Tw 1 -1.21429 Td
(The baseline characteristics of participants were not sig-)Tj
0 Tc 0.01401 Tw -1 -1.21429 Td
[(nificantly dif)20 (ferent between treatment groups \(T)70 (able 1\).)]TJ
-0.002 Tc 0.002 Tw 0 -1.21428 TD
(The majority of participants were male \(93%\), non-His-)Tj
-0.02299 Tc 0.02299 Tw 0 -1.21429 TD
(panic white \(96%\), college educated \(61%\), retired \(56%\),)Tj
-0.009 Tc 0.009 Tw T*
(and married or a member of an unmarried couple \(55%\).)Tj
-0.01801 Tc 0.01801 Tw T*
(At baseline, 57% of participants considered themselves to)Tj
-0.01401 Tc 0.01401 Tw T*
(be in good-to-excellent health. These characteristics were)Tj
-0.02499 Tc 0.013 Tw T*
(equally distributed by treatment group \(p > 0.34\). )Tj
-0.013 Tc 1 -1.21429 Td
(At 6 months after the quit date, the biochemically con-)Tj
-0.01199 Tc 0.011 Tw -1 -1.21428 Td
[(fir)-25 (med 7-)-75 (day point prevalence quit rate was 28% \(14/50\))]TJ
-0.008 Tc 0.008 Tw T*
[(in the phar)-25 (macist-)-75 (delivered face-to-face treatment group)]TJ
0 Tc 0.02 Tw T*
[(and 1)35 (1.8% \(6/51\) in the standard c)10 (a)10 (r)10 (e)10 ( )10 (g)10 (r)10 (o)10 (u)10 (p)10 ( )10 (\()10 (p)10 ( )10 (<)10 ( )10 (0)10 (.)10 (0)10 (4)10 (1)10 (\))]TJ
-0.02299 Tc 0.013 Tw T*
[(\()1 (T)71 (able 2\). Self-reported quit rates were significantly higher)]TJ
-0.00999 Tc 0 Tw T*
(in the treatment group for all time periods. Of the 14 bio-)Tj
-0.02299 Tc 0.013 Tw T*
[(chemically confir)-25 (med quitters in the treatment group, 93%)]TJ
-0.01601 Tc 0.006 Tw T*
(\(13/14\) attended all 3 counseling sessions. Of participants)Tj
-0.035 Tc 0.019 Tw 0 -1.21428 TD
(who attended all 3 sessions, 46% \(13/28\) were able to main-)Tj
-0.021 Tc 0.011 Tw 0 -1.21429 TD
(tain continuous abstinence, compared with only 5% \(1/22\))Tj
-0.035 Tc 0.017 Tw T*
[(of those attending 2 sessions or fewer)40 (, suggesting the impor-)]TJ
-0.01601 Tc 0.006 Tw T*
(tance of attending all 3 sessions of the program. Of the 23)Tj
-0.02 Tc 0.00999 Tw T*
(participants who self-reported abstinence and were invited)Tj
-0.03101 Tc 0.021 Tw T*
(to provide a urine sample for biochemical verification, 88%)Tj
-0.035 Tc 0.02499 Tw T*
(\(15/17\) in the treatment group and 100% \(6/6\) in the control)Tj
-0.033 Tc 0.022 Tw 24.57143 37.83333 Td
(group completed the test. Only one participant reporting ab-)Tj
-0.00999 Tc 0.024 Tw T*
(stinence in the treatment group and no one in the control)Tj
-0.0351 Tc T*
(g)Tj
-0.035 Tc 0.013 Tw (roup tested positive for urinary cotinine. )Tj
-0.02 Tc 0.02 Tw 1 -1.22858 Td
(Bupropion was chosen by 66% \(67/101\) of the subjects)Tj
-0.015 Tc 0.015 Tw -1 -1.22857 Td
(and nicotine patches were chosen by 25% \(25/101\) of the)Tj
0 Tc 0.02 Tw 0 -1.22857 TD
(subjects. Only 9% \(9/101\) of the subjects did not select)Tj
0.036 Tw T*
[(any drug. There was no overall dif)20 (ference by treatment)]TJ
-0.024 Tc 0.024 Tw T*
(group for type of medication chosen \(p = 0.37\). There was)Tj
-0.02499 Tc 0.01801 Tw T*
[(also no significant dif)20 (ference in quit rates for type of medi-)]TJ
0.013 Tw T*
(cation chosen between treatment groups \(p = 0.41\). )Tj
-0.008 Tc 0.008 Tw 1 -1.22855 Td
(Of the 83 participants who opted to use study medica-)Tj
-0.021 Tc 0.021 Tw -1 -1.22857 Td
[(tions and were assessed for adherence on the 6)-25 (-month fol-)]TJ
-0.02 Tc 0.02 Tw T*
[(low-up survey)65 (, 63% \(52/83\) replied that they followed the)]TJ
0 Tc 0.17599 Tw T*
[(recommended dosing schedule exactly)65 (. There was an)]TJ
0.23399 Tw T*
(equal distribution between the treatment and control)Tj
-0.021 Tc 0.02 Tw T*
(groups among those who followed the recommended dos-)Tj
-0.02499 Tc 0.013 Tw T*
(ing schedule \(p = 0.98\). )Tj
0 Tc 0.03 Tw 1 -1.22857 Td
(Patients reported medication problems to the clinical)Tj
-0.015 Tc 0.015 Tw -1 -1.22857 Td
[(phar)-25 (macist. All adverse ef)20 (fects to medications were mild.)]TJ
-0.022 Tc 0.021 Tw T*
(One patient reported developing dizziness possibly related)Tj
-0.02299 Tc 0.02299 Tw T*
[(to nicotine toxicity while wearing the 21)38.3 (-mg patch, requir)]TJ
0 Tc 21.95281 0 Td
(-)Tj
-0.024 Tc 0.024 Tw -21.95281 -1.22858 Td
(ing a reduction in dosage. One patient discontinued bupro-)Tj
-0.02499 Tc 0.013 Tw T*
(pion because of a rash. )Tj
0 Tc 0.002 Tw 1 -1.22857 Td
(At follow-up, participants reported on whether or not)Tj
-0.02499 Tc 0.009 Tw -1 -1.22857 Td
(they experienced any of 8 withdrawal symptoms common-)Tj
0 Tc 0.04201 Tw T*
(ly associated with smoking cessation. Nearly all \(96%\))Tj
-0.02499 Tc 0.013 Tw 0 -1.22856 TD
(participants reported at least one withdrawal symptom. )Tj
ET
BT
/T1_1 1 Tf
0 Tw 10.5 0 0 10.5 318 367.8199 Tm
(Discussion)Tj
ET
BT
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 10.5 0 0 10.5 328.5 346.8199 Tm
(This is the first randomized controlled trial conducted)Tj
-0.01401 Tc 0.01401 Tw -1 -1.23809 Td
[(within the US to assess the ef)27.2 (fectiveness of a phar)]TJ
0 Tw 19.42785 0 Td
(macist-)Tj
0 Tc 0.194 Tw -14.85643 -1.2381 Td
[(delivered program for smoking using bio)3.5 (-)]TJ
-0.021 Tc 0.021 Tw 0 -1.2381 TD
(chemical verification. The 28% biochemically)Tj
-0.01601 Tc 0.01601 Tw 0 -1.23809 TD
[(confir)-25 (med quit rate obtained in this study was)]TJ
-0.019 Tc 0.019 Tw T*
(higher than quit rates for the only 2 biochemi)Tj
0 Tc 17.38159 0.00001 Td
(-)Tj
-0.004 Tc 0.00301 Tw -17.38159 -1.2381 Td
[(cally confir)-25 (med randomized controlled trials)]TJ
-0.00301 Tc T*
(conducted in the UK and Australia. They re-)Tj
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
(ported intent-to-treat quit rates of 14.7%)Tj
ET
BT
/T1_2 1 Tf
-0.01601 Tc 0 Tw 6 0 0 6 528.8 246.1198 Tm
(15)Tj
ET
BT
/T1_0 1 Tf
-0.01801 Tc 10.5 0 0 10.5 537.2126 242.8198 Tm
(and)Tj
-0.00301 Tc -16.30596 -1.23809 Td
(18.5%)Tj
ET
BT
/T1_2 1 Tf
-0.00101 Tc 6 0 0 6 392.9604 233.1199 Tm
(14)Tj
ET
BT
/T1_0 1 Tf
-0.00301 Tc 0.00301 Tw 10.5 0 0 10.5 401.5491 229.8199 Tm
(at 6 months. The intensity and com)Tj
0 Tc 13.99597 0.00001 Td
(-)Tj
-0.02499 Tc 0.02299 Tw -17.3816 -1.2381 Td
(ponents of the group program may account for)Tj
-0.009 Tc 0.009 Tw T*
[(the dif)20 (ference in quit rates between our study)]TJ
0 Tc 0.00301 Tw 0 -1.23809 TD
[(and the other reported studies. In 2 prior un)0.6 (-)]TJ
0.17999 Tw T*
(controlled studies by our group, using the)Tj
-0.00101 Tc 0.00101 Tw 0 -1.2381 TD
(same intervention, the intent-to-treat self-re-)Tj
-0.021 Tc 0.021 Tw 0 -1.23809 TD
(ported tobacco cessation rates were 34%)Tj
ET
BT
/T1_2 1 Tf
-0.019 Tc 0 Tw 6 0 0 6 528.9173 155.1199 Tm
(45)Tj
ET
BT
/T1_0 1 Tf
-0.021 Tc 10.5 0 0 10.5 537.2863 151.8199 Tm
(and)Tj
-0.019 Tc -16.31298 -1.2381 Td
(36.5%,)Tj
ET
BT
/T1_2 1 Tf
-0.017 Tc 6 0 0 6 394.5568 142.1198 Tm
(26)Tj
ET
BT
/T1_0 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 402.9556 138.8199 Tm
(which are similar to the self-reported)Tj
-0.02 Tc 0.02 Tw -3.51958 -1.2381 Td
[(quit rate of 34% obtained in our current study)65 (.)]TJ
-0.02499 Tc 0 Tw T*
(Further)Tj
0.01601 Tw 2.79301 0.00001 Td
(more, the high retention at follow-up in)Tj
-0.01199 Tc 0.01199 Tw -2.79301 -1.2381 Td
(our study likely contributed to the higher quit)Tj
-0.005 Tc 0.005 Tw T*
[(rates. The choice of phar)-19.5 (macotherapy within)]TJ
-0.02499 Tc 0.013 Tw T*
(groups was equivalent. )Tj
0 Tc 0.099 Tw 1 -1.2381 Td
(The primary strength of this study is the)Tj
0.347 Tw -1 -1.23809 Td
(compliance with recognized standards in)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(198)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(LA)-250 (Dent et al.)]TJ
ET
0 0 0 0.10001 k
60 195.226 276 11.7299 re
f
60 170.8969 276 11.7301 re
f
60 147.872 276 11.7299 re
f
60 123.543 276 11.73 re
f
60 99.6489 276 11.7301 re
f
0 0 0 1 K
0.5 w 
60.5 273.955 m
335.5 273.955 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tw 9 0 0 9 69.183 279.705 Tm
(T)Tj
-0.02499 Tc 0.011 Tw 0.51186 0.00001 Td
(able 1.)Tj
ET
BT
/T1_6 1 Tf
9 0 0 9 102.6986 279.705 Tm
[(Baseline Characteristics for T)39.9 (reatment and Control Groups)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 324.1625 282.4549 Tm
(a)Tj
ET
188.5 259.455 m
289.5 259.455 l
S
BT
/T1_1 1 Tf
7.5 0 0 7.5 227.8132 263.705 Tm
(Group)Tj
-4.91641 -1.86666 Td
(Pharmacist-)Tj
0.61084 -1.06667 Td
[(Delivered)-3087 (Standard)]TJ
0.19483 -1.06667 Td
[(Program)-4337.4 (Care)]TJ
ET
60.5 221.455 m
335.5 221.455 l
S
BT
/T1_1 1 Tf
7.5 0 0 7.5 94.0989 225.705 Tm
(Characteristic)Tj
-0.01401 Tw 14.02347 0.00001 Td
[(\(n = 50\))-4004.1 (\(n = 51\))]TJ
-0.0002 Tc 13.98836 0.00002 Td
[(p)-264 (V)]TJ
0 Tc 0 Tw 1.48684 0.00001 Td
(alue)Tj
ET
BT
/T1_6 1 Tf
-0.01401 Tw 7.5 0 0 7.5 63.5 209.705 Tm
[(Age at time of study enrollment \(y\))-2092 (56.7 )-1 (\261)-228 (9.8)-3196 (55.0 )-1 (\261)-228 (9.5)-3392 (0.378)]TJ
0 -1.6 TD
(Age when began smoking \(y\))Tj
0 Tw 17.2326 0.00001 Td
(17.2 )Tj
-0.01401 Tw 2.20951 0.00001 Td
[(\261)-229 (5.5)-3196 (17.3 \261)-229 (5.6)-3392 (0.975)]TJ
-19.44211 -1.60002 Td
[(Y)92 (ears of smoking \(y\))-8200 (35.2 \261)-229 (12.9)-2640 (36.2 \261)-229 (12.1)-2836 (0.685)]TJ
T*
[(Cigarettes per day \(n\))-7607 (18.9 \261)-229 (1)74 (1.2)-2714 (20.1 \261)-229 (9.3)-3392 (0.563)]TJ
T*
(Quit attempts \(n\))Tj
17.78852 0.00001 Td
[(8.7 \261)-229 (10.6)-3196 (7.9 \261)-229 (9.5)-3392 (0.677)]TJ
-17.78852 -1.60001 Td
[(FTND score )-12151 (4.2 \261)-229 (2.5)-3752 (4.4 \261)-229 (2.1)-3391 (0.648)]TJ
T*
[(Chronic health conditions \(n\))-5106 (2.4 )-1 (\261)-228 (1.6)-3752 (2.2 )-1 (\261)-228 (1.5)-3392 (0.505)]TJ
0 -1.33334 TD
[(PSS-4)-14899 (4.7 \261)-229 (3.9)-3752 (4.9 \261)-229 (3.5)-3392 (0.785)]TJ
0 -1.6 TD
[(CESD-10 score)-10858 (8.9 \261)-229 (6.9)-3752 (8.9 \261)-229 (6.7)-3391 (0.966)]TJ
T*
[(Motivation to quit)-10260 (8.9 \261)-228 (1.4)-3753 (8.5 \261)-228 (1.6)-3392 (0.159)]TJ
ET
60.5 85.455 m
335.5 85.455 l
S
BT
/T1_6 1 Tf
7.5 0 0 7.5 63.5 91.705 Tm
(Confidence to quit)Tj
17.78998 0 Td
[(7.6 \261)-229 (2.3)-3752 (7.5 \261)-229 (2.2)-3392 (0.860)]TJ
0.017 Tc -0.00301 Tw -17.78998 -2.4 Td
(CESD-10 = 10-Item Center for Epidemiologic Studies Short Depression Scal\e;)Tj
-0.02 Tc -0.008 Tw 0 -1.2 TD
[(FTND = Fagerstrom T)111 (est for Nicotine Dependence; PSS-4 = Perceived Stress Scale.)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 63.5 57.455 Tm
(a)Tj
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 66.2795 54.705 Tm
[(Mean )14.6 (\261)-228.8 (SD.)]TJ
ET
60.25 48.25 275.5 242.826 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
5 0 0 5 291.13251 11 Tm
( at Library - Periodicals Dept on January 20, 2016)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
104 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
105 0 obj
<</OP false/OPM 0/op false>>
endobj
112 0 obj
<</A 113 0 R/Border[0 0 0]/Rect[250.388 9.0 292.133 16.0]/Subtype/Link/Type/Annot>>
endobj
113 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
98 0 obj
[114 0 R]
endobj
99 0 obj
<</Length 13089>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.011 Tc 0.011 Tw 10.5 0 0 10.5 60 730.8196 Tm
(hibitor in the past 14 days. Precautions for nicotine patch)Tj
-0.02299 Tc 0.022 Tw 0 -1.23809 TD
(included myocardial infarction within the last 2 weeks, se-)Tj
-0.006 Tc 0.005 Tw 0 -1.2381 TD
(rious arrhythmias, and worsening angina pectoris. Study)Tj
-0.002 Tc 0.00101 Tw T*
(participants who selected drugs received them using the)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(V)130 (A medication mail delivery system. )]TJ
ET
BT
/T1_1 1 Tf
0 Tw 8 0 0 8 70.5 650.9196 Tm
(MEASURES)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.013 Tw 10.5 0 0 10.5 70.5 630.0197 Tm
(Six months after the quit date, participants were tele-)Tj
-0.013 Tc -1 -1.22857 Td
(phoned by a research assistant to complete a brief assess-)Tj
-0.02499 Tc 0.024 Tw 0 -1.22858 TD
(ment. Participants who reported not smoking for the previ-)Tj
-0.004 Tc 0.004 Tw 0 -1.22857 TD
[(ous 7 days\321not even a puf)20 (f\321were invited to come into)]TJ
-0.02 Tc 0.02 Tw T*
(the clinic to provide a sample to test for urinary cotinine.)Tj
ET
BT
/T1_2 1 Tf
-0.01801 Tc 0 Tw 6 0 0 6 288.1224 581.7198 Tm
(34)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.00999 Tw 10.5 0 0 10.5 60 565.5197 Tm
(Participants invited to provide a urine sample were reim-)Tj
-0.02499 Tc 0.013 Tw 0 -1.22856 TD
(bursed $20 for their time and travel costs. )Tj
0 Tc 0.02299 Tw 1 -1.22857 Td
(The primary outcome variable for the study was bio-)Tj
0.067 Tw -1 -1.22857 Td
[(chemically confir)-25 (med 7-)-75 (day point prevalence smoking)]TJ
0.19299 Tw 0 -1.22857 TD
(cessation at 6 months, defined as having smoked no)Tj
-0.021 Tc 0.021 Tw T*
[(cigarettes\321not even a puf)20 (f\321for the previous 7 days. Sec-)]TJ
-0.017 Tc 0.017 Tw T*
[(ondary outcomes included 30)-75 (-)-75 (day point prevalence absti-)]TJ
0 Tc 0.13499 Tw T*
(nence and continuous abstinence \()Tj
/T1_3 1 Tf
14.25581 0 Td
(\263)Tj
/T1_0 1 Tf
-0.00011 Tc [0.2 (6)]TJ
0 Tc 1.43344 0.00001 Td
(mo\). Thirty-)Tj
0 Tw 5.1526 0 Td
(day)Tj
0.276 Tw -20.84184 -1.22858 Td
(point prevalence was defined as having smoked no)Tj
-0.01801 Tc 0.01801 Tw T*
[(cigarettes\321not even a puf)20 (f\321in the last 30 days. Continu-)]TJ
-0.00301 Tc 0.00301 Tw T*
(ous abstinence was defined as no cigarettes\321not even a)Tj
-0.02499 Tc 0 Tw T*
(puf)Tj
0.013 Tw 1.23774 0 Td
[(f\321since quit day)65 (.)]TJ
-0.00011 Tc -0.23774 -1.22858 Td
(A)Tj
0 Tc 0.104 Tw 1.07549 0 Td
(questionnaire was used to assess for use of other)Tj
-0.015 Tc 0 Tw -2.07549 -1.22857 Td
(for)Tj
-0.01401 Tc 0.01401 Tw 1.14758 0 Td
(ms of tobacco, nicotine replacement therapies, and ex-)Tj
-0.00999 Tc 0.00999 Tw -1.14758 -1.22857 Td
(posure to secondhand smoke at the time of the urine test.)Tj
-0.011 Tc 0.011 Tw T*
(LabCorp analyzed the urine samples using immunoassay)Tj
-0.013 Tc 0.013 Tw T*
[(\(SolarCare T)73.2 (echnologies Corp., Bethlehem, P)96.1 (A\). Consid)]TJ
0 Tc 21.95285 0.00001 Td
(-)Tj
-0.01199 Tc 0.01199 Tw -21.95285 -1.22857 Td
(ering the longest cotinine half-life and typical initial coti-)Tj
-0.024 Tc 0.024 Tw T*
(nine concentrations, a patient with negative test results can)Tj
-0.02499 Tc 0.02 Tw T*
[(be assumed to have been tobacco-free for a 7-)-68.2 (day period.)]TJ
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 288.1499 323.7199 Tm
(28)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.183 Tw 10.5 0 0 10.5 60 307.5199 Tm
(Participants with urine cotinine concentrations of 0.3)Tj
T*
(\265)Tj
-0.02499 Tc 0.013 Tw 0.55092 0.00001 Td
(g/mL or higher were considered to be smokers.)Tj
0 Tc 0.15401 Tw 0.44908 -1.2381 Td
[(Sociodemographic infor)-25 (mation, smoking behaviors,)]TJ
-0.015 Tc 0.015 Tw -1 -1.2381 Td
[(measures of self-ef)20 (ficacy/motivation, and health infor)-25 (ma-)]TJ
0 Tc 0.149 Tw 0 -1.23809 TD
(tion were assessed at baseline using survey questions)Tj
-0.007 Tc 0.006 Tw 0 -1.2381 TD
(adapted from prior studies.)Tj
ET
BT
/T1_2 1 Tf
-0.004 Tc 0 Tw 6 0 0 6 171.4966 245.9199 Tm
(35)Tj
-0.005 Tc 1.012 0.00001 Td
(-37)Tj
ET
BT
/T1_0 1 Tf
-0.007 Tc 0.006 Tw 10.5 0 0 10.5 188.0742 242.6199 Tm
(Nicotine dependence was)Tj
-0.022 Tc 0.022 Tw -12.19754 -1.2381 Td
[(assessed with the 6)-25 (-item Fagerstrom T)70 (est for Nicotine De-)]TJ
-0.005 Tc 0.004 Tw 0 -1.23809 TD
(pendence scale at baseline and at 6 months if still smok)Tj
0 Tc 21.95282 0.00001 Td
(-)Tj
-0.022 Tc 0 Tw -21.95282 -1.2381 Td
(ing.)Tj
ET
BT
/T1_2 1 Tf
-0.02 Tc 6 0 0 6 75.136 206.9199 Tm
(38)Tj
ET
BT
/T1_0 1 Tf
-0.022 Tc 0.022 Tw 10.5 0 0 10.5 83.5021 203.6199 Tm
[(The 4)-76.3 (-item Perceived Stress Scale was used at base)]TJ
0 Tc 19.71466 0.00002 Td
(-)Tj
-0.022 Tc -21.95296 -1.23811 Td
(line and at 6 months to measure the degree to which situa-)Tj
-0.02499 Tc 0.021 Tw T*
(tions over the past month were appraised as stressful. Each)Tj
-0.0251 Tc 0 -1.2381 TD
[(of)-237 (4)]TJ
-0.02499 Tc 0.01199 Tw 1.73174 0 Td
(items was rated as 0 \(none\) to 4 \(very often\); the high-)Tj
0.024 Tw -1.73174 -1.2381 Td
(er the score, the more perceived stress.)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 213.6848 154.9199 Tm
(39)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.024 Tw 10.5 0 0 10.5 222.0023 151.6198 Tm
[(The 10)-75 (-item Cen-)]TJ
0 Tc 0.151 Tw -15.42879 -1.23809 Td
(ter for Epidemiologic Studies Short Depression Scale)Tj
-0.015 Tc 0.015 Tw T*
(score was measured at baseline and 6 months.)Tj
ET
BT
/T1_2 1 Tf
-0.013 Tc 0 Tw 6 0 0 6 247.2805 128.9199 Tm
(40)Tj
ET
BT
/T1_0 1 Tf
-0.015 Tc 0.015 Tw 10.5 0 0 10.5 255.7287 125.6199 Tm
(Scores of)Tj
-0.01601 Tc -18.64083 -1.2381 Td
[(10 or higher \(range 0)-110 (\320)-25 (30\) indicate the likelihood of clini-)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.23809 TD
[(cal depression. Self-ef)20 (ficacy and motivation to quit smok-)]TJ
-0.008 Tc 0.008 Tw 0 -1.2381 TD
(ing were each assessed separately)Tj
-0.00771 Tc 13.20416 0.00001 Td
(,)Tj
-0.008 Tc 0.4922 0 Td
(both at baseline and 6)Tj
-0.002 Tc 0.00101 Tw -13.69636 -1.2381 Td
(months. Participants were asked, \322On a scale of 1 to 10,)Tj
-0.011 Tc 0.011 Tw 0 -1.23809 TD
(how motivated/confident are you to quit smoking, with 1)Tj
-0.02499 Tc 0.015 Tw 0 -1.2381 TD
(being not at all motivated/confident and 10 being very mo)Tj
0 Tc 21.95296 0.00001 Td
(-)Tj
0.039 Tw 2.61847 65.06664 Td
(tivated/confident?\323 Once participants reported quitting,)Tj
-0.02499 Tc 0.024 Tw 0 -1.23809 TD
(phrasing of the items was altered to assess motivation/con-)Tj
0.013 Tw 0 -1.2381 TD
(fidence to stay quit.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 395.6864 708.1197 Tm
(41,42)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.354 Tw 10.5 0 0 10.5 328.5 691.7446 Tm
[(W)40 (ithdrawal symptoms, which included depressed)]TJ
-0.011 Tc 0.011 Tw -1 -1.24523 Td
[(mood, trouble falling asleep, irritability/frustration/anger)40 (,)]TJ
-0.02499 Tc 0.015 Tw 0 -1.24524 TD
[(anxiety)65 (, dif)20 (ficulty concentrating, restlessness, increased ap-)]TJ
-0.024 Tc 0.024 Tw T*
(petite/weight gain, and cravings to smoke were assessed at)Tj
-0.02299 Tc 0 -1.24523 TD
(6)Tj
0.02299 Tw 0.72693 0 Td
(months. Each of 8 symptoms was rated from 0 \(none\) to)Tj
-0.02341 Tc -0.72693 -1.24524 Td
(3)Tj
-0.02299 Tc 0 Tw 0.72643 0 Td
(\(severe\).)Tj
ET
BT
/T1_2 1 Tf
-0.022 Tc 6 0 0 6 359.848 629.6697 Tm
(35,43)Tj
ET
BT
/T1_0 1 Tf
-0.02299 Tc 0.02299 Tw 10.5 0 0 10.5 375.2733 626.3697 Tm
(For participants choosing to use medication,)Tj
-0.00301 Tc 0.00301 Tw -5.4546 -1.24524 Td
(adherence was assessed at 6 months using the following)Tj
-0.011 Tc 0.011 Tw 0 -1.24524 TD
(statement: \322On a scale from 1 to 10, how closely did you)Tj
0 Tc 0.01801 Tw 0 -1.24523 TD
(follow the recommended dosing schedule, with 1 being)Tj
-0.02499 Tc 0.015 Tw T*
(not at all and 10 being exactly?\323)Tj
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 446.1616 577.3698 Tm
(44)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.015 Tw 10.5 0 0 10.5 454.3842 574.0697 Tm
(Study records were used)Tj
-0.011 Tc 0.011 Tw -12.98897 -1.24524 Td
(to assess number of program sessions completed by each)Tj
-0.02499 Tc 0.013 Tw 0 -1.24524 TD
(participant in the treatment group. )Tj
ET
BT
/T1_1 1 Tf
0.011 Tw 8 0 0 8 328.5 519.8447 Tm
[(DA)74 (T)74 (A MANAGEMENT)]TJ
ET
BT
/T1_0 1 Tf
-0.002 Tc 0.002 Tw 10.5 0 0 10.5 328.5 498.7697 Tm
(Participant data and testing results were recorded in a)Tj
0 Tc 0.021 Tw -1 -1.24523 Td
(Microsoft SQL Server 2000 database \(Microsoft Corp.,)Tj
-0.00101 Tc 0.00101 Tw 0 -1.24523 TD
[(Redmond, W)110 (A\). Data were double-entered and checked)]TJ
-0.02499 Tc 0.01801 Tw 0 -1.24524 TD
[(for out-)-75 (of range values at regular intervals. Inter)-25 (nal consis-)]TJ
-0.00301 Tc 0.00301 Tw T*
(tency and validity programs were used to check for data)Tj
-0.02499 Tc 0.013 Tw T*
(entry errors and duplicates.)Tj
ET
BT
/T1_1 1 Tf
0.011 Tw 8 0 0 8 328.5 405.3198 Tm
[(ST)74 (A)74 (TISTICAL ANAL)92 (YSIS)]TJ
ET
BT
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 328.5 384.2448 Tm
(For a priori sample size calculations, we assumed a 7-)Tj
0 Tc 0.04401 Tw -1 -1.24524 Td
(day point prevalence abstinence of 10% for the control)Tj
0 Tw T*
(group based on previous studies using standard medical)Tj
0 -1.24523 TD
(care)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 335.4752 348.3198 Tm
(32)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.03999 Tw 10.5 0 0 10.5 344.5228 345.0198 Tm
(and 35% for the intervention group based on our)Tj
-0.017 Tc 0.017 Tw -2.52598 -1.24524 Td
(previous pilot study of the phar)Tj
0 Tw 12.0939 0 Td
(macist-)Tj
0.017 Tw 2.89969 0 Td
(delivered interven-)Tj
0 Tc 0 Tw -14.99359 -1.24524 Td
(tion.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 336.9595 322.1698 Tm
(26)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 345.5863 318.8698 Tm
(The sample size of 100 participants \(50 per treat-)Tj
-0.00101 Tc 0.00101 Tw -2.62727 -1.24524 Td
[(ment\) would yield 86% power to detect a dif)23.4 (ference be-)]TJ
-0.02 Tc 0.02 Tw 0 -1.24524 TD
(tween groups with an )Tj
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 10.5 0 0 10.5 407.0971 292.7197 Tm
(a)Tj
ET
BT
/T1_0 1 Tf
-0.02 Tc 0.02 Tw 10.5 0 0 10.5 416.133 292.7197 Tm
(of 0.05. Baseline categorical vari-)Tj
-0.00301 Tc 0.00301 Tw -9.346 -1.24523 Td
(ables were summarized by frequencies and percentages,)Tj
-0.02499 Tc 0.005 Tw 0 -1.24523 TD
[(and quantitative variables were summarized by mean \261)-215 (SD)]TJ
-0.019 Tc 0.019 Tw 0 -1.24524 TD
(for each treatment regimen. Baseline categorical variables)Tj
0 Tc 0 Tw T*
(by treatment group were compared using the )Tj
ET
BT
/T1_4 1 Tf
10.5 0 0 10.5 508.2693 240.4198 Tm
(c)Tj
ET
BT
/T1_2 1 Tf
6 0 0 6 514.0289 243.7198 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
10.5 0 0 10.5 519.6522 240.4198 Tm
(test and)Tj
-0.00101 Tc 0.00101 Tw -19.20497 -1.24524 Td
(the 2-sample )Tj
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 10.5 0 0 10.5 374.4953 227.3448 Tm
(t)Tj
ET
BT
/T1_0 1 Tf
-0.00101 Tc 10.5 0 0 10.5 377.4066 227.3448 Tm
(-test. )Tj
ET
BT
/T1_4 1 Tf
0 Tc 10.5 0 0 10.5 400.6934 227.3448 Tm
(c)Tj
ET
BT
/T1_2 1 Tf
6 0 0 6 406.4502 230.6448 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.00101 Tc 0.00101 Tw 10.5 0 0 10.5 412.0718 227.3448 Tm
[(T)70 (ests were used to compare point)]TJ
-0.00999 Tc 0.009 Tw -8.95922 -1.24524 Td
(prevalence smoking cessation and continuous abstinence)Tj
0 Tc 0 Tw 0 -1.24523 TD
(rates based on intent-to-treat analysis between the treat-)Tj
0.054 Tw T*
(ment and control groups. For the primary outcomes on)Tj
-0.02299 Tc 0.02299 Tw 0 -1.24524 TD
(smoking cessation, all subjects who were lost to follow-up)Tj
-0.006 Tc 0.006 Tw T*
[(or reporting abstinence at the 6)-22.2 (-month post-quit date but)]TJ
-0.021 Tc 0.021 Tw T*
[(failed to retur)-25 (n for urine cotinine testing were classified as)]TJ
0 Tc 0.054 Tw 0 -1.24523 TD
(smokers in the primary analyses. All data analysis was)Tj
-0.02499 Tc 0.013 Tw 0 -1.24524 TD
[(conducted using SAS version 9.0 \(Cary)65 (, NC\). )]TJ
ET
BT
/T1_1 1 Tf
0 Tw 10.5 0 0 10.5 318 94.6697 Tm
(Results)Tj
ET
BT
/T1_0 1 Tf
-0.02299 Tc 0.02299 Tw 10.5 0 0 10.5 328.5 73.6697 Tm
(The results of the participant flow through the study ap-)Tj
-0.00999 Tc 0.00999 Tw -1 -1.23809 Td
(pear in Figure 1. The most common reason for exclusion)Tj
-0.024 Tc 0.024 Tw 0 -1.2381 TD
(was inability to attend all 3 sessions \(54/188\), due to barri-)Tj
ET
0 0 0 0 k
318 745 234 10 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
0 Tc -0.013 Tw 8 0 0 8 323.7231 749.5293 Tm
[(Ef)20 (fectiveness of a Phar)-25 (macist-Delivered Smoking Cessation Program)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(197)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
BT
0 g
/GS2 gs
/T1_8 1 Tf
0 Tc 5 0 0 5 291.13251 11 Tm
( at Library - Periodicals Dept on January 20, 2016)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
54 0 obj
<</BaseFont/QXIVWT+Symbol/Encoding 53 0 R/FirstChar 32/FontDescriptor 51 0 R/LastChar 202/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 549 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 250]>>
endobj
52 0 obj
<</BaseFont/QXIVWT+Symbol/Encoding 49 0 R/FirstChar 32/FontDescriptor 51 0 R/LastChar 99/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 631 0 549]>>
endobj
49 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 97/alpha 99/chi]/Type/Encoding>>
endobj
51 0 obj
<</Ascent 921/CapHeight 671/Descent -223/Flags 4/FontBBox[-180 -292 1090 1005]/FontFile3 50 0 R/FontName/QXIVWT+Symbol/ItalicAngle 0/StemH 0/StemV 41/Type/FontDescriptor/XHeight 684>>
endobj
50 0 obj
<</Length 636/Length1 636/Subtype/Type1C>>stream
  QXIVWT+Symbol   F¯ ¯¯ ¯ ¯)¡˚H˚∏˙÷˙Å
 ãã
 ãã      ™  ] ìögreaterequalalphachi002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Simpele is a trademark of Stream Technologies Inc.Simpele    áàâ     1 ∆;¸$&ã√®¯É¯†˜Ó ¸É˜xM¯E˚Z¸E˚ZN¯É˚
√¸ÉSxyÆk”¯'≥}w≥ÒX¯ˇ˜xUÑypljp¥‘{˜˜œ3L˚Dà¯˜tP *VWt\_`_xI.˚*Ÿ,˜≥¿õ°≠´†û•®≈x&ØßdØ™Æ∫∫ç˚h˜%m:¯=n\[]qtôßus´|œ‹˜∏ÊÃ∂πoeûönûNèm&˚|‰¯≈€ó¯è¯õYxKypn`Svµ˜b[˜a¯	$˚˚Üe˜:~√c≥_ãXcQ6Ügúœõ£™±∂´gMö´˚˚m¸&Ô˜)˜ßí]ïLërñZïkóuõl¨u©ãŒã≥«õ˜s£¯Üç˜?ò˜Åã˚véØ
¥
_˜é˘
endstream
endobj
53 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 179/greaterequal 202/space]/Type/Encoding>>
endobj
100 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
101 0 obj
<</OP false/OPM 0/op false>>
endobj
114 0 obj
<</A 115 0 R/Border[0 0 0]/Rect[250.388 9.0 292.133 16.0]/Subtype/Link/Type/Annot>>
endobj
115 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
94 0 obj
[116 0 R]
endobj
95 0 obj
<</Length 10305>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.019 Tw 10.5 0 0 10.5 60 730.8196 Tm
(tions, establishing a quit date, coping with triggers, and)Tj
-0.0251 Tc 0 -1.24762 TD
(t)Tj
-0.02499 Tc 0.008 Tw (eaching \322habit-busting\323 behavioral strategies that could be)Tj
-0.02299 Tc 0.02299 Tw 0 -1.24763 TD
(applied over the period prior to their quit date. Participants)Tj
-0.007 Tc 0.007 Tw 0 -1.24762 TD
[(selected a quit date 2\320)-25 (3 days prior to the second session.)]TJ
-0.017 Tc T*
[(S)-10 (ession 2 addressed problems associated with the quitting)]TJ
-0.035 Tc 0.009 Tw T*
(stage immediately following the quit date, such as managing)Tj
-0.034 Tc 0.024 Tw T*
(withdrawal symptoms, coping with cravings, managing fear)Tj
-0.01601 Tc 0.006 Tw T*
(of weight gain, and stress reduction. Session 3 focused on)Tj
-0.035 Tc 0.00101 Tw T*
(maintenance of change with strategies for prevention of slips)Tj
-0.02 Tc 0.00999 Tw T*
(and relapses and using a reward system. For follow-up, all)Tj
-0.035 Tc 0.02499 Tw 0 -1.24763 TD
(participants were instructed to call the clinic for questions or)Tj
0.013 Tw 0 -1.24761 TD
(to receive additional support as needed. )Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.011 Tw 8 0 0 8 70.5 558.7195 Tm
(CONTROL GROUP )Tj
ET
BT
/T1_0 1 Tf
-0.01801 Tc 0.01801 Tw 10.5 0 0 10.5 70.5 537.7195 Tm
(Once the baseline assessment was completed, the phar-)Tj
-0.017 Tc 0.01601 Tw -1 -1.23809 Td
(macist or APPE student used a structured script to deliver)Tj
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
[(the intervention. Participants received one timed 5)-25 (- to 10)-75 (-)]TJ
-0.039 Tc 0.024 Tw T*
[(m)-15 (i)-15 (n)-15 (u)-15 (t)-15 (e)-15 ( )-15 (s)-15 (e)-15 (s)-15 (s)-15 (i)-15 (o)-15 (n)-15 ( )-15 (o)-15 (v)-15 (e)-15 (r)-15 ( )-15 (t)-15 (h)-15 (e)-250 (telephone that included all the com-)]TJ
-0.036 Tc 0.021 Tw 0 -1.23809 TD
(ponents of standard care recommended by the Clinical Prac)Tj
0 Tc 21.95275 0 Td
(-)Tj
-0.03101 Tc 0.01601 Tw -21.95275 -1.2381 Td
(tice Guidelines)Tj
ET
BT
/T1_2 1 Tf
-0.02901 Tc 0 Tw 6 0 0 6 118.532 476.0197 Tm
(32)Tj
ET
BT
/T1_0 1 Tf
-0.03101 Tc 0.01601 Tw 10.5 0 0 10.5 126.6259 472.7196 Tm
[(and practiced within the V)130 (A for brief inter-)]TJ
-0.015 Tc 0.054 Tw -6.34532 -1.23809 Td
(ventions delivered by healthcare providers, referred to as)Tj
-0.026 Tc 0.011 Tw T*
(\322The 5 A)Tj
0 Tc 3.42397 0 Td
(\325)Tj
-0.026 Tc 0.25152 0 Td
(s\323: Ask about tobacco use, Advise to quit, Assess)Tj
-0.03999 Tc 0.005 Tw -3.67549 -1.2381 Td
(willingness to make a quit attempt, Assist in quit attempt, and)Tj
-0.034 Tc 0.019 Tw T*
(Arrange for follow-up. Standard care was delivered over the)Tj
-0.03999 Tc 0.002 Tw 24.57143 29.51213 Td
(telephone similar to telephone quit line services.)Tj
ET
BT
/T1_2 1 Tf
-0.03799 Tc 0 Tw 6 0 0 6 500.3294 733.897 Tm
(33)Tj
ET
BT
/T1_0 1 Tf
-0.03999 Tc 0.002 Tw 10.5 0 0 10.5 508.0728 730.5969 Tm
(For follow-)Tj
-0.035 Tc 0.019 Tw -18.10217 -1.23809 Td
(up, all participants were instructed to call the clinic for ques-)Tj
-0.03999 Tc 0.013 Tw 0 -1.2381 TD
(tions or to receive additional support as needed. )Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.011 Tw 8 0 0 8 328.5 676.5969 Tm
[(STUDY MEDICA)74 (TION)]TJ
ET
BT
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 10.5 0 0 10.5 328.5 655.5969 Tm
[(Participants in both groups were of)20 (fered their choice of)]TJ
-0.02499 Tc 0.00101 Tw -1 -1.23809 Td
[(either immediate-release bupropion 100)-75 (-mg tablets 3 times)]TJ
0 Tc 0.039 Tw T*
(daily or nicotine patch dosed at 21 mg once daily for 4)Tj
-0.02499 Tc 0.019 Tw T*
(weeks, then 14 mg once daily for 2 weeks, then 7 mg once)Tj
0.005 Tw 0 -1.23809 TD
[(daily for 2 weeks if smoking 10 or more cigarettes daily)65 (, or)]TJ
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
(14 mg once daily for 4 weeks, then 7 mg once daily for 2)Tj
-0.02499 Tc 0.02499 Tw T*
[(weeks if smoking fewer than 10 cigarettes daily)65 (, according)]TJ
-0.00301 Tc 0.00301 Tw 0 -1.23809 TD
[(to V)130 (A for)-25 (mulary options and guidelines. Participants re-)]TJ
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
[(ceiving bupropion received a 30)-75 (-)-74 (day supply plus 2 refills)]TJ
0 Tc 0.02 Tw 0 -1.23809 TD
[(to complete 12 weeks of therapy)65 (. Participants receiving)]TJ
-0.019 Tc 0.019 Tw T*
[(nicotine patches received a quantity suf)20 (f)1 (i)1 (c)1 (i)1 (e)1 (n)1 (t)1 ( )1 (t)1 (o)1 ( )1 (c)1 (o)1 (m)1 (p)1 (l)1 (e)1 (t)1 (e)]TJ
-0.00011 Tc T*
(8)Tj
0 Tc 0.114 Tw 0.86354 0 Td
[(weeks of step-)-75 (down therapy if smoking 10 or more)]TJ
-0.02499 Tc 0.00301 Tw -0.86354 -1.2381 Td
[(cigarettes daily or 6 weeks if fewer than 10 cigarettes daily)65 (.)]TJ
0 Tc 0.00999 Tw T*
(Dosage regimens were similar between groups. Prior to)Tj
0.013 Tw T*
[(prescribing any medications, the clinical phar)-19.4 (macist re-)]TJ
0.008 Tw 0 -1.2381 TD
(viewed patients\325 medical records for contraindications .)Tj
0.319 Tw 0 -1.23809 TD
(Contraindications for bupropion included history of)Tj
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
[(s)1 (e)1 (i)1 (z)1 (u)1 (r)1 (e)1 ( )1 (d)1 (i)1 (s)1 (o)1 (r)1 (d)1 (e)1 (r)41 (, history of eating disorder)40 (, use of another)]TJ
0 Tc 0.061 Tw 0 -1.23809 TD
[(for)-25 (m of bupropion, or use of a monoamine oxidase in-)]TJ
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(196)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(LA)-250 (Dent et al.)]TJ
ET
0 0 0 0 k
60 43.419 492 16.9 re
f
0 0 0 1 K
0.5 w 
60 60.069 m
552 60.069 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.01401 Tw 8.5 0 0 8.5 60 47.8186 Tm
(Figure 1.)Tj
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 97.2788 47.8186 Tm
(Participant flow through pharmacist-delivered smoking cessation program.\)Tj
ET
0 0 0 0 k
60 63.758 492 319.765 re
f
305.482 335.596 m
380.482 335.596 l
S
305.482 371.4175 m
305.482 219.7476 l
S
208.1021 219.7476 m
208.1021 70.9636 l
S
409.3129 219.7472 m
409.3129 68.8392 l
S
208.102 219.748 m
409.313 219.748 l
S
305.482 273.099 m
373.491 273.099 l
S
260.366 361.081 94.591 20.442 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
7.5 0 0 7.5 270.6699 369.3906 Tm
(308 persons screened)Tj
ET
260.116 360.831 95.091 20.942 re
h
S
0 0 0 0 k
261.391 288.73 94.591 20.442 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
7.5 0 0 7.5 268.2069 297.0393 Tm
(120 invited to participate)Tj
ET
261.141 288.48 95.091 20.942 re
h
S
0 0 0 0 k
326.982 315.73 140.486 38.734 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
7.5 0 0 7.5 329.9818 342.1852 Tm
(188 not eligible)Tj
1.5 -1.2 Td
(156 did not meet inclusion criteria)Tj
0.5 -1.2 Td
(32 unable to contact)Tj
ET
326.732 315.48 140.986 39.234 re
h
S
0 0 0 0 k
124.051 150.388 169.449 58.81 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
7.5 0 0 7.5 129.0513 195.8815 Tm
(50 assigned to pharmacist-delivered program)Tj
1.5 -1.2 Td
(28 attended all 3 sessions)Tj
0 -1.2 TD
(36 attended )Tj
/T1_7 1 Tf
5.5308 0 Td
(\263)Tj
/T1_6 1 Tf
-0.00011 Tc [0.2 (2)]TJ
0 Tc 0 Tw 1.36881 0 Td
(sessions)Tj
-0.01401 Tw -6.89961 -1.2 Td
(45 attended )Tj
/T1_7 1 Tf
5.5308 0 Td
(\263)Tj
/T1_6 1 Tf
-0.00011 Tc 0.47485 0 Td
(1)Tj
0 Tc 0 Tw 0.81997 0 Td
(sessions)Tj
-0.00011 Tc -6.32563 -1.2 Td
(5)Tj
0 Tc -0.01401 Tw 0.81991 0 Td
(did not attend any sessions)Tj
ET
123.801 150.138 169.949 59.31 re
h
S
0 0 0 0 k
318.5 150.654 183.168 58.81 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.015 Tc 7.5 0 0 7.5 323.5 182.6475 Tm
(51 assigned to standard care session over telephone)Tj
0 Tc 1.5 -1.2 Td
(51 participated)Tj
ET
318.25 150.4039 183.668 59.31 re
h
S
0 0 0 0 k
318.5 97.914 182.534 45.477 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.00011 Tc 7.5 0 0 7.5 323.5 132.241 Tm
(3)Tj
0 Tc 0.81985 0 Td
(lost to follow-up at 6 months)Tj
-0.00011 Tc 0.68014 -1.2 Td
(2)Tj
0 Tc 0.81989 0 Td
(declined to complete follow-up assessment)Tj
-0.00011 Tc -0.81989 -1.2 Td
(1)Tj
0 Tc 0.81988 0 Td
(died from causes unrelated to study)Tj
-0.00011 Tc -0.81988 -1.2 Td
(0)Tj
0 Tc 0.81989 0 Td
(withdrew consent)Tj
ET
318.25 97.6639 183.034 45.977 re
h
S
0 0 0 0 k
124.051 97.914 169.449 45.477 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.00011 Tc 7.5 0 0 7.5 129.0513 127.741 Tm
(1)Tj
0 Tc 0.81986 0 Td
(lost to follow-up at 6 months)Tj
-0.00011 Tc 0.68014 -1.2 Td
(1)Tj
0 Tc 0.81989 0 Td
(unable to contact)Tj
-0.00011 Tc -0.81988 -1.2 Td
(0)Tj
0 Tc 0.81989 0 Td
(withdrew consent)Tj
ET
123.801 97.6639 169.949 45.977 re
h
S
0 0 0 0 k
124.051 66.819 169.449 24.486 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
7.5 0 0 7.5 129.0513 77.15 Tm
(50 included in primary analysis)Tj
ET
123.801 66.5689 169.949 24.986 re
h
S
0 0 0 0 k
318.5 66.819 182.534 24.486 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
7.5 0 0 7.5 323.5 77.15 Tm
(51 included in primary analysis)Tj
ET
318.25 66.5689 183.034 24.986 re
h
S
0 0 0 0 k
329.495 261.896 140.487 18.979 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
7.5 0 0 7.5 332.4952 269.4738 Tm
(19 declined to participate)Tj
ET
329.245 261.6459 140.987 19.479 re
h
S
0 0 0 0 k
351.888 243.1419 m
351.888 235.4652 331.2969 229.2419 305.8965 229.2419 c
280.4961 229.2419 259.905 235.4652 259.905 243.1419 c
259.905 250.8187 280.4961 257.0419 305.8965 257.0419 c
331.2969 257.0419 351.888 250.8187 351.888 243.1419 c
f*
BT
0 0 0 1 k
/T1_6 1 Tf
7.5 0 0 7.5 279.066 241.4339 Tm
(101 randomized)Tj
ET
q
352.388 243.1419 m
352.388 235.189 331.573 228.7419 305.8965 228.7419 c
280.2199 228.7419 259.405 235.189 259.405 243.1419 c
259.405 251.0948 280.2199 257.5419 305.8965 257.5419 c
331.573 257.5419 352.388 251.0948 352.388 243.1419 c
W* n
1 w 
352.388 243.1419 m
352.388 235.189 331.573 228.7419 305.8965 228.7419 c
280.2199 228.7419 259.405 235.189 259.405 243.1419 c
259.405 251.0948 280.2199 257.5419 305.8965 257.5419 c
331.573 257.5419 352.388 251.0948 352.388 243.1419 c
h
S
Q
BT
0 g
/GS2 gs
/T1_8 1 Tf
0 Tw 5 0 0 5 291.13251 11 Tm
( at Library - Periodicals Dept on January 20, 2016)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
96 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
97 0 obj
<</OP false/OPM 0/op false>>
endobj
116 0 obj
<</A 117 0 R/Border[0 0 0]/Rect[250.388 9.0 292.133 16.0]/Subtype/Link/Type/Annot>>
endobj
117 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
90 0 obj
[118 0 R]
endobj
91 0 obj
<</Length 11885>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.024 Tc 0.024 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(ered by phar)-25 (macists suggest that it is feasible and ef)20 (fective)]TJ
-0.00999 Tc 0.00999 Tw 0 -1.23809 TD
[(for phar)-25 (macists to deliver such interventions.)]TJ
ET
BT
/T1_1 1 Tf
-0.008 Tc 0 Tw 6 0 0 6 245.5343 721.1196 Tm
(12)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 10.5 0 0 10.5 254.0412 717.8197 Tm
[(However)40 (,)]TJ
-0.019 Tc 0.019 Tw -18.48011 -1.2381 Td
(rigorously designed studies employing control groups and)Tj
-0.02299 Tc 0.022 Tw 0 -1.2381 TD
(biochemical verification for smoking cessation have yet to)Tj
-0.0251 Tc 0 -1.23809 TD
(be)Tj
-0.02499 Tc 0.013 Tw 1.13132 0 Td
(conducted in the US. )Tj
-0.01401 Tc 0.01401 Tw -0.13132 -1.21905 Td
[(T)-1 (h)-1 (i)-1 (s)-1 ( s)-1 (t)-1 (u)-1 (d)-1 (y)-1 ( a)-1 (s)-1 (s)-1 (e)-1 (s)-1 (s)-1 (e)-1 (d)-1 ( t)-1 (h)-1 (e)-1 ( e)-1 (f)19 (fectiveness )1 (on )1 (biochemically)]TJ
-0.008 Tc 0.008 Tw -1 -1.21905 Td
[(confir)-25 (med reports of smoking cessation of a face-to-face)]TJ
0 Tc 0.05 Tw 0 -1.21905 TD
[(group program conducted by a phar)-25 (macist team versus)]TJ
-0.02 Tc 0.02 Tw 0 -1.21904 TD
[(brief telephone assistance delivered by a phar)-25 (macist team.)]TJ
-0.011 Tc 0.011 Tw 0 -1.21905 TD
(Biochemical verification of self-reported cessation is im-)Tj
-0.02499 Tc 0.022 Tw T*
(portant to establish accuracy for studies using high-intensi-)Tj
0 Tc 0.02901 Tw T*
[(ty interventions, which suf)20 (fer from inflated quit rates if)]TJ
-0.02499 Tc 0.013 Tw T*
(based on self-report alone.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 164.6634 579.7197 Tm
(28)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 10.5 0 0 10.5 60 548.6197 Tm
(Methods)Tj
ET
BT
/T1_2 1 Tf
0.011 Tw 8 0 0 8 70.5 527.8196 Tm
(STUDY DESIGN)Tj
ET
BT
/T1_0 1 Tf
0.00101 Tw 10.5 0 0 10.5 70.5 507.0197 Tm
(This prospective, open-label, randomized trial compared)Tj
-0.017 Tc 0.017 Tw -1 -1.21905 Td
[(the ef)20 (fectiveness on 7-)-75 (day point prevalence quit rates of a)]TJ
-0.02499 Tc 0.005 Tw T*
[(face-to-face 3)-25 (-session group program conducted by a phar-)]TJ
-0.02 Tc 0.02 Tw T*
(macist team versus one 5)Tj
-0.0201 Tc 9.67551 0 Td
(-)Tj
-0.02 Tc 0.56281 0 Td
[(to 10)-74.5 (-minute standard care ses)]TJ
0 Tc 11.71449 0 Td
(-)Tj
-0.017 Tc 0.017 Tw -21.95281 -1.21906 Td
[(sion delivered by the phar)-25 (macist team over the telephone.)]TJ
-0.02499 Tc 0.013 Tw T*
(The intervention team consisted of a licensed clinical phar-)Tj
0 Tc 0.349 Tw T*
[(macist and advanced phar)-23.3 (macy practice experience)]TJ
-0.01601 Tc 0.01601 Tw T*
[(\(APPE\) students. Physicians at one V)119 (eterans Af)23 (fairs \(V)]TJ
-0.017 Tc 0 Tw 21.24701 0 Td
(A\))Tj
-0.02299 Tc 0.02299 Tw -21.24702 -1.21907 Td
(community-based outpatient clinic in the Rocky Mountain)Tj
-0.019 Tc 0.019 Tw T*
[(region referred patients who smoked to a clinical phar)-25 (ma-)]TJ
T*
(cist via the electronic computerized patient record system.)Tj
-0.00999 Tc 0.092 Tw T*
[(P)-10 (a)-10 (r)-10 (t)-10 (i)-10 (c)-10 (i)-10 (p)-10 (a)-10 (nts were randomized from October 3, 2005, to)]TJ
0.037 Tw T*
[(March 30, 2007, with the last 6)-25 (-month follow-up survey)]TJ
0.106 Tw T*
(completed on November 6, 2007. Analysis of data was)Tj
-0.015 Tc 0.005 Tw T*
(completed in December 2007. Participants in both groups)Tj
-0.01401 Tc 0.004 Tw T*
[(were of)19.6 (fered their choice of immediate-release bupropion)]TJ
-0.034 Tc 0.024 Tw T*
(tablets or nicotine patch. The V)Tj
-0.03391 Tc 11.51352 0 Td
(A)Tj
-0.034 Tc 0.92803 0 Td
(provided medication with-)Tj
-0.00999 Tc 0.011 Tw -12.44155 -1.21905 Td
(out cost to participants. At 6 months after the established)Tj
0.01801 Tw T*
(quit date, self-reported cessation was biochemically con-)Tj
-0.035 Tc 0.002 Tw T*
[(fir)-25 (med using tests for urinary cotinine. A visit was scheduled)]TJ
-0.033 Tc 0.02299 Tw T*
(within 3 days for the participant to provide a urinary sample)Tj
-0.034 Tc 0.024 Tw T*
(at the clinic. Participants in the treatment and control groups)Tj
-0.035 Tc 0.01401 Tw T*
[(set a quit date 10)-108.7 (\32014 days after the first intervention contact.)]TJ
-0.034 Tc 0.024 Tw 0 -1.21904 TD
(Those who did not elect to set a quit date were assigned day)Tj
-0.02299 Tc 0.013 Tw 0 -1.21905 TD
(12 after the first intervention contact as their quit date. The)Tj
-0.019 Tc 0.009 Tw T*
(trial procedures were approved and monitored by the Uni-)Tj
-0.035 Tc 0.013 Tw T*
(versity of Montana institutional review board. )Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.011 Tw 8 0 0 8 70.5 146.4196 Tm
(SCREENING AND ELIGIBILITY CRITERIA)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.009 Tw 10.5 0 0 10.5 70.5 125.4196 Tm
(The flow of participants through the study appears in)Tj
-0.02499 Tc 0.00999 Tw -1 -1.23809 Td
(Figure 1. The patient electronic medical record system was)Tj
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(used to identify and exclude patients with a diagnosis of)Tj
0 Tc 0.022 Tw T*
[(schizophrenia, who require a dif)20 (ferent approach to help)]TJ
-0.002 Tc 0.002 Tw 0 -1.23809 TD
(them quit smoking, and those with prior participation in)Tj
0 Tc 0.05901 Tw 0 -1.2381 TD
[(the phar)-24.1 (macy group program. A scripted questionnaire)]TJ
-0.007 Tc 0.006 Tw 0 -1.23809 TD
[(conducted over the telephone was used by the phar)-25 (macy)]TJ
-0.002 Tc 0.002 Tw 24.57143 65.08572 Td
[(team to screen patients referred to the study)65 (. Individuals)]TJ
-0.009 Tc 0.008 Tw T*
(who planned to leave the area in the next 6 months, used)Tj
0 Tc 0.13 Tw 0 -1.2381 TD
[(phar)-25 (macotherapy for smoking cessation in the last 30)]TJ
0.009 Tw T*
[(days, or used for)-25 (ms of tobacco other than cigarettes \(ie,)]TJ
-0.02 Tc 0.02 Tw 0 -1.23809 TD
(cigars, pipe tobacco, spit tobacco\) in the last 30 days were)Tj
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
(excluded. Eligible patients smoked one or more cigarettes)Tj
-0.002 Tc 0.002 Tw T*
(daily for 7 days, were at least somewhat ready to quit in)Tj
0 Tc 0.019 Tw 0 -1.23809 TD
(the next 2 weeks \()Tj
/T1_3 1 Tf
7.34986 0 Td
(\263)Tj
/T1_0 1 Tf
[0.2 (4)-268.8 (on a 10)-75 (-point motivational scale\),)]TJ
-0.02499 Tc 0.01401 Tw -7.34987 -1.2381 Td
(were willing and capable of attending 3 scheduled sessions)Tj
0 Tc 0.05701 Tw 0 -1.2381 TD
(at the clinic, and were interested in participating in the)Tj
0 Tw 0 -1.23809 TD
[(study)65 (.)]TJ
ET
BT
/T1_1 1 Tf
0.002 Tc 6 0 0 6 342.6914 604.1197 Tm
(26)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.033 Tw 10.5 0 0 10.5 351.6627 600.8197 Tm
(Patients excluded from participating in the trial)Tj
-0.02499 Tc 0.013 Tw -3.20597 -1.2381 Td
[(were treated outside the study)65 (. )]TJ
ET
BT
/T1_2 1 Tf
0.011 Tw 8 0 0 8 328.5 559.8197 Tm
[(STUDY ENROLLMENT)111 (, RANDOMIZA)74 (TION, AND BASELINE)]TJ
0 Tw 0 -1.625 TD
(ASSESSMENT)Tj
ET
BT
/T1_0 1 Tf
-0.011 Tc 0.011 Tw 10.5 0 0 10.5 328.5 525.8947 Tm
(Following successful completion of the screening pro)Tj
0 Tc 20.95285 0.00001 Td
(-)Tj
0.02 Tw -21.95285 -1.23096 Td
(cedures, eligible participants were sent copies of an ap-)Tj
-0.02499 Tc 0.008 Tw 0 -1.23095 TD
[(proved consent for)-25 (m along with a self-addressed retur)-25 (n en-)]TJ
0 Tc 0.037 Tw 0 -1.23096 TD
[(velope. Those who did not retur)-25 (n the consent materials)]TJ
-0.011 Tc 0.011 Tw 0 -1.23095 TD
[(were recontacted 2 additional times. Consent for)-25 (ms were)]TJ
-0.02499 Tc 0.005 Tw T*
(collected for all participants invited to participate. Once the)Tj
-0.01601 Tc 0.01601 Tw T*
[(signed consent for)-25 (m was received, the participant was se-)]TJ
0 Tc 0.05701 Tw T*
(quentially enrolled into the trial and randomized to the)Tj
-0.02499 Tc 0.024 Tw T*
[(treatment or control group by the clinical phar)-20.6 (macist. Ran)]TJ
0 Tc 21.95294 0.00001 Td
(-)Tj
-0.01199 Tc 0.01199 Tw -21.95294 -1.23096 Td
(domization codes assigned to each participant were com)Tj
0 Tc 21.95294 0 Td
(-)Tj
-0.006 Tc 0.006 Tw -21.95294 -1.23095 Td
(puter generated by the study statistician and stratified by)Tj
-0.024 Tc 0.024 Tw T*
[(sex in blocks of 6. The phar)-25 (macist team conducted a base-)]TJ
-0.005 Tc 0.005 Tw T*
(line assessment over the telephone, then notified partici-)Tj
T*
(pants of their group assignment. Participants assigned to)Tj
-0.01601 Tc 0.01601 Tw T*
[(the face-to-face treatment group were infor)-10.7 (med of the de)]TJ
0 Tc 21.95301 0 Td
(-)Tj
-0.01401 Tc 0.01401 Tw -21.95302 -1.23096 Td
(tails regarding the first group session. For participants as-)Tj
-0.02499 Tc 0.015 Tw T*
(signed to the control group, the standard care smoking ces-)Tj
0.013 Tw T*
(sation components were delivered over the telephone. )Tj
ET
BT
/T1_2 1 Tf
0 Tw 8 0 0 8 328.5 278.1697 Tm
(TREA)Tj
0.011 Tw 2.5477 0.00001 Td
(TMENT GROUP )Tj
ET
BT
/T1_0 1 Tf
-0.024 Tc 0.024 Tw 10.5 0 0 10.5 328.5 257.0695 Tm
(Participants assigned to the treatment group participated)Tj
-0.01801 Tc 0.01801 Tw -1 -1.24762 Td
[(in a face-to-face 3)-25 (-session group program at the clinic de-)]TJ
-0.017 Tc 0.017 Tw 0 -1.24762 TD
[(livered by the phar)-25 (macist and APPE students. The 6)-25 (-hour)]TJ
-0.02499 Tc 0.024 Tw T*
(program consisted of 3 in-person sessions \(3 hours for ses-)Tj
-0.01801 Tc 0.01801 Tw 0 -1.24761 TD
(sion 1, 2 hours for session 2, and 1 hour for session 3\) de-)Tj
-0.013 Tc 0.013 Tw 0 -1.24762 TD
(livered at 2-week intervals over 5 weeks to a small group)Tj
-0.02299 Tc 0.02299 Tw T*
(of smokers that varied in size from 3 to 10 participants per)Tj
0 Tc 0.002 Tw T*
[(program. Groups were for)-22.6 (med about every 3)-48.6 (\320)]TJ
-0.00011 Tc 18.58912 0.00003 Td
(4)Tj
0 Tc 0 Tw 0.75187 0 Td
(months)Tj
-0.01199 Tc 0.01199 Tw -19.34099 -1.24764 Td
(depending on the number of referrals. The treatment pro-)Tj
0 Tc 0.056 Tw T*
[(gram, adapted from the \322V)113.5 (ets W)40.9 (ithout Cigarettes\323 pro)2.7 (-)]TJ
-0.02499 Tc 0 Tw 0 -1.24761 TD
(gram)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 6 0 0 6 338.5216 129.3696 Tm
(29)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.013 Tw 10.5 0 0 10.5 346.7172 126.0696 Tm
[(developed by the V)130 (A Montana V)110 (eterans Health Ad-)]TJ
0.02499 Tw -2.73497 -1.24762 Td
(ministration, uses multiple theories of behavior change, in-)Tj
0 Tc 0.017 Tw 0 -1.24762 TD
[(cluding the T)35 (ranstheoretical Model of Change)]TJ
ET
BT
/T1_1 1 Tf
0.002 Tc 0 Tw 6 0 0 6 512.4053 103.1696 Tm
(30)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.017 Tw 10.5 0 0 10.5 521.2085 99.8696 Tm
(and the)Tj
-0.01401 Tc 0.01401 Tw -19.35319 -1.24762 Td
(health belief model.)Tj
ET
BT
/T1_1 1 Tf
-0.01199 Tc 0 Tw 6 0 0 6 399.0457 90.0696 Tm
(31)Tj
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0.01401 Tw 10.5 0 0 10.5 407.5038 86.7696 Tm
[(The program, described previously)65 (,)]TJ
-0.01199 Tc 0.01199 Tw -8.52417 -1.24762 Td
(used peer support, goal setting, behavioral strategies, and)Tj
-0.02499 Tc 0.009 Tw T*
(cognitive techniques to elicit and support change.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 513.3357 63.8696 Tm
(26)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10.5 521.4933 60.5695 Tm
(Session)Tj
-0.01089 Tc -19.38031 -1.24763 Td
(1)Tj
-0.011 Tc 0.011 Tw 0.73901 0 Td
(facilitated preparation to quit by assisting with medica-)Tj
ET
0 0 0 0 k
318 745 234 10 re
f
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(195)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 Tc 5 0 0 5 291.13251 11 Tm
( at Library - Periodicals Dept on January 20, 2016)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
92 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
93 0 obj
<</OP false/OPM 0/op false>>
endobj
118 0 obj
<</A 119 0 R/Border[0 0 0]/Rect[250.388 9.0 292.133 16.0]/Subtype/Link/Type/Annot>>
endobj
119 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
86 0 obj
[120 0 R]
endobj
87 0 obj
<</Length 11935>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60.5 17.75 391 13 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.024 Tc 10 0 0 10 60.5 23.9116 Tm
(194)Tj
ET
BT
/T1_1 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 38.117 492 484.824 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tc 27.357 0 0 27.357 59.7366 502.7603 Tm
(A)Tj
ET
BT
/T1_4 1 Tf
-0.00031 Tc 10.5 0 0 10.5 77.875 515.7603 Tm
(s)Tj
0 Tc 0.63859 0 Td
(one of the most accessible health)Tj
0.03999 Tw -0.63859 -1.23809 Td
(professionals in the US healthcare)Tj
0 Tw -1.70238 -1.2381 Td
(system,)Tj
ET
BT
/T1_0 1 Tf
6 0 0 6 91.7871 493.0603 Tm
(1)Tj
ET
BT
/T1_4 1 Tf
10.5 0 0 10.5 97.4553 489.7603 Tm
(phar)Tj
0.004 Tw 1.80151 0 Td
(macists are in a key posi-)Tj
0.022 Tw -5.36869 -1.23809 Td
(tion to assist individuals with tobacco-)Tj
0.04401 Tw 0 -1.23809 TD
(cessation services. Moreover)Tj
-0.00011 Tc 11.62426 0 Td
(,)Tj
0 Tc 0 Tw 0.54342 0 Td
[(phar)-24.7 (ma)0.3 (-)]TJ
-0.00999 Tc 0.00999 Tw -12.16767 -1.23809 Td
(cists are ideally situated to interact with)Tj
0 Tc 0.185 Tw 0 -1.2381 TD
(individuals obtaining medications for)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(smoking-related illnesses. )Tj
-0.03101 Tc 0 Tw 1 -1.23809 Td
(Phar)Tj
-0.036 Tc 0.021 Tw 1.734 0 Td
(macists consider tobacco cessation)Tj
-0.02901 Tc 0.01401 Tw -2.734 -1.2381 Td
(an important activity and are interested in)Tj
-0.015 Tc 0.056 Tw T*
(providing such counseling.)Tj
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0 Tw 6 0 0 6 170.5263 389.0604 Tm
(2,3)Tj
ET
BT
/T1_4 1 Tf
-0.015 Tc 0.056 Tw 10.5 0 0 10.5 180.8163 385.7603 Tm
(Few phar-)Tj
-0.036 Tc 0.021 Tw -11.50631 -1.23809 Td
[(macists are for)-24.1 (mally trained to provide to)]TJ
0 Tc [0.4 (-)]TJ
-0.03999 Tc 0.009 Tw 0 -1.2381 TD
(bacco cessation counseling.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 165.172 363.0604 Tm
(4)Tj
ET
BT
/T1_4 1 Tf
-0.03999 Tc 0.009 Tw 10.5 0 0 10.5 170.2291 359.7603 Tm
[(However)40 (, op-)]TJ
-0.03799 Tc 0.02299 Tw -10.49801 -1.23809 Td
[(portunities for phar)-30.3 (macists to receive such)]TJ
-0.02299 Tc 0.007 Tw T*
(training are increasing,)Tj
ET
BT
/T1_0 1 Tf
0.00301 Tc 0 Tw 6 0 0 6 150.9804 337.0604 Tm
[(5-)24 (7)]TJ
ET
BT
/T1_4 1 Tf
-0.02299 Tc 0.007 Tw 10.5 0 0 10.5 161.1892 333.7603 Tm
(which has been)Tj
-0.03799 Tc 0.02299 Tw -9.63707 -1.2381 Td
[(shown to increase confidence, quality)65 (, and)]TJ
-0.015 Tc 0.34599 Tw 0 -1.23809 TD
(provision of counseling.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 165.2502 311.0604 Tm
(4)Tj
ET
BT
/T1_4 1 Tf
-0.015 Tc 10.5 0 0 10.5 174.2579 307.7603 Tm
(Automation)Tj
-0.039 Tc 0.024 Tw -10.8817 -1.23809 Td
(technology and certification of technicians)Tj
-0.015 Tc 0.05099 Tw T*
[(are freeing phar)-25 (macists from traditional)]TJ
0.052 Tw T*
(dispensing responsibilities.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 169.8637 272.0604 Tm
(8)Tj
ET
BT
/T1_4 1 Tf
-0.015 Tc 0.052 Tw 10.5 0 0 10.5 175.7837 268.7603 Tm
(In addition,)Tj
-0.03101 Tc 0.01601 Tw -11.02702 -1.2381 Td
[(updated phar)-25 (macy practice laws allowing)]TJ
-0.035 Tc 0.02 Tw T*
(for collaborative practice agreements with)Tj
-0.03999 Tc 0.01601 Tw 0 -1.2381 TD
[(physicians are empowering phar)-23.3 (macists to)]TJ
-0.015 Tc 0.03799 Tw 0 -1.23809 TD
(initiate and modify drug therapy for pa-)Tj
-0.03999 Tc 0.013 Tw T*
(tients, including tobacco cessation.)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 191.9375 207.0604 Tm
(9)Tj
ET
BT
/T1_4 1 Tf
-0.002 Tc 0.002 Tw 10.5 0 0 10.5 70.5 190.7603 Tm
[(Phar)-25 (macists in a wide variety of set-)]TJ
0 Tc 0.06 Tw -1 -1.2381 Td
(tings have begun to provide direct pa-)Tj
0.29201 Tw T*
(tient care, including smoking cessa-)Tj
-0.021 Tc 0 Tw 0 -1.2381 TD
(tion.)Tj
ET
BT
/T1_0 1 Tf
-0.02 Tc 6 0 0 6 77.8656 155.0604 Tm
(10,1)Tj
0 Tc 1.61148 0.00001 Td
(1)Tj
ET
BT
/T1_4 1 Tf
-0.021 Tc 0.021 Tw 10.5 0 0 10.5 93.0344 151.7603 Tm
(Although there is growing inter-)Tj
-0.02 Tc 0.019 Tw -3.14613 -1.2381 Td
[(est in expanding the phar)-38.2 (macist\325)55 (s role in)]TJ
-0.009 Tc 0.009 Tw T*
(tobacco treatment, only 15 studies have)Tj
-0.024 Tc 0.024 Tw T*
[(assessed the ef)20.2 (fectiveness of phar)-25 (macist-)]TJ
-0.00101 Tc 0.00101 Tw 0 -1.23809 TD
(delivered tobacco cessation interventions.)Tj
ET
BT
/T1_0 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 235.052 103.0604 Tm
(12)Tj
ET
BT
/T1_4 1 Tf
-0.00101 Tc 0.00101 Tw 10.5 0 0 10.5 243.6636 99.7603 Tm
(Five studies)Tj
-0.024 Tc 0.024 Tw -17.49177 -1.23809 Td
(were controlled)Tj
ET
BT
/T1_0 1 Tf
-0.022 Tc 0 Tw 6 0 0 6 122.1177 90.0604 Tm
[(13)-23 (-17)]TJ
ET
BT
/T1_4 1 Tf
-0.024 Tc 0.024 Tw 10.5 0 0 10.5 138.1808 86.7603 Tm
(and 10 were uncontrolled.)Tj
ET
BT
/T1_0 1 Tf
-0.022 Tc 0 Tw 6 0 0 6 242.3518 90.0604 Tm
[(18)-23 (-27)]TJ
ET
BT
/T1_4 1 Tf
-0.024 Tc 10.5 0 0 10.5 258.4148 86.7603 Tm
(Fourteen)Tj
-0.022 Tc 0.022 Tw 5.67478 1.24748 Td
[(of the studies tar)20 (geted smoking)]TJ
ET
BT
/T1_0 1 Tf
-0.02 Tc 0 Tw 6 0 0 6 442.6683 103.1588 Tm
(14)Tj
-0.021 Tc 0.98021 0.00001 Td
(-27)Tj
ET
BT
/T1_4 1 Tf
-0.022 Tc 0.022 Tw 10.5 0 0 10.5 458.7691 99.8588 Tm
[(and 1 tar)20 (geted chewing)]TJ
-0.019 Tc 0 Tw -13.40658 -1.2381 Td
(tobacco.)Tj
ET
BT
/T1_0 1 Tf
-0.01601 Tc 6 0 0 6 351.7194 90.1588 Tm
(13)Tj
ET
BT
/T1_4 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 360.1223 86.8588 Tm
(Of 8 studies on smoking interventions conduct-)Tj
0 Tc 0.032 Tw -4.01165 -1.2381 Td
(ed in the US, none included a control group)Tj
ET
BT
/T1_0 1 Tf
0.00101 Tc 0 Tw 6 0 0 6 504.0873 77.1588 Tm
[(1)-1 (9)-24 (-21,23)-24 (-27)]TJ
ET
BT
/T1_4 1 Tf
0 Tc 10.5 0 0 10.5 536.8394 73.8588 Tm
(and)Tj
-0.02499 Tc 0.021 Tw -20.84185 -1.23809 Td
(only 2 used biochemical measures to confir)Tj
-0.0251 Tc 16.48023 0.00001 Td
(m)Tj
-0.02499 Tc 0 Tw 0.99822 0 Td
(self-reported)Tj
-0.005 Tc -17.47845 -1.2381 Td
(cessation.)Tj
ET
BT
/T1_0 1 Tf
-0.004 Tc 6 0 0 6 358.5977 51.1588 Tm
(19,20)Tj
ET
BT
/T1_4 1 Tf
-0.005 Tc 0.005 Tw 10.5 0 0 10.5 374.5769 47.8588 Tm
(The studies of tobacco interventions deliv-)Tj
ET
0 0 0 0 k
60 565.9189 492 106.556 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 0.011 Tw 16.8 0 0 16 60 644.837 Tm
[(Randomiz)20 (ed T)124 (rial Assessing the Eff)10 (ectiv)20 (eness of a Pharmacist-)]TJ
0 -1.5 TD
[(Deliv)20 (er)19 (ed Pr)25 (o)15 (gram f)9 (or Smoking Cessation)]TJ
ET
BT
/T1_3 1 Tf
10.5 0 0 10 60 584.837 Tm
(Larry A Dent, Kari Jo Harris, and Curtis W Noonan)Tj
ET
0 0 0 0 k
60 717 492 21 re
f
0 0 0 1 K
0.5 w 
60 721.886 m
552 721.886 l
S
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc 13 0 0 13 60 729.1355 Tm
(Drug, Alcohol, and Substance Abuse)Tj
ET
60 60.25 m
294.002 60.25 l
S
BT
/T1_3 1 Tf
-0.02499 Tc 8.5 0 0 8.5 60 48 Tm
(Author information provided at the end of the text.)Tj
ET
0 0 0 0.14999 k
239 123.262 313 399.679 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.024 Tc 0 Tw 7 0 0 7 251 502.3882 Tm
(BACKGROUND)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 300.6395 502.3882 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
-0.017 Tc 0.017 Tw 8.5 0 0 8.5 306.1609 502.3882 Tm
(As trained and accessible healthcare professionals, pharmacists)Tj
0 Tc 0.036 Tw -6.48952 -1.29412 Td
(are in an ideal position to provide tobacco cessation interventions. Of \the 15)Tj
0.254 Tw 0 -1.29412 TD
[(studies identified in the literature assessing the ef)18 (fectiveness of tobacco)]TJ
0.037 Tw T*
(cessation interventions delivered by pharmacists, this is the first rand\omized)Tj
0.155 Tw T*
(controlled trial conducted in the US of a pharmacist-delivered program f\or)Tj
-0.02499 Tc 0.011 Tw T*
(smoking cessation using biochemical confirmation.)Tj
ET
BT
/T1_6 1 Tf
-0.021 Tc 0 Tw 7 0 0 7 251 433.3882 Tm
(OBJECTIVE)Tj
ET
BT
/T1_6 1 Tf
-0.015 Tc 10 0 0 10 289.3604 433.3882 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
0 Tc 8.5 0 0 8.5 295.3208 433.3882 Tm
(T)Tj
-0.01469 Tc 0.48544 0 Td
(o)Tj
-0.015 Tc 0.015 Tw 0.81925 0 Td
[(assess the ef)14.1 (fectiveness on smoking cessation of a face-to-face)]TJ
0 Tc 0.205 Tw -6.5189 -1.29413 Td
(group program conducted by the pharmacist team compared with a brief)Tj
-0.02499 Tc 0.011 Tw T*
(standard care session delivered by a pharmacist over the telephone. )Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 7 0 0 7 251 397.3882 Tm
(METHODS)Tj
ET
BT
/T1_6 1 Tf
-0.0004 Tc 10 0 0 10 285.9947 397.3882 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
0 Tc 0.37801 Tw 8.5 0 0 8.5 295.8854 397.3882 Tm
(An open-label, prospective, randomized, controlled trial was)Tj
0.04601 Tw -5.28064 -1.29412 Td
[(conducted at a V)55 (eterans Health Administration, community-based outpatient)]TJ
0.05499 Tw T*
(clinic in the Rocky Mountain region. Participants were randomly assigned\ to)Tj
-0.00101 Tc 0.00101 Tw T*
(receive a 3-session face-to-face group program conducted by the pharmaci\st)Tj
-0.01401 Tc 0.01401 Tw T*
(team or one 5- to 10-minute standard care session delivered by the pharm\acist)Tj
0 Tc 0.22301 Tw T*
[(team over the telephone. Participants in both groups were of)22.7 (fered either)]TJ
-0.01801 Tc 0.01801 Tw T*
(immediate-release bupropion or nicotine patch at no cost. The primary ou\tcome)Tj
-0.017 Tc 0.017 Tw T*
(of self-reported abstinence was biochemically confirmed by urinary cotin\ine at 6)Tj
-0.02499 Tc 0.011 Tw T*
(months after the quit date. )Tj
ET
BT
/T1_6 1 Tf
-0.032 Tc 0 Tw 7 0 0 7 251 295.3882 Tm
[(RESUL)74 (TS)]TJ
ET
BT
/T1_6 1 Tf
-0.0228 Tc 10 0 0 10 281.5823 295.3882 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
-0.022 Tc 0.022 Tw 8.5 0 0 8.5 287.4646 295.3882 Tm
(One hundred one smokers were randomized from October 3, 2005, to)Tj
-4.28996 -1.29412 Td
(March 30, 2007, with the last 6-month follow-up survey completed on Nove\mber)Tj
-0.02499 Tc 0.02499 Tw T*
(6, 2007. Analysis of data was completed in December 2007. Using intent-t\o-treat)Tj
-0.02 Tc 0.02 Tw T*
(procedures, confirmed abstinence rates at the end of 6 months were 28% i\n the)Tj
-0.00101 Tc 0.00101 Tw T*
[(pharmacist-delivered face-to-face treatment group and 1)74 (1.8% in the standard)]TJ
-0.02499 Tc 0.011 Tw T*
(care telephone session control group \(p < 0.041\). )Tj
ET
BT
/T1_6 1 Tf
-0.02901 Tc 0 Tw 7 0 0 7 251 226.3882 Tm
(CONCLUSIONS)Tj
ET
BT
/T1_6 1 Tf
-0.0204 Tc 10 0 0 10 300.5199 226.3882 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
-0.02 Tc 0.02 Tw 8.5 0 0 8.5 306.4263 226.3882 Tm
[(This study demonstrates that pharmacists are ef)21.3 (fective providers)]TJ
-0.015 Tc 0.015 Tw -6.52075 -1.29411 Td
(of tobacco cessation interventions. Greater utilization of pharmacists i\n tobacco)Tj
-0.01801 Tc 0.00301 Tw T*
[(cessation ef)18 (forts could have a significant impact on smoking rates, prevention of)]TJ
-0.03999 Tc 0.011 Tw T*
(tobacco-related diseases, and overall improvement in public health acros\s the US. )Tj
ET
BT
/T1_6 1 Tf
-0.028 Tc 0 Tw 7 0 0 7 251 179.3882 Tm
[(KEY)-397 (WORDS)]TJ
ET
BT
/T1_6 1 Tf
-0.02 Tc 10 0 0 10 293.4316 179.3882 Tm
(:)Tj
ET
BT
/T1_3 1 Tf
0.02 Tw 8.5 0 0 8.5 299.3419 179.3882 Tm
[(nicotine addiction, pharmacist\325)18 (s role, pharmacy)74 (, smoking cessation)]TJ
-0.02499 Tc 0.011 Tw -5.68728 -1.29412 Td
(intervention, tobacco cessation.)Tj
ET
BT
/T1_7 1 Tf
-0.0251 Tc 0 Tw 8.5 0 1.80673 8.5 251 153.3881 Tm
(Ann)Tj
-0.02499 Tc 1.96762 0 Td
(Pharmacother)Tj
ET
BT
/T1_3 1 Tf
8.5 0 0 8.5 322.581 153.3881 Tm
(2009;43:194-201.)Tj
0.011 Tw -8.42129 -1.7647 Td
(Published Online, 27 Jan 2009, )Tj
ET
BT
/T1_7 1 Tf
0 Tw 8.5 0 1.80673 8.5 365.3453 138.3881 Tm
[(www)55 (.theannals.com)]TJ
ET
BT
/T1_3 1 Tf
-0.0251 Tc 8.5 0 0 8.5 437.3008 138.3881 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.51686 0 Td
(DOI 10.1345/aph.1L556)Tj
1 g
/T1_8 1 Tf
-0.278 Tc 0 Tw 1 0 0 1 -1000 1792 Tm
( )Tj
ET
BT
0 g
/GS2 gs
/T1_9 1 Tf
0 Tc 5 0 0 5 291.13251 11 Tm
( at Library - Periodicals Dept on January 20, 2016)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
36 0 obj
<</BaseFont/FOLFJJ+GillSans-Bold/Encoding 33 0 R/FirstChar 32/FontDescriptor 35 0 R/LastChar 122/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 271 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 781 0 771 802 635 0 0 0 0 0 0 0 0 0 0 656 0 677 604 719 0 0 0 0 0 0 0 0 0 0 0 0 531 583 500 583 552 302 542 583 271 0 552 271 958 583 594 0 0 448 427 406 583 510 0 0 0 521]>>
endobj
44 0 obj
<</BaseFont/BUTFVK+Helvetica-Oblique/Encoding 41 0 R/FirstChar 32/FontDescriptor 43 0 R/LastChar 119/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278 0 0 722]>>
endobj
48 0 obj
<</BaseFont/YOMDQD+Helvetica-Bold/Encoding 45 0 R/FirstChar 32/FontDescriptor 47 0 R/LastChar 32/Subtype/Type1/Type/Font/Widths[278]>>
endobj
45 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space]/Type/Encoding>>
endobj
47 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262178/FontBBox[-170 -227 1001 963]/FontFile3 46 0 R/FontName/YOMDQD+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
46 0 obj
<</Length 313/Length1 313/Subtype/Type1C>>stream
  YOMDQD+Helvetica-Bold   @¯ ¯¯¯¯˚>˚w˙}˙W
 ãã
 ãã      ≤   Äçï002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki      ¸wü¯ßö˜,óíüòã˜£ó¸|ãı
˜ å
_˜™˘
endstream
endobj
41 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 46/period 65/A 80/P 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t 119/w]/Type/Encoding>>
endobj
43 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-214 -224 1198 931]/FontFile3 42 0 R/FontName/BUTFVK+Helvetica-Oblique/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
42 0 obj
<</Length 1421/Length1 1421/Subtype/Type1C>>stream
  BUTFVK+Helvetica-Oblique   E¯ ¯¯¯¯˚:˚t˙|˙7
 ã
 o
 ãã      ¸  !¨  l Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    " O  1 I B S N D P U F X  M T    < ~ Å √ ˝â¬!s∫ÎHÜñ´%ú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷¸ú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è”†v¯üwõ˘I˘Y¯ü4 ¸.â&¯.)&¸.â'¯.,˜+¸üÂÒ¯)çÙ¸)Ê¸ãı‚Û˜Sı#!¸@†v˘awŒ„˜/˘a3˝a˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛu°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
33 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma/hyphen 65/A 67/C/D/E 80/P 82/R/S/T 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o 114/r/s/t/u/v 122/z]/Type/Encoding>>
endobj
35 0 obj
<</Ascent 716/CapHeight 682/Descent -221/Flags 262176/FontBBox[-177 -230 1167 929]/FontFile3 34 0 R/FontName/FOLFJJ+GillSans-Bold/ItalicAngle 0/StemH 0/StemV 145/Type/FontDescriptor/XHeight 728>>
endobj
34 0 obj
<</Length 2541/Length1 2541/Subtype/Type1C>>stream
  FOLFJJ+GillSans-Bold   A¯ ¯¯¯¯˚E˚zè˙5
 ãã
 ãã       C±  	« }ãîCopyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans    3 B O E P N J [ F  5 S M " T H U I & G D W 1  % 4 L $ V  C     W «	c™Rw…ÃÓ.Gâ‹•‰$Rô›C]¢˚4øË@¸¶†v˜©˜˜/˜◊˜>˜K˜C◊˘>˝>˜>˜©ºÁ¶˚˚&‘˜O+˜\vﬂEÆŸØ≤√ã÷ãÒ8È˚ ã˚˚·À¨qXQ]w\1˚Ç·˜ºÏ¨˜'˜˜%¯ß˜siÄâÅ|Çî¢˜f<≤˚BHxfO˚
∫πÕ©≈ üi`à˚UO:u˚Q¬T’Ωπô±√fï¢|ª≤ƒù£≥˚t⁄usn~pqv°¶π¥ü·™H†v¯	„3Ï«˜%˜A˜%ÿ˜a¯a˚%¸a˜%∏˜Ωƒ±¶ûØ¥™pJ˚≠˜%˜π˜+¥CP^uV]HÇÏ3„˜±Ï˜hwÆ˜'˜Y˜%º¯†˘>˚%˚Öûddïa˚/)˚!˚Á%˜º±ò¨¥|f˜%º˚%˜pmrÄlG`√ﬂÁ∂¿‘•≠|†SÇ·˜«·∞˜/˜f˜/¯¡˜z˜E˚& ˚˚˚9˚1˚%˜,˜+Ò˜1√˜K˚/è&gSGTXÆ˜Û∂º ‘™O1˜»†v¯	ÏÇw ˜%˜[˜%˜[˜%º˜d¯a˚%¸a˜%‹˜…µÆ±°±∂∏r@˚•˜%˜ªæ¨≤¶µ¿´fI˚¢˜%˜ºÙ@–"FVnFOÕkU´;npÜÄpºqqzrt¸†v¯awÂ˜4¬˜4˚,˜%Ë˜d¯a˚%¸a˜%0B˘G_gg__Øg∑∑ØØ∑∑gØ_˚ãÓ˜õÓû¯mµ¯a(˜j˚Å˚˛¯mÓ˚Ä˜Ä˜˛)Ç·˜◊·∞˜*˜_˜¯í˜#ZG^zQ0Sª›Ü˜ﬂ˜<í˚Í˚˚"&'˚!˚$Ù-˜6Ø‚ã»ﬁ˚‘˜{Àë∞∞ƒ√±eLë¸–†v¯¡˜˜ß˜>˘H˘>˝,˚˜ã¸¡˜>¯¡˜ã˚^†v˜‚˜ÇwÀ˜%∞˜e¯a˚%¸a˜%˜[–‡´≠Ω¿¢§Ås±≥˜a™rñnãS[^+`â¸†v˘>w ˜%˜d˘>˚%˝>˜%˜†v˜˜˜ù˜7ãwé˘õÿ¯o˘>˚Y˚ß˝>˜Hæ˜˜≈√˚˜K˚µ˜í˚fËÔ˜ù˚sÇÏ˜ûvæ·∞˜Í˜¯¯H£[`ïQ˚>R6˚+˜yóãHvp~`T\ûü\%Äü“t’˜œ¡Î˜.˚yçãæ´¨èû®…d ˚ ˚z·˜ˇ a¿ ˇ GaHˇ I·Hˇ õ˝pÏ5·ß˜˚˜1˜˜˜%˜ÚÄ¯¶¯a˚¶˚:c˚RÒ@6—[∆ÇâpÖR~Zj§y™ÇâÙ@%qvYdNøB˜V˜)Íªˆ¢ÑØm©Ò@?ÿ˚D]¿¡˜[››ÚÄ§§úÆ¥¶Ñ°{ßÕÍÄ˚ÌB∫Ø∞ªΩ¨fa[fc]]e±∏Ù@˜\¸lcpK>aûÆ≠µ†œ”¥yj˚àÇˆ˜úÓŸ˜%¯¯a˚<˜%y˚U˚loÕ˚Z˚ﬁ_Î∏±ì†æÙwdoÑm^q®∏˜R˜<H†v¯ ı˜hw…˜%˜@˜%˜c˘>˚%˝>˜%˜∫º≠®†≠∏©kF˚õ˜%˜∫˜6æ7R\sVaâ|ã˜˜8˜˜#˜Ÿ˜>¯Ÿ˜˚·˜8˜À˜˚À˜#˜⁄˜¸Ñ˝>¯ã˚†v˜˛Ó˜˜Çw‹˜%Ë˜v¯a®»Æü∏õñäÜ±ÿ˜	Ëéueëo˚	6D˚tI(Õ˚˛˜%˜˛ÕÓ˚*ÇÚ˜óv™ˆ≥˜/¯c˜sKlÉh8T¡›‹√ø‚Ø∑Äw±˜ ù[Oó\˚,˚'˚!˚$Ù-˜6ººï†≈˚ óv¯jwç¯é˜kÇ‹˜h¯j˚.(˚í)˜í˚/ë†v˜¶˜˜2˜ﬁ˜>˜M˜Cﬁ˘>˝>˜>˜¶˜˜1œ˜ÎËE˜˚0˚˚«Á¨vQXoo=<˚—†v˜9˜Ø˜ô˜Ω˜æ˚ô˚˜ô˜,ã˜¯D˜÷˜>˜·˜C÷˘>˝>˜Æ˜§˜˜$˜X˜O˚˜/˚ç˚˚˜˜5 (˚	'X˚˚?˚]Ç˜¯V˜∂˜C˜@˜C¯™˘∞5Fõ?˚2%=˚
˚â˜Ô¥ã˚chtJ@O¢Ã)˚'hœ∆l˜˜,˜◊˜˜Ç˚ÔnãÚ≠≤°»≈∆z_Ó)†v¯aw˜Öw ˜%˜d˘>˚%˝>˜%˜wç˜G˚w˜F˚P˜}˜H˜x˚>˚G˚xâ˜Ç˜"¯4˜"∫˜C˘\˜d\)Oo2˚"&‚˜˜Ò·˜%ﬂ◊oa÷˜,≥H6ü,˚ô˚)˚>˚J˚D˜˚@˜ù”ûºÍHÇÏ3„¯	w«˜%˜A˜%x¯˜%¯a˚&∏˚∫^|ci_eh¢Ã˜±˚%˚ª˚ŸSÊ≈∏°¿π¸óvÍ˜Ω˚=ÌïŸ„ÔŒb∫P\hj]fõuÆ}ë[uTnqHÇÏ3„˜±Ï˜hw≈˜%˜Y˜'º˜_˘>˚%|˝>˜%ºÆn≥∂|π˜‰Ó˜"˜!/Ï˚^oÉp]-£≠°ìß«¿b).`VGnqó¶lÇî˘>î˚zî˜äó˜Ÿí¸∆îÓ
å
yXO	˜™˘
endstream
endobj
88 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
89 0 obj
<</OP false/OPM 0/op false>>
endobj
120 0 obj
<</A 121 0 R/Border[0 0 0]/Rect[250.388 9.0 292.133 16.0]/Subtype/Link/Type/Annot>>
endobj
121 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
71 0 obj
<</CreationDate(D:20090130162302Z)/Creator(QuarkXPress\(tm\) 6.52)/ModDate(D:20160120060548-08'00')/Producer(QuarkXPress\(tm\) 6.52)/Title(Layout 1)/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)>>
endobj
xref
0 122
0000000000 65535 f
0000040790 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000001838 00000 n
0000028444 00000 n
0000028864 00000 n
0000028657 00000 n
0000015667 00000 n
0000032564 00000 n
0000032853 00000 n
0000032650 00000 n
0000015513 00000 n
0000033108 00000 n
0000033542 00000 n
0000033334 00000 n
0000015127 00000 n
0000059134 00000 n
0000059722 00000 n
0000059519 00000 n
0000058476 00000 n
0000016848 00000 n
0000017634 00000 n
0000017429 00000 n
0000016055 00000 n
0000151892 00000 n
0000152290 00000 n
0000152078 00000 n
0000148433 00000 n
0000065584 00000 n
0000066099 00000 n
0000065886 00000 n
0000058032 00000 n
0000150024 00000 n
0000150392 00000 n
0000150181 00000 n
0000148824 00000 n
0000149334 00000 n
0000149634 00000 n
0000149421 00000 n
0000149183 00000 n
0000112159 00000 n
0000112462 00000 n
0000112262 00000 n
0000111878 00000 n
0000113175 00000 n
0000111390 00000 n
0000037164 00000 n
0000037564 00000 n
0000037349 00000 n
0000014749 00000 n
0000001942 00000 n
0000070899 00000 n
0000071204 00000 n
0000071473 00000 n
0000071766 00000 n
0000072061 00000 n
0000072346 00000 n
0000001882 00000 n
0000002044 00000 n
0000002118 00000 n
0000002399 00000 n
0000000016 00000 n
0000155171 00000 n
0000000097 00000 n
0000041089 00000 n
0000041114 00000 n
0000070641 00000 n
0000070699 00000 n
0000016759 00000 n
0000002656 00000 n
0000002681 00000 n
0000040831 00000 n
0000040889 00000 n
0000040934 00000 n
0000041033 00000 n
0000070744 00000 n
0000070843 00000 n
0000136420 00000 n
0000136446 00000 n
0000154910 00000 n
0000154968 00000 n
0000124196 00000 n
0000124222 00000 n
0000136159 00000 n
0000136217 00000 n
0000113552 00000 n
0000113578 00000 n
0000123935 00000 n
0000123993 00000 n
0000098223 00000 n
0000098249 00000 n
0000113289 00000 n
0000113348 00000 n
0000085907 00000 n
0000085934 00000 n
0000097960 00000 n
0000098019 00000 n
0000072631 00000 n
0000072658 00000 n
0000085644 00000 n
0000085703 00000 n
0000085749 00000 n
0000085850 00000 n
0000098065 00000 n
0000098166 00000 n
0000113394 00000 n
0000113495 00000 n
0000124038 00000 n
0000124139 00000 n
0000136262 00000 n
0000136363 00000 n
0000155013 00000 n
0000155114 00000 n
trailer
<</Size 122/Root 70 0 R/Info 71 0 R/ID[<54CC03BDFAD32658546AA337B43BB61A><81581253D21DB2110A00F20910000000>]>>
startxref
155399
%%EOF
